var title_f24_49_25360="Seldinger cricothyrotomy step 5";
var content_f24_49_25360=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F65251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F65251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Seldinger cricothyrotomy technique: Step 5",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 415px; height: 565px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thread the combined tissue dilator-airway catheter over the guidewire and advance it, following the curve of the dilator, through the subcutaneous soft tissue and into the trachea until the cuff of the catheter is flush against the skin of the neck.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_49_25360=[""].join("\n");
var outline_f24_49_25360=null;
var title_f24_49_25361="Posterior impingement test";
var content_f24_49_25361=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F58355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F58355&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterior impingement test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 418px; height: 430px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The posterior impingement test is performed by placing the affected shoulder in 90 degrees of abduction, 110 degrees of extension, and maximal external rotation. The test is positive if it recreates the athlete's shoulder pain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_49_25361=[""].join("\n");
var outline_f24_49_25361=null;
var title_f24_49_25362="Merkel cell carcinoma - forearm";
var content_f24_49_25362=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Merkel cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 254px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD+AYwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDyQSbQSmG57d/8+lN85kAJ3EbsYz/nmklyWcZwO/8An+tRE5J4BOM8969Jx7GCfcm8wt65Pc/1qF5M4wdzLwPbnrnvSKckDkgnqD/Ko5UJQLgg9/ep3KHSsCuM7V9ew+oqISENtzk9QeppA3RDyfY9ajkBC7gBt9e9KxVxxkypKkbRwRj9ajYqee+eAT1qNTznOep9qDkgtgYxnkfzFSNCtIccjGOMHv8AWmlwmTjOenNNfCgEhiB0we1N69RuPUcc0rDTFQsCQB83f/6/869J8Hxr/ZsIJyDzycdTwfbnrnivMN2N2SMdc8/5Fel+FZC1vCoGflwRjkj0A71x4z4Trwluc9F03zcoVTJTueTj+6R0Pdvp+FPsbSaHXri7QxvayAttOcMxxjI6gGoNKnUxKCyYAI3A5X6g/wAOeBx9etbVrLtO2TePlzgffYcZx2ODwM+9eHJnvQfKjVtJMvaghtx+YbsBlB/Q88/TArRiPmF2ypQAhlIBDZPQjquev04rDtZT/rVCum7awGdo4APuM9Bj3xzWpaOwby3b5VUEdA2M4yD0OOnP1rLVaCkuv9f1/W5r28m6QfvMhmYqScE9AMNjGD/IVbilQKcs7Nn5htJLcfxL+ue30rMQhGG9fnUsG29OoJyv6cfrUskR8xFJIQdGVuDwOh7f3cHr9a0Uupm4p6f1/X9M0owiOShZpGABLHKsOcY5wu72HQYqabGxpE5kXPz8bivTJHf+eBVQYLOxJBxjIU7iO+R/EBwAffvUqTcuZUbcclgBgKT1x/d7Yz3Nab6P8zO3Us5USsV+eM4yN2ATgcdMjPb6VKZAS0f8RA8vacMxx27HpjHXANVEkaTYVYlWyAwxkgdcHoR2xTJlJD52bg25ht4XjnA7YBAz15qlK39dyXHUvF1YKQQMnaQFJzxjp1B7DHaiRctyVYnJGDgEjjIb3ziqJiD3kMjSugRuFDcEn39umDxk1MDlwRmNgMOFXJXPXI9hxxnk81Wjt/WxNrbE87naxwzsDgFAAT+Hfnj6UodZBu2qq5GUBBGcYwuPu89PbNVo1cKzOFCf3TnAOPmAOc8D9aWcNvUKwhII+ZgA3HfHQ8cfU0XC3QlRz5jElhLgjdkhj2BHZhyB+tV2BjBLMQitubGcAd+OxB4H4+tJnepydqAbeWJAP8xgfrUdyQjIflztJGWOenY9CB/OjmGou4MWOI3U5AyCOMHPO09wc4A/wqvIFVGG4B0OSV7Y6kjpxkDIzTUkdyxdcDAHIPbrlfUDqfWoppPLkiyCrlQBk/Lu9M9vl5575FNLTQvlY3zAo3NxDuIwr9s8hT14ONo/KoJpXWURb8SquWI4Y++B8pz078570+8wsfmA7T8vyso3bTnBI/jAB59fwqtcIpeB42+RXKsS3C+x/ukDn6mqUv0/EVr6kVyB5LIzYjOMkZOOOeOoIyAPrmoY32RqzIFKrggkZBB7HOMHoB604wGWUIsjiZSBg5ye6HH8QweffioIyPs1wjnYIj858vopzywP3SOpx+PatI7mbGyvuMqxMAD83C4GQOCV68dPqfWm2sipiN1CIyfKgYYXHVQw6Y6gH603Y6wRzHgoSq7jyfbdnJ4559qhmOHjZGw6HGcLkA/dJHT64/lW8P6+ZjPclHmS3CtudZl+8w+916kfxDp0/i96mlYN9wkRryQclV9foy/ic1WJYtvG1VKjAYkqB6f3hjlue34VYBkDnB+Yjr0Lc8exBGScfpWaavc6LOwrEtFjDLJjG0dTjkgf3lxzn1PrXgvxvLNewMc/ISDnjHuR2PY+/WvecKFA52MR649iV+8Dnknp+FeKfHJAgtDgqW5AbHHsD+uO1dcI20POxHc4z4auw8WWO9TjPyjP8j6jsK+zdPdxZxnHIAzxx9WHQgjqecn3r4s+HkgXxRZhSCTINo2+/UjuPWvtDSAGsoGJJUL0zwPUZA+U559cfWvQg/c+ZwS+IfOy+eA2QrY+9n+fXK/1qSVd0YTYCwG3BK/KSclfQg/e+tRSQ4vWAYtIW4AXBY9uP4gfw9qmwpHyMDHgZbtg9Cf7pz6dqva1iO5k3VqjksuME8lgSD6Fh1479PesbUbBEjJKkAdAzD5cfwhunGM9zjFdO4yACMk5wMnLHuAepz15PbjvWVdMpcgSbiMZOBg+hI6DJ4+WtItmckjgby1kWdpY2cS9Sdpy2fVe4PUngfnU+jeIpLJnhnMf2dujSjcEUdACRwQck/lW1fxo0fT5WGQueCPQHrnPr2rButNZmkKDMnPIOCT6emG7Y/DvTlrqxRVtDoZJ7bUUP2RibliAVVRuPTK4zlhjnOe34VWbUT/HPOp/6YsSDz1OBgH1FcaFudPuPOt3YR55Izgg8dOo+bjnj861h4hGBueVSOCGxwe+PbP+HakpJbjcG9jxJZgR8n09Pof/AK1RFgy8cY/z+dRFNqkjn2JoyRyuSSexzWJYHIA28E0wv09fr0+lOD5AwcADg+/9Kil4IYct70PQq41wDuI49T6cdxTXbJGQD/X6U4gMAcg85yfXt/k1C+VKqudvep0GmxCepBAX6dKazDggkA8AZ6+2aQ8jCdT/AAk80wgY2jIUYI9aWqKuOZsHDDpxmmK/fODn9PrSMQUy3DAYAPFNIPBABPXpSY7ivkg4yD1I/pXpPgw5sUVW24wD6ex9vTnvXmeCMfMMdOucCvRvBo3W0YjGS38Oevt6HPXmuLF/BdHXhXedj0CxOwxn5+QcD+IAdR749vpWvBM6lSAmwZzkEqGC5GR247/4VgaQxygYbU4AJzj/AGT6j3x+tblvIQUdhkBeBkbjz0B6e/NeHVVme/T1Rr2T4m3FWQsCVDDDAex/ix/Or0DqquoKqFPUJ8ucHgr24Oc/hWNFk4ZPmV8E5zjPbjrzyePTua07Jyqq67mVDhQx4YZ45+vJB9qy5ipRNKydwU3OTFwBubDDjjDegFX4pS86BtyqowHzyvJypHTjg5/lWdZsEbATMb8kbQM+xXvk85FX7bMmwFgQCCr7h17EH+HJ6g/TmqV7WM5bl+HEccfzgNkAA5xkDseo4OSOPSpA6KqOoGduCCPmwF49iByfx7VSj3YLNmQlOcuMyDcPwbnn6VZ2kpyocqT8pGAx+n8OSM96rmMmixanEeFACJyUPCHkk59OPmJ9cUy5cIkRzgAjYSwB/wBnnuO+Pw4pJHbzMsQeBggct16Hvzjg9hSPu2jdyGwcBevPOR2yQDkdh61p0siFvclMplYopKBQPm4PHYMvtySfTH1qNPuodys2FB3vxnqMMOmep/CmwzI7IwfOQx3ZIyeO/Xk+vpT52fzXVffI4yc+3Q84/Kn1u2Nq2hLGfMfEasW2ghwh3EE8bh3HUmk3KsCkoo2k9RlO+Pcdz/nNQud6RBow/csqnGc4PuM//rp0koMDSNGWBHX7vGfXoeePw/CpuraByseWkNwQpYcIQSQGz1H19/wxUF1GSgCMdjd85BB7EDpyS3FPlTgxyE7AGJGOv975fU9jS8MypyWXgMZOuOOG9+Bg8/lVX6C2d0V4ciTITPPyr0LH/ZbuD1we1VJX/eMhIIIBVwvPXjI6e/Hp+NaB2ohWQkZJLZ7jPPy9+eM/j7VnXTgRME2kruO8nIyDyFPUZHGPY007LoUnd3GyN/ql4YAbGTPBGc8E/dyeeelRSOyGRWfcWUbOgbcDwT659uw4pDxkSsWDcMVTJbpggdDzheTn8sUl4dx2MflXJYA8IRjeP9n0GK1WncmRUkcs7v8AKUZSNu3Kuc9+4OfXtz71CJG80SeVkv8AKQz88/3W6YYnPrx3zViRy43uSjo2DhsFv9oY68YXn+VVfJiPnQthYmV8kdRg9CPUdBt7elUnrcnpqVbh/LS4WPDA7UYhDjBOVLKT13ZH0FUr2USIkvDAbtq7vlJJ+YKff+VaU6+dslYqxY4YDoGA5we2RxzVO7VFnKpnPBO3GfUHPQ46cfy4ropvqYT7E0BJiABcyE8gcOeeCR33dOvapoAGUElSnTP8LAnnH907uB24OaqocgI+QoLfKBkL6gL1GOgz6kcVft3O8OT8+cEiTGTjk7ujDHGKmekrM2i/d0En3OzbvmkyTjnOT1wf4gwwOTnA715T8cLESaRFc7QQp5lC9RnAJHb049M16/KqiJhsCjG4qBnb6/L6rwM+/GK4n4j24vPDVyjxESIGxxxuHUBuvToP/wBdbU5XRx11eJ4P8PIf+KpswwLAnoMZbnkD3+tfaGkFvssQdzkAfMOucccdwRxx+dfHvwviM/i+1VlwUJ5C5K++O9fY1kAtqm4ALtPQ5Ax1GeoIHOBx9K9OHwWPMfxBtLyMpCKuCSBypHT8CDgcnpVuXKANJuLnPfkHHIB757YHX8qqx7hdcZVwRgcZzjg4HB4yOe9SSOCpH3Ux154Hb3yvt61TJRk38vlo6RuFBALMqcY7Er/47yf5VkySEgM+cANgbuenzBW9uMADnvV/WEO8DjIJIz645A9OOfm7/nWbE+UO1iN235sZwf4CfXHOdvf2raOkTOWrKkxZpZVYkkHkqvIIHVl75HHJ6/lVWUotuGZsJgKuTlcd9pxxg8cD1rTdPkZQmFTJweij6dVI65P0681QupfLYlT8zEAEtjJxwd3RgRycD064zT3EtDHvVzIdwIc7twHVTjn/AHhjHU55/CqJ06JzufyxnoTnkf54+oNbJ+eIRqmQFBx2X0yP4SOuffjrVZlmQ9IznnBbOPoe/r+OO1ZSijSLvoeBGQvuJypz2NCPtfLAYzkgjOf8aWcjB3ZzyRx3/wA81G+AGHAGRUtCQMvdTgknOOPy/wAKikJ6EYAqTceB0HTPU4qKYAqpIPsM8D/CjfUew1iByBkc/j/jUbbtuDjkdP8APNS5GAePwH9KgkI4Yceg/wDr9vWkNDCMPnd+Hr9Ka+MHI9jx2p4JAChQAx7jn8qidRjnHIwCT0/wqStRHCn7uTx1FNUlMnp7Hj60Elc4yR1wQOKCQw5PI7/rQ7jVhowSA2cjPX1rv/BEu+3HByOWwM5Hrjv6f/qrz47S+cDpnryBXZ+BJipdJMYzgKeR+Pp0zXHi1emdOHdpo9OsZcgEJjClWGTx03Dd/D7f0rYtiZG8oSbSAOQRkn1A6HjC5/D3rBsWCkOpywBAOef9k56f55zWzbMqQMSAFPByMj2BHXrzXh1F1PoKb0saELD7JifHyDBIOcc889scdK04nRl3SADhhwRnPfHY8YHPr+NZtuzeXEEYMwxjLDqemG6c4yfwqzbPkgRHjqQFxuB6blJ9QTmsHpv2NWbUCRSOEJKoFAOMnB4/HIHHFaIk8kDJyFIC4AGOuV/IDr68c1z9rJIkLny1dw5C5bI5Gcbvflsf4VdEhYkBlLsFILJy3BwSO+TnJPoDTTSM5RbZ0AH7xWL7DwDgjOeuT2IwOo9akWTAVj91TkZONowcjPVdo456ZrNgkkSIljkrxgDj6f7POTgVNNIxGQWL9lzkk465PUHrz1rTZaLsYtX0LTKCyA8lxkg/nj/aG09P680+PaUWPG7YQQ/J2nJP/AcDjPvn3qEyjnBG3YpLA4zwcZHXOfT0z0qONirAugKnJClvfoD05POD6elPRMW5KrpHfLErBJCGJ5AIGBxnuAD07E4q1FHucohO7jaNvQ4/u9uM8+v51U2qJJGBDS4A3Ac+2eOcn07U9mMbNJuUp1QDJU59D1Bzzz2H4U1oD12LKOzR7iQpBHzeacL6Dd2wO3vTNi+YcDlxkAduOmDx05pvnMpI3yMcjJONxz1z65P+RSl/mXa+7I9dy56DI7ZP6Ck9iRyCJVOACv3UJU4H93nqOAahE3l7RhlckAdiR/LjGf8AJprF2G4KSUyAuSCT3wx+9k449ADxUJVg5O0un3vu5Jb1Kn1ORn/GmrPVDSvuSzyZKcKU4DDPQ5446jjJ445qgZFjhR425U4yG6A9Oe2BnrVuX/U5dSQBkt6gkAgHtzwB6DHAqNoz5jDJxzkjGT65HQhuB7jFUrji1sUvN2W4DoTk42OvHI6Bed3HzcelRkiZVdeMABZQcAdlO7+H1OfXnOajlZGckjdHkoWzxj1B6g5IHGMfTNMneR1VGU+YBygPzDgBsdjnjH0PtVp6tXCS6gzBDsO8q0eFDAAEA9MdH9f0qKZwGURyZxjbnseoOP4QRz+Ge1SzhpDEwCA4yzheCc4JI65P3cjtUFyge2f72FBXGRwAedrdiDwB7elaRIK58oxzKmPvK689fTGPvYOTz+vSqEzrPveMMpUZCbcEnPQjoAeTxWgiEJvDkycF9vVjjByvfPTj/wCvVO6h8qRnGwxOm0HduVP9r/Z6bfpWtPTfzMqmo6FFm8qWIjqCGOcH+6c4yec5z+OauMwDEJuCkAkYGSOwI6fe+bjnv7Vn6bKS+Cp3EEHAwTz8wBH3+2Prxir7xlSY2w2GySF4U9Mlf4T/AA/Xj3p1Vd3QU2W1cSRDnfs6AnIz/P5uc544rM1u2Wezl3HcHQkHdyR0B3dOvbrj8quxoxA3Agccew67T1IHQZ/CoL4uhdWGWXO7n7p77gOOmBkfz5rSldrUzreR4J8P7b7J8Q2tygbbI3ybSc85xjv6/rX1jZOfKjZSSwAXee/907+2Txj+dfNPg+zWX4nzn7qnBBBPHuD1BHT0/CvpeyTylHy/MoOezLjG4emB27/jXqQ+A8fqLys2zaCp/wCWeMZGeQFz8xz/AIe1SOT8xYh3UkZDZOepyf4Q364zUZTyiXYhdx5POCeMH16YH/18mojKXZmY7QM4ywG0d8N0+X8/wrS1ybmXq+PLzu68g9Nwz1H947uOe3txWTE68qV5wdw79fmB/ugn09McCt3VIyqP2znPB5IHII6kY/DJx15rn7QM8uNwCrjaxcYT0Ib+Ejp+nOK0T0Jtr/X9f1qWpIy0OQVxng4OCfUHGTngc1juqrM4bg4JYDgkD7w9ODj7v4d66mKNVib5cFwcjb82P4h/tAZ3fU571z+qWxDNsA4PHyjap7H/AGeM564P504vUTIJZkUBQoZ/9knGe+O/PTnjr04rLdn3Ekn5ud3BLe+f0/CtBLfCoFDDcAQp+9j2/vbevNZ1+txJcfuuQo2kYA2n0xjA7Hj19c1DeupS8jwUKo3lf0/l/TFQbdik4JHTgcj1qaQPlgpwcZPbP+PrUe7JOwDOAMmk3qJIbkAfMcjPTH+f0okAJ68kHv1Ht60A5wMng9zwP8KbMCUG3O8k8DjI+vepZRAOATwRjBApr/fAB+b17nNPJODtOGHGf/r1FJk8joTx6ikURtnBAyVznJ7/AIUwsyqBjnnnPP8Ah+FPOM598c8/rTOuGQnaMHtxSENYK2AfTrjH41GcYX5TjkdcE/j9aeQNhO45HTB6fn0pApHBUexx+Xt0pDQ194bIbPcgLn9Pet7wbPsu3QMccdDz+f1rnt5PXHFa/hyZU1JdnUHke3+FYV1eDN6TtJM9ds5JFABTkg5BA/HjtntituJkeIq6qFI5POM4656+3pXMWtwFt12BchflHp6HHbHrW3Y4miU3LFyc9ZNq4/u56HA5wefzrwqkT36Uuxv2H3EDEhwgGNuCR346cHgfj1qxbgu5dyDgkFVyVBxyAOoB6fy5qkirE0SRFVztIBXj/Z+U+2akhmPmGQfLE44bcecZwN3tyf1rldzqWupsWs4gJVnYFio3bgDt7nPQ44HFaUPlPb7kVPn+ZkXOFzncMdQR0B/nWIomIjjVCSo3KuwZB9CvTnJPH8qurN5S70Y+VlVU7z2HHPX1JB/Sq9SJK+xrbmkBUthQWAcEcA45BHbHy4/DrTjMpaUkMWy24Y47A5HtxyP1rONwWvIEWIbex3cbV6A84PJ3evFSRkRSs7hW2v8AKNvHX5T689eOOPSntsZ27mn8zRyKxwgOHffgA4APzds8DFOEpYoi/KCATjngA846NjgVkpeRxS4cn5cM2RyP7vPTqSefSpLjUEjTY2I1YZVWGA3/AAH7xz14649qLu5LRqCbdHJ5igJ3BJwvIz7rgemevepd6o7BioJU/e4bPTg9Dxxz3NclLrh3oIRuijQMkr8leTtORgAfWq83iCVIijCJsrjBU/P7bc/NzzkfShx0THyNneK0MpIeQBG++qrgrx1PpgccevegyhBHGzIMcLk9+nBHtxz3I75rzYa9JISRMVcEYZIwMenzdVzyT61Lb+I5SyDfk5BVnjAJ54PH3jnJ56j6mtLvWyB4eZ6G8hVhlhwMSHf8wA6E9iR0OO/1ocRogQhRg5OOAvHTHUYHPPr3rkIfEqSnLxgOgblDlWGeAR1XJ54z0x05rZtdRiuYEIuByQA7P1JPGT3JPr1ApXTffYzdOUdzTZB1V8FsD7vI4656Ebf196qTEeUqYCduf4OeCR2256/jzmpd+d4AVmwAVI+9z0I9zg5XsPrVOaNFRWI6AEMxzjJ4x35PHPH6U+XlWgou+5UaWdJ1dgNnzjLEAHqMBu/Hb+tMV33uyBVbIZd3bjAO3oMDqfxPSnr5bh/Q8BgAN2D+ROeoHP41Wu1GHSNmYZJZAeCRjOB1G7rn2yM81ou7KbvoPSUiHO0ER4JOc7fVQeoIHOPcGnKGjdipK+aCFBQD12nB4Ix196ZA4CLkhywG8rJ98HgHPQnOB+GOpqGWPdaeWDmRc7k2n5sHn5fc9x6UJ2JaIwY47Ztg8uPd/EThR6H+LI61DPIqwRpPv3J8o3EA89sjjH8XP19qknlw28OsiSg/OG/i/wB8evTHtxUTR4ba5z5i5I2Abh/u9Dzxn8K3hOzM5xutSuhRJX8twoJDA8/gSDycdTitMlZUQqu1lyAu7px93PbAy2DzWVdrIsTKh3MgPQnHBORnqufQdMd6uaXIzJuMm/dklz1PI5HY5OFye3vWtRJq5jDR2NMnbHlD83GRj7xx8pIx82RzkfXjFUJ3ULzny1AwDxsGeD/sEHnmrGQA6TKNvII5IP8Ae9854GOKzrwFVw2SScZUc59s8c9PmpUnbbz6jmro8btdci0D4mSTS58uQ7TzkHnoT/EO+Pwr6a0fUre+tY5LeRWHDDvgYyrEdvUt36nFfG3xAby/EswbdgnPufr649v510Xw6+I114enigv5JJ7DnuSVB649PrXrUppqzPHkux9as4ZORuUjg8885IB6nnnH+NVpEfzMx8v2+UfgSPugHn/61Y/hzxHYa9aCezulIKjPzDI9ye/93H+NbLEBdhU7ACdmzoP4sL/Djsa1vYgoXMyPEwyPLwMElsEZ45+9kHn6daxUZ47wD5t/p8oJ9QP4cN19fTvXQ3MQlDuGUMScsHwCcf3vQjjHvnvisOWAG7KOGB4IUIMgeuzoNuQM+/NXFktFyKQbfvBoyeW5IPPykjqcnOcceuBis26ZXkGBng4G7nGeQD0HPrzir0reTEPMO0gnOGOAf4hu69Og9fpWczCSbaN2D1PGenBA6Y7c+ueCcUNpBa5VvSWUBEBO7+EZ3sehI/i3eowOO1VTCkiozy5BHyknPH5cc54rQ8mPDySqiqnVWyVA/iz/ABZXtjjnnivO9f8AiZp2n6nLbxZcrje20Y3e2O2MVOi3B3seVCQ7GBOAf/1/5NMJzk4GDwe+fUU5wJF4bdk9v501VOcHGw9D/L60m7jSsBAAXByR1z3qN+u0j5eoBOKkY4RcYOOOD0H+eaiP7xQPvHqQOKY7CZXI2DccZ/xGahkVs7eCD1HfGetSyJtTIJUYwAetQkHHPUevpUvzHYjyMtj04Peo2HBLAbvfipWyeVHy54we9QzAZA3DaBj3I/z6VPoOw07ArfxLjnnHf1+tNYnGMEls/LilJ4HYZwSDkUn34/nzu4xkf0FDGkMJQtnqQRmpbVmhuonJ9BjHJGartyd2BgEkgnGKbvKtkcnI6Hv2+tZtJotLU9c0afeyk4bjlcZBPf35rp4tywBwx5GeMZIz+XXjnmuD8NzK8UOGA4Bz/d9s9sda7a3uTtVQAqlQMdQT/XIyea8StGzPaw8rxRt2ksYtVLAHg5TkhRxuGDz19KtRT7trMRncd3OffO7tnAGCKxoZCownKhV75xjOCe4xyTipoLomYPHkKNw56Y9OOvrzXJKKO+EjpbeYbFic5QqWxtGApI3cex7jtUyMGSRwxMrPtZsggYGW5PQHgYIzWWrBFEkeJDujCD6g4JHvyTilmvYYIlX75K8lcZxkgAe45PPanCMm9CJNJXNFr0+YIpHVd4Y+aTtVcck+jcbhn6c9qzNR17zZSsKEJFu3McqBkcj1GAQABwPxrEvdTd5JBGF2TfKDgH6g9jnrx/8AXohs5J5tsLpvADLvJVIwBne3dcHJP6ZzkdHs76ehHNb3n/X9f8OXX1Eybpbk4ckbpAM4PtngnHGDWdc6owSYqsjtt5IBGASMksemOAMVRur63BCFZ7lFI3uWAEhGOB+Wfy9KsW1/cTR+XJHBEqlXUxpl1P8ADgk/LnPJ/Gr9lGOpUeap8KIpr+6w3mKIlJJPJ5PfgdeOOaa5ZlLyTs0fvx24J5/Dim3Np5kzSTSvNyAz7ySVB4G71HX07VYuNLigMaLIZZJTiMIOCD049+T7Y/GnGCex1wi4W5irLLjGVGBnpk/7wHcfjUhuFERYk7279Ocdz0PHGBjrVcJuViJAPLxwSxBweDn1z+dV5em3JzjjGM4z27e9S1Gx1KFy79qIHLOQgJyvYeoHUY4FWrfV5Y2DmUgsxyDjnI5G7GDkf54rKbO4ZXIwAG9T2P41WnI8jcAxfGCSQcDt29fX+dJQRnUpX0PUPD/iBJBHDLNsDAbWyT5Zx94r2A6ZHr71uzzeZGMnkqRkNlUP8S7uvA6DHX6CvDrO7a3cLuwpOBxnnrgjqQTzxXonhvxAtyYobhmzgYLNyCTwQR0BPXPp3qJQurHmVYcjudOZt+FO1Jm5IA6ZHUL06ZHr37VAjK6K64GDw+fur7n73APbjn0zVNWVy0SEMCeR13ZPPyk8kkcEentUku/ych8SxkcnnJz1z1UH9Md81C0lp+DItcWSdo94jYoGyPlwCRjHGOCMevOfbmnxvGVKFvkBwSc8Ej5TjrwPT8KqzgGBXdsswwQoA3Ddz7MdxA+nFTAO7orDplWUDHueP4c9sdh6ihSto/ItrS412/dO5AAibKYIztI5APQY680EqbZkjVQSVK5Xgtg7Tj+L5PT+VPjcNvG4OxI+bOAR0yCOvPHP/wBaqTIyyukqsSIyAAAcgNz14BzgcVUWt15kNdwvHZbRJVZgYlyvHKpyFH+zt5603TZUWTg4WU7l54zjoT0bjn681auFDxpL8hjYHIwdpzjP+0c9OfT6Vgk+RctGrfdwQSMNj/0Hrxx/9au2LdranI9GdLcEGKNhkFFUjuR12nH8OBnp+FZmo3AkiMgC7CNoUknI9M/xHvz9KsKwlt9jHLAMSB068jGMjPr0/Cs67dHics46HL55PbOenXC4PNYp/wBfMtrTU+f/AImpu17eRtb0Ix2HPHtz+tccspDggjHHc4H/AOqu3+KUZivwQjDJPt9fyNcLGwYZbNehHbQ8qS1Z1PhDxnfeGtTSe2kYIfvx54I+nSvpXwH8RdO8QwJGJEhuBtyr56j7p9Sc+h/Wvj7+6OcHpxjNXLK/udNuVltZjHKhPK5Fbwq2XKzOUddD7invxksgJGCMgjdjPIB6DnnmqgdmZNgUsxUg7TgnsSOpzz0/WvF/h/8AFD7c0Wn6vLHFIRgS9iRxn3OOOa9TuPEWlWFp5s9zCiAHIDZwP4h14x22/oMVutdiHZbmxs325kZmd0XAO4ZAzgYP8OCO/pjqKw9T1ez0m3lfUJEjXlsEgBvX/eyec15z4o+NEFuZIdJhE7c4ccIDjBIPU5HHNeMeJfFWqa5OXvpyVP8AAOB7flwKHUUCeWUtkeheP/ihcahEbXRrjZCML5gB3MB0I/u/QV5JJdFpHZ13EnOS1MEu6MAk5GMd6aJARnHPfNcspuZqopHdEFB8mTk809SdnXJ6nPQ+1OVsqT0AGfp/n1prDKdgMZ4rsRmREcggnp34/wA8+tIV4DcEnjAoYl2wVI560EkL0ICn8qNwIWZt5HX365/Go5DzyC2OOR29cdamY5TnofQ9KhkARv5j2pDISx27TjH161GBwc54HfsPpUxxxwRn5fpVaQc84/HrS0Y0NfO3oDwQcelMc4YAEHp0PfH9al3Hk8nnBJPT8ahJIJUkDPUHtUsoQy7euTnnkUm0E4PQ44pH2mM4wMDOc46+9MUMB8wI57fwj1x3pMZ2/hC5CxqD8wHHHP4+3vXb2sqBA2Ttxg44yO/Pc5/T615h4WusSshGQo7/AOc16BYOTE0gJAPTgfQe3HevJxMLSPUwcrqxrzyMYFVCrOrEheo56nHUA/0qazuTHGMkjP3iH68+vc9vp7VmmURryvGNoGOB7euR1qYTKEZ9ylwOuR+Gccf/AF65+U7eex00Fyo02FQRzliWBwBn5uO2egx+lYn9os97IpnMcSvyxXJbnBAPvkA544qm97IscECt+7DGQL6YJwPXgknjrnvVOwR5lklLFTnJYnOQck5I7cZ78mrjT00End3exvWc8cYu5pnCuqEjIX5c+g9c8cc4qeItc2aG0WOKGHLyl3BZiD904Bb5hgAfdyTmqdppk+p2jTmMEKVaNyfmwRncynqMKckdCD1yK2dL06/ksLq3sZVRVGWgdtjDI6cjIGDn8vWtlGzLspq9/wCv6/q5lwvp0WlzEb3vZnClZBlkj5O5T93OcD1xU4tsr/rEmXlsAlm6AkHvnsO3HaqupxyQTWSP5bGJcKEGAwzlTjo2eefpW5oUYmui4KxLGhlZ5PuqB3J6jA54z2rOa5rI9GhFQTmRm3jaMThj5hbYVAAOTwCG6dOOf5HNVtavDb3y2tsyqsa7XaOEqQQcHGT14AyuOOKu6xcRvBHbWQTEnPm79wYjog7Y789zXPSozsCCAVAO4jGB2zn9cUnaKaR0QhztSlsJMhDI2GDFcNk5AHXIPbPTke9QP82Wdsj8f5d/SrTZdVcbgW5+g9B9OtPh066nUyQwyvGOpH3fxPTnrWN3ex08qS1Irxmd97yNgrjAbIUY5T2wMAVnthYwrZGDk+h9x+HFa08DKCsT7k4JIGceh55GO9VQEaVAzrtdgrlTyRxwc9SeT74q9zNqxkXCLtViRt5yOmBxkZ9R2xSCQptSMmMI2Q3QsSOee3B78de/NX5reQJcJkNHGGJO3lecKQDyM55P51nzsGADhCwI2k8nGMAFu/r+FaQ0ep59eCkjuPC2pyXkEguB/pGfm7YAAwx+g445/Wt8MJAXbhRnAHzBfUL3GB0zxkmvM9Hu1s9QhYA+XMqrgHGO4JHT6/nXoMLgxZDv5ZBXPJyOSOepOeue2M8Gsa1OzPMjJrQ0YD+83b1XgKSMc8YBJ6HC8cc5P405chCq7o1TBAUdB2wOoIHf16dDUdrgzxhl3FxgAoMnjpjp82M/hUkwRljkJypUHJ+6fc9+SOccYFYONtv60Nb30Y1WwA4JRzwTv747sOCMc/U05wXALKQMbgoQ5GOhC+wOMj1xQ2Y0UuMtIODuUFh1xnpnPPPYelRANND+7KORkEYOGJ9u4b2447cVUGloKWuoqOWZiuAqscZY8ccqX68DkcdT6iua8QSSW+qxFQVDAMNqj0+U7enTqfX3rckcR/NvaRhg7zknHrnsc8c84HtWTraRvHvcAtjONvDDv1+9k8gjtz0rppO+py1Y2J4r/b5JYlE6Yx93rgeuV646ZNRXpDPIY+GIOAT1yO3Yjvzzn3rPgIlVPvHZzkfzx1UHpjnj2NWLu5AiDtuIYYI6ls9s/wARyOPanK6lb0GrONzxv4nh2JZ8AKRjBP6152RhcqRjk4r034nZmiVlO8hs4B7euPQ+3pXmW7aCD39a7Y6q55c/iYiMwbjHFO37mGfXHTtSAggg4xQq9SvIHWrIJWfawKMAVPB6VYfUbySFVkuZGQcKpc/L74qkN/GN2Mf1pXbIGcflTUntcLXFVznJzx6Ghfnf5hjnFICuCOrdM+lS20bEHHYdqFdjQTQhcbcYqIq4PA/WrM0z8KzZK8ZPWoZZmLZI5I5xTmktivU9AdcZ6k+3+e9VshDyeo6GpckbsDpwfb/69RMwI6A4GcE8V2nKN6fMSCpPrj/P0pWBOccn0/l9KAQSNxyO3pTJM7PlyCM59qA0GAEMGDfmeoqJsAFGAYjrz+NTdCe7dfr9aicZAbOBzye3+elIdyJgQeSCfX+VQHOCXwynPWpm4ALbVHOe2fX61HITuBGNoPHPSl6jREyiRQR0IxmoyoboGA68VJKSAcg5bI4Gf84qHPPzISR17jP9KXoPzGvuXuM+w/TNIjALglSMdwf5UrSsTjPtjdimgAoCFAABzzSdxov6M4W7OG4YclT6V6Ppcqm3VCMls8f3j9O+f/rV5XaMYZ1kGBhuOOlekaORJaoW6MM8jI+uO+PauDFR2O3Cys2jYkkRYBh8kEHIOfl9c9RzWfcyn95PG5AHzAEDnjnjvz+lSyhvkbHB4wR0PcZ7cc1g3cjQSPCn3ZATnGB/9eueEUddSTRuQM8l6I93zAcnGcYyf1x2rVXfblY43iHlKW87cAv3udp6Hrjp3NYmnAPFI8nXbtHqh9PbAH610UV0VWwW6jVsxPtZ9rhhkcHsePpg4/vZq0tdS5t8qZ0GjXgtLeY2OXvZ8RosedrMVwTt7kg4BGcHOOprbH2nUVvYBNCZViRkUsqcnOcE/wAW3jn9K5SMfLbz2zCNSQ5QMS0DHAJPGRjHOBxnHFa1jO0skl3HGUC42rjIHHTn73yjv/eOahy5TuhTjy8y3K1tYTTlo4LVpGjjMc0fTa24A9eCcjAAroPF1vJBbW8KureXgSIkY+Q7QwyQMjOSM9OM+tWbO5tPPe7MTpdIFDFnYGQsPkl/2cAkEjrkHrVLxfql1cz21nMZDAifI33Qc56dOB1ww4+lU9Y7msak5VY6bGLql0JoLSPy7dGiQ5aJSGct6n+Ijhfp+dZ0MpVi5UPICRsC5HTBOO3tSztJtGWJxhVyRxxx+lVlQsThtqhepB9vyx1rlk1sepTVlY09MspronyN8jKpcvH0UDknP145ptxb3lm25vNjJG7YTgkd/l6da3vBerafod2t5dxTyzDhUUqExjoxPUc7sYzWt8RfEGla9LFdWFw5dCsX2Z4yu8YJEnP3euPoO1a8q5b3sZSrVI1lT5Pd7nJK897pTGa7jSCxXCRMeu487e5yTjH1rnpSiREk4k5GOp98duDx/k1e5IR34Eq7lAbkLnufbBOKRrWQygyDaVkUqvXjqW2/Tnj1rNrmNrqNyBrZ3tJJnQhEfY23JCsevvj096o3Vqixq7Ny6byykcDODjPvjj+tdP4gltzuurdYI4rjGIIi22MLgL3znrnP6DFc/cyxzCEiNVMcWAFTHIJz354Oau3Kzkl76vb+v6/4BhozR3QwdkSncUIJ5x82O/vXoOmXG+DaZFKD5VfdyG54z6EYAB9a88uNrvLvfDJs2Hd8p5wM556enSvRLGITWwA3JOgQp0zyMgenHXJ6CnWd0jxpK1Rm1bszrESMR5I27Tx2OF/ixnGfwNXAMx4fd+7bJxk7O7DPVeOnXnms61dsCOPO13BVGOee2e/PJyPStFeXjZfujaqsTyP7pyOnOTyK4W02bJOxLdKPMUElRk7SVAyOx9GAGAc9zUbYAIOI8EhkHVfw7bfb8akMeI5FWJjhdy5X75B6H+9k88VCHbytwGQuDz0H933XJz/9aqV018hW0sVJW3xqzMvzDb14HHUEdRj+9396x9UU+TNEzMdq7DkchQe/YYGM7a2mdQ3yk7JAGXnHmDPT0Y7ue3HNZeou8u4MFUoOVOefQ4/h3ZPTPStaLXXcyrRdjnbCdhNIkhRSCQoIOAccj16dM960JHR42j452ncSDxjjPY4HBA/nWaWTzi6ng8K4b7w7c9+fX0ouJGd2WPOTgkbeT6jA9+eOo5rpmtbnNB6W/r+vzOH+JEQ+xjZ8o5JUt93n068evfNeVOVbb0A9q9R8bnz9OwdzMh5YDvn1ry10ORhSRjOa6afwnBU+JgVwhPOD04pqHDZwODShwAcjPpSqckYyOmDmrMwT5uOBnuaVlzxz+dNUdSeeKUjoAeT7U0MUoVBOCBT45SiggYPfNRhsZ5A55HrT1OduefQA0CQoKvJ0J6jg0skTFslskjOQOtNQZlJJ45yasiZlGIzkf1q4x5tykzsZmKb+xzx/ntULEAHZjI/D/PNK6k7t+M5I9Pwpqkhjkkf7XT9a67pnNqPBHy8jk8/1pruQM54zwf5fSl+UjaQcMOw/zmmuozgt8g4z6/4U3oG4mADuGfc45I/z6VE/c87alkG1DjrnjA6/hUYPyfPnBPOKWlxkDAe5Pbp+FQkAK2R0zj2/zzU7BTISd2e+BUPLcnJyOec0hoiZuAWGScYPrUZRsfJ0A/zmpHQLtHIBP5/59qhyypj7v0z19R/Kl6giFlGAc9enFN3bMKdo245/lUqH5juBxg45BqJxumOAc9Dxn61I2Pjfru+4ScYP6V3Phy78y0VM5cYwOn0+mfauCkRAOGAJ+o/Gt3wrMY5XVgAnUA/rx/KsK8bxN6MuWVzvy+YU4yWIAIOcf5NY2rxgHfty8bBjk8nP6VqQsrlT5i9M53YHp1/TFU7yJn82MplCMYC5+Xvx7V58WejNNxNPTkby1aLE6OdwXacEAkdOuTmrt3cC10ueW68z7NEp8ogAHduBKkkc55GPoeorF8LX7RqsUrsrxuchWKnOOTnr04rsrrSlvfCWsmK5SQK3neUVCkMBneE7HAIyvXJ4raPxWJqTfs7rb+v6/Ms6BCpsLeW2ddyIZdz/ADBuoyB1+bpg5xg8+lu4jS6iI0+E22EaRkZ8gtux948YzkBTjj35rz3wprN5ZCO1cKzqxPlS8K5xjI5/Ij14r0PT9cmvNDuPKtrZ7hohCzKPm2heGXH+zgfh9aUlG1mddCrJpPf+upb8N39tFbSQ3obyCCEfbwJCQSuORtOOuOnJ5roNNt5y1xBNbKWIBBZw8bRE8KrdRzgYxjrXCrf+fZR2Co0dtGxcKQTsJwWz3OMDpjqa6fSJpJbx0tIZpo4mUEkt9/r68IOwPofWsYytK3Q6qyfxbHNarY3lncTm5jZACSN2Bvw2CMeufxqhFIpZixLZAznOCfX15r0nxhaXL6TDbXRANsB9okhUbd2SFcR5Bb0OPU46V51JCLe5MJxIw5by2zgHtn6c9O9RUhZnZg8Rzx13HLIFIGevfjpnr6deKkmkifYkUCvISQBGCQ5J5HPPPbH61O0Nql2I5bhVhYhvMXBGMYzj+LjI7c/nULXlpFHILUSrIdqpI+PkHQ/7uPb6e9CVux2e0vsaepT2sNrafuJWvI3BlunB3yPn5tnYKOnTJ/Om3j3kccS3cSXcMJLyow3AyspyMD720kDjjPWq9jrlja2ny2Fol2jMcvHu80lcdRjAA+b64781TuNVe8061hZpcRrhijAfKCSvHtznHc+9WpHHySvr/X9f1sZU00gnJIKsDhmPGfUc9AeBUE0x8mcLkpLjGBwozyfQ88VYVZLx/MDqrk873C47ZP0BzmqN+fs7NGAQTksvcAgAD8RyfTI9KzSuFWoooz2t1lvHVCXJkxkrjABBPrivTNFhWCMyLuMUjEq+MHA+Xv1yePx7VyHhCJ5psRoS0TblkJ4A/hIHt7g9a9Dt43cB8MFKeWoP3uD3PQg8n3+tKtKyseZ8U+YVk2zMzgxqmV2jsCOSfTGAOOvU81at2zFIUCkcknJxuHXB756c9/ajZlEQA7RsYMV+7n7pIzkepqeJQisU4yMkeZ044Bbpxy2Pf3rib6s0VrACHdk27McnjnacZ4Py8HjimFR5REi4ZSQQNxHT5gM/N045pibSyhEO47dqsh544+TsDyc/gfWrCS+bDvi3YVVwxbO3rjLdRg8kfj1pxld6ClGxRuYvIVWAKsMnORwPXPQ8cfX6YrL1OEyRgDAUZ4C52DvheuV9enNbUxwD8pGRwNoGT6Y6HP3v/wBdZV5IVt/3b5XjqenofUc9RW0NPwIkm1r/AF/X/BOQKGOaYkjzVLAnpzjpu/p+FVTMS44GCRjrjHrjvjpkfWr90whlV5FJBwAO+D29ODzzzVFNstxJjBYnpjjJ6Z9c9ePSuxWaucD0ZzHjDElpKSN20HPOdvqM9v8A69eTZy+Bwe2DXr/iNClu5B4UZBxnjsfbnPWvJJ0AlkyMAE9R39K6aW1jiqfG2QsM5zkHuPSmkEHI9aXGCOQfxpHY8Z9MVbMwVsA/409WDMcg9wOab8oXIPzemKRVJ6HrTQXsK4OTnOc801j078Uvr1yfQ9adgtkKDijcBqORnHU1YSSMLyCfQ0wgGNieSB6YqMoR0I/OhOwHbyY2kc5zxx/n8qM7gBxjPH+Ht60SEAPsG4Hpg5P5980wAxtv45/X/H0xXczFDySgJ6t6fyNJvIQEE84xSAggA8g57dBn9KcBl/l5Yn160MSGyNuYhVHGT06fhUbsSc9Dj1x+Oakk2ldv9Tio8FOGBznOB9P1oGRFjuCBST0Axn9KgI3g4JyB6/1qwy5GVYAAZ7/55qB8ZyucjnH+etJlJkLckBiR7D9OKheXPsR6/wAqnkYZBI4HB9/p6VEwH8QB75Bxn8aQEaEKg46+vGaiZWEgCHI6Zz27VJtG47VJB7YyCPpUDfe5IOO5H9akb3FLOzgEk9fer+lzbbhFPC5yCf0NVDIvyMACRzjGQcHripLdUWaNzyN3OD09qmauhxdnc9CtZJFhEgySAcZI6emenvWhvSSFXCod2CcqevY49/yrM0wh4AobDdh/XHTnpWosEYVwuMYHG44HqPX8K8uTPWp3cTLuomsb+K9iyYwfmIbHGcht31r0DwfrOJjaz26XEFyd4Vhko46MB36k5964+a3byfJbczEEYAHf9MH/AD3pvhLUTpss0dwxZIwwCYJycYB9RgnFXB3aZM1yq3cveJYLi7vmijulF/a2+VhLEtPErkoyH+8pDfIOgHcmneENbto7yVL5vKlZg4G0HJP6DOc56etL4r0xNS0Y32mhx4gtl+17Vf52hyfMA+nBA69cVR03xR/b2mINW07zY7bbHNfRxlT5jcK8gHBPbI5wBnJrRq6ujmhVdKTj0OvuERbmdo5C5JWVi7BcE8YI+vPA6Ee9dn4OKWTQCKedUvQRG4X5c9MgdyGz15wO46+aeGNVs5fElzpV1dvJbx5+y3EsgzGwXayEnjGBwD2Fa15rMhieG0gMNuxP7yJWCEDjCnJz+feudwcWenTxHt4ezuegeINUlh1cxX38caQlEVGDgnOW68Fj1GMiuG8Y6c9lfksS8JYGCYNnK44GR3B7nnGKr20quPMluYrXcu9JCx3rzxjA47fzrqfEF3CfC9xJ51vcZEb/ACglxIcbwBxxgA4ONueM1TXMjdSVBrl1PPop5FUjyopFYY+Zj/jye9KJd8YB25HGT6+v4/0qYwLPYQzxOqzyyMDbs3OM4DD07j/OKmttHvLoWyKYQJm8uNTMoYZ6gDOeMdT/ADrJwf8ASO6OJT3f9f19xTWPzSgR8iXAyBkkE4H45/zirOoNaSOqRR+UkShAAM7sZySCflJP4VFqUaWF1NavH+8j+UqCQS2MEnPQH0Hes2R28nzJQzB1+RnB5A4yOMnGf88U0tLCdVbkt5cITGLcMEYDcWbJZux3fxZ+g6e1UZbiSd23FzuOXLdSAc9O3P8AntSurSQmeNAsaYRzu+ZjjB6n+X+NauieHnvoS8isiKd2d4UAAdSM/r0oclBXbOSc3LRHReD4tumJgqsYbIypGSfvDd1O7gY6fQV1FlGjSbyrbSvPy84zjO3oeePoPalhtlhUByWfbtJyARgdC3Q7R2Hr3q3boNsYAVUQBdg4XtnKnnpzn157YrgqyvJvz9BRSS0JVRP3hb5gQflUEj/aA7jPGO3pjmljYhTlmEuOGyMk9M56HPSmRoMlXZlyAFk3dMdDu9h1B9eetOW2lSQqykMATjYOCP8AZ6cDnP8A+qsruyaQadWMaGJiwcL5ewnAzj3wPvZHT6ZpquzNu3HzRjGHHGeuD054HPp2qVmCojuwUI3DMxIHHHzdenbp+PFQwojE7JGXaMLuABx1HHQ468+tXFjaGM0rRyh+duS4K9ecZ29+cLkf1qheRF1lDYXaCOG4A/iUHt2AH4cVoTFZcKFCjowOThvfuOOfT9BVG9YLsOCNvCv3AA+U5+mc559ea0jv9xm9tDlNRXzYlDbd5xkk43HOM+jDtn/9dc6ZGtrhixYKcgj+5g8/7pHTj+VdTqCAGVULbGwwBHJ74I9R144rkJVeWR1kYAIeAw6fT049a7acm4/ecNZWdyr4ilae0kblN2R8p6nHIz3rx+fcHfr1Pf8ApXrOrAJaNG0of5eD0OOwPrivKZ/kmf5R1Py46V2Uex59TchBIxngUjDJB4+b2pQAScED0pjjBx/LvWjRF7iEfQ0qFlwefTikyQPalTB6kDHrSECnJOTx9OtWPkZckAY46fpVdcbuBwfelYsuQT+tVB2AfNGVPbn9aaA+OM/nT4gWBz6ZxjqKn4/2P+BGq5Lq5SOqdsk7coM9B2pFOcjr9adyBgnnrkd6YNoVemzv711LU5mKRgA5wAc7j2prFimO/qf880Ln+MfKKdIWLOFCjPQH/PeqtdhewyTPUkkAZI+vv2pCwIAJ4/z/AJ/GnjrycnHT1FMfksB1zwf6UguRPnOThQOoGeBUORgqAMk/w9eamO5X5OQP0H+eKil5GR0wQcj/ADml5D2IDHkkZ+7xUDLtGeRk9xViYlc4bDfpUW4bs8EZyDnr/k8UmCIyeig44xk1GQGfIzt47+39Ke/GNy5A7Hk+v4UmzJ3Atx83rSGRsuCCM7iAfp/kU+CUxOpBwAeAeMCm5A+9jrkDPahmDEEEen15/rUSQ0zvNFZ5YECjqM4VePcY7+tdHGWQHawBGDu9PQ56gVyfhqY7EbcQuBkcdPX8+K7CJxu3MAScggfqB3+ma8urpKx7GH1iPtPLkAwAN5AUdOPp3xyc1larbSLN9pg6x/K3JJ/+tkc1um3ABwCDkcggZPqexz04pfsm3KMdyhefQDPOB2x05rKM7anROlzKxPoOpWVs9tczwFGK+TFKIhIn3ehORk8nk5xnoMU3+xrW/e5t7lDZ3aJ5SvbjbI6r8wVuzHHQ+wrDdDY6j5G0C0dyxV24yeGAI/D/AOvW7Mgu4I302SdbqBAJIP48dQ8Yzk4xz+Y9K6oy6o4nBNtSOatPAHn6kDpuu2khd90Uc0DgNycBuMA8Hrx9K9bv/CrvYs+mzC1uXgXdtdYkcLwGxnk5y2VIOOtefi6NuWuGgJSQlmG0rtIPzhT/ABDpwema17zxJc39+9vb6q9jBLboHYKDuJX/AJZqRgE4ZcAjpkHtT5rxuzKpTUNjEjttYjv/AC7m2V5QcGSQB2I6DaG7HqCDg5HPSptQvGS4tIbFpoVkGJUnUsZ+Fbaw6Z4bHOOee9R2+u3dnPbWbta3lksAhEzIC8DOQCc4/gOcr0OT3o8V+LrhLaC1urUC9jYmSUj5sYwUDc5ToVIwecdqShZ6Eyryas2M08y3eq3R0/QpYYgMoLmTiBScqwyfp049Kl1iKWzufJO+3nJ3kYIyT0IY/eBGf15rR0K3sLpEutYMsdlNF5kJuJNhRjnBLHnGPT5Txn0rP1VbnWtQiOlXctrGiFHZj+5jUFsHccgDtg5B4xS5TWGJnHRamVe63OkiI9w8hQBQJYw2FByFwe3Yj8PerjpNdPJcRxGSH5cEFtu0/dUk9jg4HTj6VVt7KXzI4rmRbhkOBtTahOOu36Ac/wD1q7vStHL7JpJHaZgu52k5A/3u20cc/pWFWpGKO2nGpLV6FXRPDgvooJ7tI4jGgISNCGkAJ2M38PfHHYfU129rFHBbJF5ajGTkRnnJ6Z69fw/CnW1qlv8AulBZznKAfKvHQL3wOc+pzVyRgwy+wOONwJO0jjJPUYXr257V586kpXOlJbGe6qIjvcMeOmPn+nb5jxn61JDgq3mfMg7DJwAeuPvdfT+WTT0WJ22HCoxCquOvHTHRiBz798Yp0iBFUhmLZ4xyV47n+EY9PWseZvU1a6ERn3YJXdjKnByXOeRnpz7/AMqVXJicbQTnP3chueuO+Txx6fjS4SPawOxXzgk4x6HPQ4759ewqNFPmuijDddp7ZHTHsOeP8Klu2noNJdBZiWDOwYhshsEZx1I3Y456Z9O9V7SFkM3mtkSc7Rjax7nHR89OKssAY42jAP3dpPY4+U5+mSc1HEpzsUFTjC8DOM8Zzxx14/QVUG3qD0ViPJ80nJkVgU6klRnOR3Xn5cc/1qrcAyKfMxh8kkchm7gf3s9s81eABiMWBujkyAQcZxxgfeHGTzUJMZGN5GQCGZgCfTLdDjkkfyrdasyloczfhjENwBkTAJxz9cdvTiuR1nEcgdQTuBDbe/PI9SQfX9etdvfwhi6ggDsnX8l6jj5s/wBK4vxFbfZ90kTFjlQW9P7uW9/SumjKysjjxEbq5z9xE6xyeaQ5fOO4B9/r7V5nqEY+0zYIxknP+ea9Wk/eWpXPygfdC9ffb3I55rzDXInivnzkZPf1r0qPU8upuZZUgbgCPf8AnTWOWGf5dalR8Ek0xcM2FBJrSxmIehPb0zS7ccHr3/8A1UbQGXA3YPQ9DTW4zjp9KVu4DRnnNKOuDijceTnr706MgvyCfTn8qSEWoSBGWH5A+tRy5DfMMkjNR+YRwB04/Cjcx53sPxrVTSWg0u52rglcg54yM+v+eahJIwQcnv78cVKygq4OAo9D/n9KiU7idxOMdPWulW2OcUMoXK4yOeO349qc7dV4AOecZH+e9Iu3HPrTSBuC5+XoD609UMVeoY4Bz1zx09aifOcD7pxwKkOQNwOcDHNCcqDwSe3b/wCvR1sDIiQx57E4HPFREAkq/BPAJ7ehNSOMyHkk+oPFRtySOMN1xSAhZskhvTjFQnLHgk59MVYdFJII/H/PSoOVTOADx17+1IEQygK3ynp+X1pjOyg9Mn3/ADp4B43biTnkd+e9JI29hnIBPBpMoav3sHhM8Z9OxphTeWCduMHmnyqhVTkH2xxz196YilOQe/r1qGUkdV4Of5/LbGQ2QMZ5+nv1rt7UIAj7iN2PmycexJ615p4ZcvemJjhW65r0vT9wI3guBjBDd+/0B968zEr3j1MG7qxrIhkCqp9sEckfTp71bhjKnAC4DgZzxnsfX8OlRWjDJ6hefx5647ntx2q1JGjsVPyuCfwH8QHp7VxN2PUjG5WmtIbpSsiMI+gY4zjt044OffFY7abd2Vz51sFmiibCKBnb+HXpk8V00du0UW9CCCMNxwxPf/a9P1q5Gisd2PlIIKg4KDv05GOgxQqzgEsMp/1/X9eZxmn6gqQva3sXm28mAf3pR09GRuqn19az73So5nAttUuEtmyuydBuAyCBkEZ+YA59vc13l1oVlqLrGdizHJyeF3Y6A45z054zWc3hW33MszyjI6pzj3P8uOvWt44lWOOpgtXc4oaPeTyiOW7trgPIFczSeWWHJ5ccqCef8a2rpGuHjTWLs3cKKvlxJN8hw3cFSSfXaRmukt/C1kyZMsvGQcN0HcDv6Yz+FaFv4TskVnle6MnUrxt6dyeCMccc5oeL6kfUUtzh2kxNgqtwsXEMUjFkjHoB1weTzW5aRXd+qSTiafeVwSNq+zccHk9MdPrXVWug2ca70iQBe5Q5GfTuCOnoe3etiC3VXZ5FwxHJV+/1+6eD7ck1zzxPMzop4aEDC0nQIreWKQqGccugU9M9GPbn0+lb6BVVcPGiqPlC5wTnoPXcfX09asrAoO3zjGAFBGwkAY6gZyCBxUrLEAx27XwVBDAYHTlu+B0GPbqK5JylJf8ABOhNFYAAMJCzAjkAYLDd3HTr6fzyKsKN6cldxbaATw/qB35Prxxz2qS3Te53OWZRkKF6HsQv+7nkdzUgWJHgzJgqm7Ib7nHHzDkED880Jvdj0IPLRkwcMobJO0c++ehyeOOcD1pqhDEwlOPKzwVJIGcnaOoOe57flVkzEswjIDEn5Dzzjn2Ixznjn3qu4yhKYweQeTt9Cf4uB1x3P1rNJK1g33Kt4yyGM+Y7k8ckAE9xu6HJIHT+dCjlFfjIGeMZGeuPrxkenrxUixhCGHcbVHHT+XHXnuaZb7XdgnAHPzDgHtn8P7vf3pybcrl3VidwFhk3ODwwfbIRnnJG7644I96qlTGEDNk4JGUGSMjkKTjnOKkWQBmwzI2MIxPPHTkDjHXmo3EbkBgFXsAe+O/Y8EnjvQ2tlboSlbcbs3Ss5y0f8bA8f7Q3feHPHpx64qJlMQkSQfvTkkgABjnkgdMHgc4NSLLyNhJ8sAIxBYqcfL7qBzkHPNQShQxcAgSDpxzg8ZPRiOvFXGTtp5kyRRv4w4IG0kAkn05HPrkcLxx+FcfrcTSbxIBjLDr14+YDP4Y3fjiuzu1OE8rcdvKgDG3j0/hB5J61zuqfPJ0O3szc59MtjkjuDXXCVnqc1SN0cBC4xJGSc5wcdD/ngcV574lyNRkBycZ/Dn+lehairQ6g4jChXIGPu/59ciuD8Roov9xZT0O7mvUou9rHjVVZ6mKx5O1eTkHmmbfmYgkYzyBSvgkAcY4HrSB2XHQ+nNdHqZtWGZGc8YNLvJI6+wzTlYBff3FImN/bH0qfIBrn5SCOQfSjYVJB4IPIPBpCpLHByevWkyV4HQ+tISFGcg5H1pd/qCfxpAeMGlG08lsfhQvMZ2UpPIx5nOfSkClxtOMn9KcMc7ecdcnpTVXrgn5uSB/L3/8ArV237mVhoyoz7fiKcgJ5AIz2/wDrUiPvOc4I705mATDY+bPtn8KNwsNyOpyAOA1NcY46HP1/Snj7vHQ8elMcHBOT/u//AFu9CYNDACNwHb5t1REbjnJHtnrUzNzj/wCuKZIpyMjJ9OMH/wDXRfoFiq+emB6jHQeoqNyflbtn/wDV7cVOxwcLyOtM2KxOOmcE+tDBIgbAXOB6EYPFRiIljgAehz1p74LFtpA7kHr/AIUxyUUBycYyCf4hUPYpXIsP5mBwowM+noaVpG2BSB39v1p4ddxLbW5AIK1G4DcoccdRU3GkXtJbyrqORQB7EY/GvS9KucrD0Gent7fh15rymMNFMMBi2eg5z6ivTNB2zW6MSDgZzn9Sf0rixK0ud2DdpWOzs16AAbuBx3PvnjB5PHeriASMr5z0CZzwO3vkdTms2yfgKM5B4A5OPZfbpWxaA5Ln7qjBOc4PQ89s9AOma8mb6s96BZhj2RsHYKzYGPXnoT0Pr+VHkMP9WDlWJXIxjPQ46juSamSNSAQeW5xjqPUdjjp61OhRnKOMIvBXnCnuPXjtjI9KwfkarQrL8sqScA7fuseo9C3Q884P0rQh2OdsShM/NtbkNz12+/UkVXnh8qZS4DHGNwx+nbp8vPerS+WsattAReo/Hn3yOnFDlZ6ilZoUWwjZju8tGAKkMSDzwS3Uc9QabNLPFPGCzFcEbGiBDc9CvTrzUkQjYZjJV+nXgeoB7ADpnualEyM5jYbMjJUDuOM47kDjj1pXTehFrb6joQN8mSgOSMEnk9ueoyev0pYpJIGYbuDjAYAdSP8AgJ55+lNR1bYVZwTwOPmjx1Geq47deTTeSsolKYIHOQAf6Nxx25OetTqtgST3NFUZgD5iENu3g5O7P8snnj0+lSw8MzhQ23lWP8Xpk+5xnPOBVK2LhZAG+6MbT1TA9Oq7f61btnYp8w4bO47uM/gOcDnnv70NkOI+1jjKsTkluSmOvPPHfJ54P6VJKgMh3D5k6Mec+uP7ob39PpUMY8pRuID49CMYPUjtgdcdzUijynYyf6vomDgD2z1468/4VCT5bJf0xu173GSRozn5mO7qoP3/AF4/iJPp2HtT3PLFyCVGDgnA9eeq5/IfjSTIBIXG1H7g44z0z2xjnjnPvUZn37yh2RptAY87SP1+Xr360OVm79wtdCzECJSSNg9B9/tn0bnjnHH1qsAu4nBYFWyoXtn5hj+HnpjsPakkeRoyFUDj+96Z4z0OAc/U1D5hCfMCNvIGwnaexCnnpyff3qLpq5SgWF45ba+WOSTjJ4z8wHOenPTFNlXMTDLDaRkAckeuOnX5eO3tTQ/zAqxU8AMWAI7gFvb72D9fakbOGBAy3O0qAMnoQvQ+px3+tVd/mK2omFwxYBhjBHOM/wAQBHPPGM1HOGLbSfn5y46kevp6DjmmSSBZTtZlUDAYscjnjccZBHUg+3oKikkYNGEjwXJCg9DxnGOh4+bPWqUlt6CcbjZI/wDRm3BSqHlQOMY+bAzu4PQ9PTiue1VQCDjD4KlhgfUZ6YPTHWuicZRlLbge5Gdp/hyeozjJAyK53VgdjDGTgheOTzx9SOvzc10U3oYTRwHiRGSRthxtJb/9Q9R0z+IrzvxGQ8yty3tu6etem66gltmfOWTORj/PXrxXmPiAhXG1h/d4HbrmvYoO54mIVpGKpKsMY4oPzEkg5p/ylev4n6UgXqQQcd+ldK2MmDqgwBjODk+tJswM5/DNOUtnndg9Of60Nuyoxj/ZApuxJFggnt3GBmkLb2PqetSq+eGCsT/ET3qNUzkjHAPHrU+QCEDgcc45pMkcBgKOR+dOYuTn5j+FJIdjspOTkdF+bmmcgEtg5wPSpXzg5G5gORnp6/SmYD8ctk9K7OmhkIBwD8vX0PFLjHXB46ZzSgkLn0B/zmkXBUgcv6DqaYDWByRjAPr2pAMfL/EfXp+IqR2ydx+73IPWhVUE55Pp3x9KPICE5K5UceppjdiTx9P096ldiWJXAXv/AIUjAcj+LPpzSBIqSlThgMjpxUJDBcEsfcf55qztOwEgH1Ge2ahY5zwWwPy/+tSew0VgX3NgZ7Yx/nFMb7wz0I9f8asZAztz0ycGopAjN/s5wcd6TGRMgb7uQe+DkCmFH4wCSPanGNhITxx3I/pTlO0fPjgnALY/yahrQoZDnIOQT7j3r0DwuHeKNkPTsOfw/rzXFr2x97OMV1XhK6+zy4PKngk9hn/Irnrrmia0Jcs0d1Zs28qoA5yOwPoT6++K6SwfAQnLDHygnlR6eox157cVz9kyykkZ3HPAAz7jHT0x+tbtixRxlhuY8t2+vr6DmvHqrSx9DSd9TWt4GPKkYY8c8Me3PRs8mp4rfc22NumOuRgdie6++O1QR71ZiTg98kZI7+3HT1q7bMd+TgOM7sHhT3x36cZ5H4VyPe7N7v8Ar+v69CsvEx3uRkgKMcHnp/tc5OD9KnwZZGRc7weBgfgcdgT3H6VJOEYkhR0OSOuPr046YqtGr+e4Kn+IlQvQ4+bA68DvUvYpWlqPwFRWX5+vKn8MZ9c84Pb2p8DN5mVj37hjaQMn8Pf2P6UO0izLIHxt4LZx2/vduOMH1qUKqxbWQr1O3H4cL32j/Cpv1/QBqROLbcXDpkFSpJx6H15Pr2H1pHgDbiN7NznGF3Dvz068/SpVBCu6khsnqT125IJ6jirEQdbVNxKmYg7SvA49OhwP504q4m7f1/X9bjbVJkjBTbIM/PxxzwCB15PH4VZgXavOfXduw2M+o468c9h7GoYfMRW3Ls55wScDvnuMD0+lW2DqAXOGbGTx1x+vHrUt3RL3FMQ2cckA5HXdg9h7noR+HWgIxDEsrJ/fJOcdvm7ZPGMe1CqQjKx+QfwnsMdwP7vt6+lKAS3mkqCCMDPTI5Ge3GTz9PSi66kkabkh2yIGBOCgHL8jOF789D6D2qOQs25hgqnDkHofXPUA8Dv7dTVtRgLtAGQp6cexP97A67f0ps+du6JANueR/DwfxXA559amzsrAmiHKsp3Nt3bsYwC3PJHY88f5zUBCkscKSDyoz17+4yemPw5p0EhdlK8E9yQMnHGezcZ6fTvShYw22PK7cdRjbxwcdRtAzx+mKetx6IjEYba24sQfvAfqO2M8c/41JIqqkpYcnKkKMcfxd+ueBimBsZ2kJG3q3BOOBn+LjLc0gRlISMNgYblOnZTt7e+Pp0pxtYTv1K08W1WaQ7+Tgj19u4B6DP8AOldN9uWkUfL69/U8cEjpxSRoDKGbdtJwMng8dN3Xjk805pNrbE9AQCQCfTI6YPJyOaab3dxy7f1/X5jbsAoVZF3DOVGTs9QB/D2x161z2pR+ZK7OPkYcuO5x3P8AFzxj+tbjqX2lyNqgBB1wM8Z7gjk+lZWqcKWBbJ4Vfw6Z6Yxk+vbrW8Wk7ehg1ocJ4hiVYmjAKjGcE9up49vavLfEeBMIzjcp7HHP1/zivV9WQmTBwxG0rkEA+hx159q8z8VW4+0I4LD246ZNevh3qeLilqc28WMfTGB1pvlspIK9TnH86kAxgJtLdlx1qZX3DjBf0BPP+FdaONytqVQoPXGP71NdQcAZ9flNWVjBkJOSPU4/AUwx7iQOflH/ANYVXQq9yNk5DDOD0qI5RQccfTg1OdwbqBxn0ph5GGOcHAANDRS2GBsuWcDd37UqoG5yo7cmnBNyjaSDjPWkCqc5GOfQGpG0djLnLHp9RjiolQ/eUY9j2qWT5mO/BxxxxTATnkk4yQP611oxAD1xj/H3oiX7w5244x9KVsFW7+w70uCq4Xp2yKAQjEHHIGOw6j2phAVSFwcdMD+lPGQd5PP1/X/9dI2dzDbhPzoAiAUpnkNjB5prLufjp6gf0qeRSO2e2Cev0qEkAYxhevP+H+FK4IjJKgZPJHU81EdpOOQD2zUpAb749RzxUTBsFdvPc479abAhaMgEsAD2J4xVYxYIIBIPPHJFWZWLD5uwzkVGSqqMFvc4zUsY1AzuPbjn0qUx4G5Tz1BpI13feOB3P+elMlY5OAcYJPv649ahj8gChF+XAGOODWj4euJIb/IYYbH8XX2zWdvZcqckAnoelS2cuyVGIKv/AC5qJq6sVF63PWNHI8pduF4Bxj8jtrpLD96oZgNwOM5/Qt+uP681xWhXWYFzyCcHB9ufz9q67TnwoO44C5Bx29fUenNeNWjqe/h5c0Tesnb5QOnBG4dfQ479yT+PNWBLtztYgAcKT0Geh9MHnHSqSDKE4wTnIHQnuM9D7Yqb5uB0dB97pg4646qMcc/yrhkrI74pNly3Z2l82PBJIUDHBPb2OeTz/OpQMZYMOxU4OB6Z79eeKjhIWJg5ABzuIPt09GI4GOPwpzAOQwb5l6qMkj19wMdxWb31HuTgEYYrzxjIx36Z6deeachG3ZwynBHHftn6nrj8c0wSMY2yAFA6jkfXPfA4wfX0qRYgsuCmODlAuSvHPHbA9P0qVtoHqXYxGUO5stj5Tu7fXqOeeagX5diADlhwejdex+9knPH9RSgEkncqc/ezwOP73X7vHPc06NlBXHygjPbIH8uB6evFDJSsWo4z5iFX3BAvzHPHOAfVefXsMc0km9IySoO7OewbnkZ6Nk8/hTpnB2ggKozjknHHI456evGfzpUUhy7HGevtxwc9Dgdcc5/GjrYhd2OTcEPJOCCB93Pvt6rk/X3zmmqykFivA6nPXn1789j6fSpfvIqAFCvIXbjHHp14Bzkcc01Gk2buF3EDJI4OP73pj178e9D02EhSwACxnOc8de/P0DHuPSo5myhIII/vKCQcHg569eOfx4p0xKgIvGR8oPO0diFHoBnI+o6U9vublHI7ls446bu3HP4++aF5sNtSsFEe0lWOSQyYGW5+bjpyensPpTlXbMVb5ioznBxnv7jd/Tv0ojCnHlDDEqRlPbg7eh75Pr+dKwdBtw23bznnZjsT1XHXj8OaL9UDKdw+EyQxDD5iWAJ+b+90PPH0GenFLcRnd5fDdcrtJGeN2F68nofwpjvg8ZU7uCQBnIyPYjv9fzqFDvPyuQDjGSeB2z346nFSvPyKtYlKOMMHJbqXzyfff7nA59PbFRGJ4snYdrg5XbjPPzYXvz0IqZyGRXwc5+X246ZA9Pm5/nzUcoKW5YDdjBUEdT/CT6+p2/rTilYltkL+YZHXI3DOW6DPfnqM8Lg/TpWRq43Bs85GeOc+pA6Ng8Z6/wAq3LVSYldQVOMAEHgdh6jHXmsrVcElcDc2MKTwx7Z7Pnrx/Ot72syOtjitSw1yQ/cEMM5x6/TPtXmvjFVTa469CT0P09fTn+VetXlsGhV2OHUDHz84zwcfw98mvLfF6cSqyjAJA9M+me9erhZHjYyJx8Ei55X6nv8AlUkx3NwcqPy9arrEHGVYbsgD61JggAg8Yx16c+v613dTglEMDGc8Y5Hemb/VcgjjHb/ClZucYNPChSMglMjqKpFEasGcl2+Y8EVHIgxtQD345+uKtSoqtkY6YPv/AEqrhhlcAncOD6//AF6dx7kZUrnjB680qpkZAbH0FPyTtzx/+upXRRjY2R7Gk0VudS6BR688E9hSq3YYyvOCP8/pT49uSTk9uv8Anr6UxwSAp3Yxnmuq5zobEuHJU98Z9KQjjy+cD0709XxEdxOB/nFIOF+bp6f59aQ7C4AU8Hg4yT+maQKNhCDH8x+FK4AYEkkc9+tDJuJ44xjGKAIW5KkdunPpTM/L94gt6/0qQuAcfeY5Gc4prkYPfPYCmCI2X7oJJ9M9qiBILHGST9OaeVbaDnqeoHX/AOsaRsSE9gB+YqWNEGwFiGPHXOKryAM2MDnBGO9WXXC7vbqP1qFtyS9Sx6n396QxrB1Hf29qANjncTkY69qRWGRnGfoePWj752g/NnjJ/wA9algM2iRx8uCRgDHT8P1prJtf5ceoO6gqw5J49PT8KBK27Eg5GcAD16ik+w0dt4XmDW4Q889COcew9utd7pzA4AIwCAOeM+568+/FeWeHLvEwQMOuMD0+n6V6Pplwoc5JYjr7D0z29P0rzMTHVnq4SppY662OYVCklsDA7kdj6e57/WrIBjYMOF6AdgeuPXrz6VlWVyuOgx7dCe59DnpWrHtdsyDagHzuBjaMc89VxwO/9a8uotT14N9ScA7Qy53kDGQOeuPbnnOefWlt+ZAccLyAT7+nXOef84pq4EBTb14wFxuP8QHZuwH6ZqaFSJBu4ABLe3v6jjjisnsbJ6FqH51J3DceMZ4PoM9OTzg1JtUBNuCByBsP4Hb169T6DmqquxZ0zhR0IPPoQOxx059e9X4mEkYXauAfmXnA4wc9+nAx396z3YpaCqSyqw+bHfOe/Td25557c+1LtPl4QbmzkqVHzc9cdDuNRhcEMzbB1OOo+npjOOfWrEZRYnUjGcgqoweOo564Hp69+KXQl6bEy7WA+YlQOu84H1PUc/y9qmTAYIQGPpnO76Dodx5z7dqigPyBS2CDksG+7x27rxxz396lt2Xox2rkAgtjj1/2iP61W7TuZPS46HGGJbKjB3HJ78E9xk8cdvaklgTZhi3AyOANwzyAe+SO/YVI+VK4UAqOn/PPHXjquB9cZ96iVlUn+Ikn5gePqT/FgcfX6VNtLAn1QS5B2vlhuO4EdfcgdmOOnp25qQlfLBkYnAHzbucfXtzxz29qiClQR5ZUjGV242e2O2BzkH356VHHjaSxxk5DMcgH6+w4we5q27aBa4Jh1+6GB4ZM8N65H8We2MfhT5UDHIfcuDzgnHPUdxk8fQZ6CpVj+TbhkyOQTyB2OOnyj09fXFRkYk+bGwE9ckA46f3uBzzxk/hUJafd5A3d6FPyWJJcEF+owPmH8Xs3P049qjP+rJbLbWwcDn0PHbdwOOuO1W5HKuXQFGwMHAGPQ/3Tgdfc81RljBjx9xOu0qflx7HkEDn8fpSej08y1d7hI6xpvJBDA5O7g89d38Rzxz2FMmbJ8rBY8llx9Mjb0APGCP0piE+aTuIY8Bt4B9RlunTnB78+1OjUhAoHuFI6YHXbnqvXPvmne/4A1YMkopHzbTjfzj064yf7uD/9es3UIBvDuhEnO4AYJXPzD0I7DHOOlau/B3CP5lGD3I68Z7cc4P8A9aqsuGwUIJPKjHf+E4PDcZJPHqcdK0jt/wAEy1TON1tXWFyTgc5APGe/vzx7fSvN/G4jdXkRSiscgMdx6evT29a9P1dAZGwQUHbJyoHPXqMda868YIGtHAK9Sc9QT/LnrzXp4R+9Y83Gx9255ttdC3yk5B+Ujj3FSb1JJYnJ4J9vrTJGDZUKOO/P5mpGUYGG+gznI9M/rzXp6nlSIjywUYwowVPH5/nTgDlc8fMcfN+f0qOIFpMAn8s5qWORi5GcIcnGOP8A63+Fadbj2Q6Rm3MS3B6GmbwfvAdQCce1OAB3HhgSM4700x7hleMYz169jigQ3arOQB3zu6dqiZBwGGcD1FOyRnGQMfpUyzFeCWXvyvXPeiw2dZLwxHOMcjHQ/wCfWolDbjkdO2OnvT58pI46kfeNR7sY7sTxmt0r7GaYoZNpzk47jnH+JFOjBUEbOOmCM4P07VE/AMncECnlSMjjBGfr71QWEDLt2lhuIAz705sqCGyB0IzyPw9qagPLHHA5AFDDLbAflJ4471PUBCoOTk5Pf/PtTM/PnaSvUjOPrTz0cr2B/n/jUCDepbg4IznvVCFZh1Yc9QPTimMMsQeo9R39fypxRmO0nOO5NROSERs5Dcf5/KpY7jA2B0O0AHnt/wDqqAqSCRndk5wcfj71YcDeQCeBzVd04yzEr06DNLdjuMwONpPGOR1FDyLHCQiDcTu3eg9BTQrGQKx469aSRsKxyxC8DmpbtuC1BZVVgGXPGMfhxSRhGBPO8jjn9c0kioY1zneeOmRjNNCMDuVuQPXn86ltFdC7YSGG4Q89ckccV6NoFyrop3Ht8x7env8AnXlsOY3XONvfHHfNd94eJeFeAGPbJ57nnrjpxXLiYXVzqws+WVj0G0XJ+UkZHTcM/T046+tbdmMgANgrjbz+XuMjJPb8K5vR3/0XLZPOCR9evv6fSugsyJCqFf8AWdOex6/TpxXiVbHvU5M0bYKEBT5Rxzjrzxk98cnH/wCurcbbQUA+bI2gjp34HUd2z+PSqKbVjL44H3iOvvx056VMsYedIzj5xkcdu/PXIxj6flXO03ojoWu5cj+Q5jPLY+Ynr/dye/uDToZthGzOMDCnqBn07c/Nkf8A16hiRdjsfurgPjAPPUDtjp1p5jCuqMchgSOOM5wT69MDr0rNu24y0kgdSwZWbPBLcZ7c/wAWeTg0gRJWAUlWGMYQZYZ+U7enXk4P6U232M5O1gMEMA3ODzwfbGP84oKq0gQ4Ck7sBflBPB+XPpx1qWlcm9iWIosYcMOOOp55PGevqef/AK9W4JU8wfNgnBXJALeh9OeScf41WRBjJznHrz1x1+nFSqBgsVUoxORtHBJwcDofaq1SE9S15qNDgEsBwAxJ78cdQc8//W5pqsBKSCCC3BJBJz0G7phuuPbinxxiUkN9/G4EcD6+o44xSp5SxuWBCrndjnbyBwOhxwBn9Kq6b1Mr2Gq67cJyPlONvXnhsdeT3Hp7Gl2qUzkcgg9Oeem4ep5we31zTtqsqKVUGQbl7jk4+o4HaoJyNzlPlMe7cccqB6euAcc+9Fna9hLXRAhMTld+/wCYkBh97nghe+49SPSm3Mo3bg+4DkfMc4z/AHuo55+gqJisjYIwjE4AA46A/lxjGO/SpSc425V05Bz0+h7ccd/6UNpXT/qxfW5TV1G4ZZyx4Upjdz2GcHJ7/lVeQKVO3exGecE8Z4J7jLcccYFWSwKZxhZMjgdB7+uB06dTUU6/OqNgbMkYyQOgOOeOPfrWSSexqm7kBlKMCVJznJ/vc8gY68+vOBSSTCOTbk5BySTjJ6Zx/tHj5asHJjkkQ4K4yBwc9Bz3wPbvUU5/dxnop4XAAHfjHbA7ir21ZIRyxeXyc5GA3JP3ucenPHPYVTutqs6sNzZYEYzu6Ej0bJ/u+nGasoMySBQfMUEkZwBjAHI5PHY1Su3/AHBI4QMVU/3T0GB049ev0q7p6GdmmYGs7mkRlJxn72Ovv6rycemK8/8AE/HmCReCOcHk+oz357fhXoV+N8xG1VcLvAySOmOp56c49fauF8T7ZAzjOD8p6DpwP516OFT3PPxi908puyrXUhVcDOQo5A9vWm+bgc5HTjoPz9qmvIxBeEMMgt0HSk+/tcljkY7V61zxGyMkLEflAYkjAPb/AA60ImWDHByOST+tI6gN8rHBY8kClRCCvPoauOpV9BBweAcAdxjPr0oZscMABnBwCP8APpUm0Ku/sfz/ABqLHmD5j/FgcVexI5GAUZI4wQQQeKcDycIo55yO9MKIG4BHr9elPEOVGGKjHQGpvYbaW5//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large, eroded Merkel cell carcinoma nodule arising on the forearm.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Fitzpatrick, TB, Johnson, RA, Wolff, K, Suurmond, D. Color Atlas &amp; Synopsis of Clinical Dermatology. Common &amp; Serious Diseases. (4th Ed). McGraw-Hill, New York 2001. pgs. 268 &amp; 289. Copyright &copy; 2001 McGraw-Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_49_25362=[""].join("\n");
var outline_f24_49_25362=null;
var title_f24_49_25363="Sarcoidosis - papules on neck";
var content_f24_49_25363=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F56226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F56226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutaneous sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple skin-colored papules are present on the posterior neck.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_49_25363=[""].join("\n");
var outline_f24_49_25363=null;
var title_f24_49_25364="X-ray angulated fracture of proximal phalanx";
var content_f24_49_25364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    X-ray angulated fracture of proximal phalanx",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 333px; height: 656px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The AP (A, and magnified in B) and oblique x-ray (C, and magnified in D) reveal a ventrally angulated displaced fracture of the proximal shaft of the 5th proximal phalanx of the left hand (red arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_49_25364=[""].join("\n");
var outline_f24_49_25364=null;
var title_f24_49_25365="Captopril: Patient drug information";
var content_f24_49_25365=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Captopril: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=see_link\">",
"     see \"Captopril: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/20/18760?source=see_link\">",
"     see \"Captopril: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F145364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Capto&reg;;",
"     </li>",
"     <li>",
"      Capoten&reg;;",
"     </li>",
"     <li>",
"      Dom-Captopril;",
"     </li>",
"     <li>",
"      Mylan-Captopril;",
"     </li>",
"     <li>",
"      Nu-Capto;",
"     </li>",
"     <li>",
"      PMS-Captopril;",
"     </li>",
"     <li>",
"      Teva-Captopril",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help a weak heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691388",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help heart function after a heart attack.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691575",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to protect kidney function in diabetic patients who have protein loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat Raynaud's disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701703",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to captopril or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703368",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A block in the kidneys' arteries or hyperaldosteronism.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699474",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store liquid (suspension) in a refrigerator. Throw away any part not used after 1 month.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020796\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11677 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-213.134.24.46-F1BE05E961-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_49_25365=[""].join("\n");
var outline_f24_49_25365=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F145364\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020785\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020787\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020786\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020791\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020792\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020794\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020789\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020790\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020795\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020796\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9145?source=related_link\">",
"      Captopril: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/20/18760?source=related_link\">",
"      Captopril: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_49_25366="Osteoporosis prevention and treatment";
var content_f24_49_25366=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/49/25366/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/49/25366/contributors\" id=\"au5515\">",
"       Harold N Rosen, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/49/25366/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/49/25366/contributors\" id=\"se178\">",
"       Clifford J Rosen, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/49/25366/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/49/25366/contributors\" id=\"de1470\">",
"       Jean E Mulder, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?24/49/25366?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      OSTEOPOROSIS OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Osteoporosis is a common problem that causes bones to become abnormally thin, weakened, and easily broken (fractured). Women are at a higher risk for osteoporosis after menopause due to lower levels of estrogen, a female hormone that helps to maintain bone mass.",
"    </p>",
"    <p>",
"     Fortunately, preventive treatments are available that can help to maintain or increase bone density. For those already affected by osteoporosis, prompt diagnosis of bone loss and assessment of fracture risk are essential because therapies are available that can slow further loss of bone or increase bone density.",
"    </p>",
"    <p>",
"     This topic review discusses the therapies available for the prevention and treatment of osteoporosis. A separate topic discusses bone density testing. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=see_link\">",
"      \"Patient information: Bone density testing (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      OSTEOPOROSIS PREVENTION",
"     </span>",
"    </p>",
"    <p>",
"     Some of the most important treatments for preventing osteoporosis include diet, exercise, and not smoking. These recommendations apply to men and women. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"      \"Overview of the management of osteoporosis in postmenopausal women\"",
"     </a>",
"     and",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link\">",
"      \"Treatment of osteoporosis in men\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Diet",
"     </span>",
"     &nbsp;&mdash;&nbsp;An optimal diet for preventing or treating osteoporosis includes consuming an adequate number of protein and calories as well as optimal amounts of calcium and vitamin D, which are essential in helping to maintain proper bone formation and density.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h3\">",
"      Calcium intake",
"     </span>",
"     &nbsp;&mdash;&nbsp;Experts recommend that premenopausal women and men consume at least 1000 mg of calcium per day; this includes calcium in foods and beverages plus calcium supplements. Postmenopausal women should consume 1200 mg of calcium per day (total of diet plus supplements). However, you should not take more than 2000 mg calcium per day due to the possibility of side effects. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"      \"Patient information: Calcium and vitamin D for bone health (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The main dietary sources of calcium include milk and other dairy products, such as cottage cheese, yogurt, or hard cheese, and green vegetables, such as kale and broccoli (",
"     <a class=\"graphic graphic_table graphicRef67824 \" href=\"UTD.htm?28/58/29611\">",
"      table 1",
"     </a>",
"     ). A rough method of estimating dietary calcium intake is to multiply the number of dairy servings consumed each day by 300 mg. One serving is 8 oz of milk (236 mL) or yogurt (224 g), 1 oz (28 g) of hard cheese, or 16 oz (448 g) of cottage cheese.",
"    </p>",
"    <p>",
"     Calcium supplements (calcium carbonate or calcium citrate) may be suggested for women who cannot get enough calcium in their diet (",
"     <a class=\"graphic graphic_table graphicRef70454 \" href=\"UTD.htm?36/37/37468\">",
"      table 2",
"     </a>",
"     ). Calcium doses greater than 500",
"     <span class=\"nowrap\">",
"      mg/day",
"     </span>",
"     should be taken in divided doses (eg, once in morning and evening).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h3\">",
"      Vitamin D intake",
"     </span>",
"     &nbsp;&mdash;&nbsp;Experts recommend that men over 70 years and postmenopausal women consume 800 international units of vitamin D each day. This dose appears to reduce bone loss and fracture rate in older women and men who have adequate calcium intake (described above). Although the optimal intake has not been clearly established in premenopausal women or in younger men with osteoporosis, 600 international units of vitamin D daily is generally suggested. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=see_link\">",
"      \"Calcium and vitamin D supplementation in osteoporosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Milk supplemented with vitamin D is a primary dietary source of dietary vitamin D; it contains approximately 100 int. units per 8 oz (236 mL). Another good source is salmon, with approximately 600 int. units per 3.5 oz (98 g) serving. Experts recommend vitamin D supplementation for all patients with osteoporosis whose intake of vitamin D is below 400 int. units per day.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h3\">",
"      Protein supplements",
"     </span>",
"     &nbsp;&mdash;&nbsp;Protein supplements may be recommended in some people to ensure sufficient protein intake. This may be particularly important for those who have already had an osteoporotic fracture.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h3\">",
"      Alcohol, caffeine, and salt intake",
"     </span>",
"     &nbsp;&mdash;&nbsp;Drinking alcohol excessively (more than two drinks a day) can increase the risk of fracture due to an increased risk of falling, poor nutrition, etc., so it should be avoided.",
"    </p>",
"    <p>",
"     Restricting caffeine or salt has not been proven to prevent bone loss in people who consume an adequate amount of calcium.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Exercise",
"     </span>",
"     &nbsp;&mdash;&nbsp;Exercise may decrease fracture risk by improving bone mass in premenopausal women and helping to maintain bone density for women after menopause. Furthermore, exercise may decrease the tendency to fall due to weakness. Physical activity reduces the risk of hip fracture in older women as a result of increased muscle strength. Most experts recommend exercising for at least 30 minutes three times per week.",
"    </p>",
"    <p>",
"     The benefits of exercise are quickly lost when a person stops exercising. A regular, weight-bearing exercise regimen that a person enjoys improves the chances that the person will continue it over the long term. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"      \"Patient information: Exercise (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Smoking",
"     </span>",
"     &nbsp;&mdash;&nbsp;Stopping smoking is strongly recommended for bone health because smoking cigarettes is known to speed bone loss. One study suggested that women who smoke one pack per day throughout adulthood have a 5 to 10 percent reduction in bone density by menopause, resulting in an increased risk of fracture. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"      \"Patient information: Quitting smoking (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Falls",
"     </span>",
"     &nbsp;&mdash;&nbsp;Falling significantly increases the risk of osteoporotic fractures in older adults. Taking measures to prevent falls can decrease the risk of fractures. Such measures may include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Removing loose rugs and electrical cords or any other loose items in the home that could lead to tripping, slipping, and falling.",
"      </li>",
"      <li>",
"       Providing adequate lighting in all areas inside and around the home, including stairwells and entrance ways.",
"      </li>",
"      <li>",
"       Avoiding walking on slippery surfaces, such as ice or wet or polished floors.",
"      </li>",
"      <li>",
"       Avoiding walking in unfamiliar areas outside.",
"      </li>",
"      <li>",
"       Reviewing drug regimens to replace medications that may increase the risk of falls with those that are less likely to do so.",
"      </li>",
"      <li>",
"       Visiting an ophthalmologist or optometrist regularly to get the optimal eye glasses.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Prolonged therapy with",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     high doses of certain medications can increase bone loss. The use of these medications should be monitored by a healthcare provider and decreased or discontinued when possible. Such medications include the following:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Glucocorticoid medications (eg, prednisone)",
"      </li>",
"      <li>",
"       Heparin, a medication used to prevent and treat abnormal blood clotting (ie, anticoagulant)",
"      </li>",
"      <li>",
"       Certain antiepileptic drugs (eg, phenytoin, carbamazepine, primidone, phenobarbital, and valproate)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      OSTEOPOROSIS MEDICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     The non-drug measures discussed above can help to reduce bone loss. A medication or hormonal therapy may also be recommended for certain men and women who have or who are at risk for osteoporosis.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Who needs treatment with a medication?",
"     </span>",
"     &nbsp;&mdash;&nbsp;People with the highest risk of fracture are the ones most likely to benefit from drug therapy. In the United States, the National Osteoporosis Foundation (NOF) recommends use of a medication to treat postmenopausal women (and men &ge;50 years) with a history of hip or vertebral fracture or with osteoporosis (T-score &le;-2.5). An explanation of T-scores is provided in the table (",
"     <a class=\"graphic graphic_table graphicRef74669 \" href=\"UTD.htm?30/26/31147\">",
"      table 3",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     In addition, the NOF recommends drug therapy for people who have osteopenia (T-score between -1.0 and -2.5) and an estimated 10-year risk of hip or osteoporosis-related fracture &ge;3 or &ge;20 percent, respectively. The absolute risk of fracture can be calculated using the World Health Organization FRAX calculator (",
"     <a class=\"external\" href=\"file://www.shef.ac.uk/FRAX/\">",
"      www.shef.ac.uk/FRAX/",
"     </a>",
"     ), click on Calculation Tool, and select country.",
"    </p>",
"    <p>",
"     However, some people who do not meet these criteria will benefit from a medication to treat osteoporosis or osteopenia. The final decision about use of a medication should be shared between the patient and healthcare provider.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Treatment in premenopausal women",
"     </span>",
"     &nbsp;&mdash;&nbsp;The relationship between bone density and fracture risk in",
"     <strong>",
"      premenopausal",
"     </strong>",
"     women is not well defined. A premenopausal woman with low bone density may have little increased risk of fracture. Thus, bone density alone should not be used to diagnose osteoporosis in a premenopausal woman; further evaluation is generally recommended. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=see_link\">",
"      \"Evaluation and treatment of premenopausal osteoporosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Bisphosphonates",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bisphosphonates are medications that slow the breakdown and removal of bone (ie, resorption). They are widely used for the prevention and treatment of osteoporosis in postmenopausal women. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link\">",
"      \"Bisphosphonates in the management of osteoporosis in postmenopausal women\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     These drugs need to be taken first thing in the morning on an empty stomach with a full 8 oz glass of plain (not sparkling) water. The person must then wait:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       At least half an hour (with alendronate [Fosamax&reg;] and risedronate [Actonel&reg;]) before eating or taking any other medications.",
"      </li>",
"      <li>",
"       At least one hour (with ibandronate [Boniva&reg;]) before eating or taking any other medications.",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     These dosing instructions help ensure that the drugs will be absorbed, and also reduce the risk of side effects and potential complications.",
"    </p>",
"    <p>",
"     An enteric coated delayed-release formulation of risedronate is also available. Unlike immediate-release risedronate and other oral bisphosphonates, delayed-release risedronate is taken immediately after breakfast and with at least four ounces of water.",
"    </p>",
"    <p>",
"     Patients should remain upright (sitting or standing) for at least 30 minutes after taking any oral bisphosphonate to minimize the risk of reflux.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Side effects of bisphosphonates",
"     </span>",
"     &nbsp;&mdash;&nbsp;Most people who take bisphosphonates do not have any serious side effects related to the medication. However, it is important to closely follow the instructions for taking the medication; lying down or eating sooner than the recommended time after a dose increases the risk of stomach upset.",
"    </p>",
"    <p>",
"     There has been concern about use of bisphosphonates in people who require invasive dental work. A problem known as avascular necrosis or osteonecrosis of the jaw has developed in people who used bisphosphonates. The risk of this problem is very small in people who take bisphosphonates for osteoporosis prevention and treatment. However, there is a slightly higher risk of this problem when higher doses of bisphosphonates are given into a vein during cancer treatment.",
"    </p>",
"    <p>",
"     Experts do not think that it is necessary for most people to stop bisphosphonates before invasive dental work (eg, tooth extraction or implant). However, people who take a bisphosphonate as part of a treatment for cancer should consult their doctor before having invasive dental work.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Alendronate",
"     </span>",
"     &nbsp;&mdash;&nbsp;Alendronate (Fosamax&reg;) reduces vertebral and nonvertebral fractures, and decreases the loss of height associated with vertebral fractures. It is available as a pill that is taken once per day or once per week.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Risedronate",
"     </span>",
"     &nbsp;&mdash;&nbsp;Risedronate (Actonel&reg;) is approved for both prevention and treatment of osteoporosis. It can be taken once per day, once per week, or once per month. Risedronate reduces the risk of both vertebral and hip fractures.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Ibandronate",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ibandronate (Boniva&reg;) can be used for prevention and treatment of osteoporosis. It is available as a pill that is taken once per day or once per month. It is also available as an injection that is given into a vein once every three months. Although ibandronate reduces the risk of bone loss and spine fractures, there is no proof that it reduces the risk of hip fractures.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h3\">",
"      Zoledronic acid",
"     </span>",
"     &nbsp;&mdash;&nbsp;A once yearly intravenous dose of zoledronic acid (Reclast&reg;) is also available for the treatment of osteoporosis. This medication is given into a vein over 15 minutes and is usually well tolerated. Yearly intravenous zoledronic acid can improve bone density, decrease the risk of spine and hip fractures, and decrease the risk of recurrent fractures in high-risk patients with recent hip fracture [",
"     <a class=\"abstract\" href=\"UTD.htm?24/49/25366/abstract/1\">",
"      1",
"     </a>",
"     ].",
"    </p>",
"    <p>",
"     Side effects of zoledronic acid can include flu-like symptoms within 24 to 72 hours of the first dose. This may include a low grade fever, muscle and joint pain. Treatment with a fever-reducing medication (acetaminophen) generally improves the symptoms. Subsequent doses typically cause milder symptoms.",
"    </p>",
"    <p>",
"     Intravenous zoledronic acid is an appealing alternative for people who cannot tolerate oral bisphosphonates or who prefer a once yearly to a monthly, weekly, or daily regimen. However, the ideal duration of therapy and long-term safety (&gt;3 years) have not been established.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      \"Estrogen-like\" medications",
"     </span>",
"     &nbsp;&mdash;&nbsp;Certain medications, known as selective estrogen receptor modulators (SERMs), produce some estrogen-like effects in the bone. These medications provide protection against postmenopausal bone loss. In addition, SERMs decrease the risk of breast cancer in women who are at high risk. Currently available SERMs include raloxifene (Evista&reg;) and tamoxifen. Raloxifene can be used for the prevention and treatment of osteoporosis in postmenopausal women, although it may be less effective in preventing bone loss than bisphosphonates or estrogen. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/31/499?source=see_link\">",
"      \"Patient information: Medications for the prevention of breast cancer (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     SERMs are not recommended for premenopausal women.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Estrogen/progestin therapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;In the past, estrogen or estrogen-progestin therapy was considered the best way to prevent postmenopausal osteoporosis and was often used for treatment. Data from the Women's Health Initiative (WHI), a large clinical trial, found that combined estrogen-progestin treatment reduced hip and vertebral fracture risk by 34 percent. A similar reduction in fracture risk was seen in women who took estrogen alone.",
"    </p>",
"    <p>",
"     Estrogen had the additional advantage of controlling menopausal symptoms. However, the WHI found that estrogen plus progestin does not reduce the risk of coronary artery disease, and slightly increases the risk of breast cancer, stroke, and blood clots. The details of the WHI are discussed elsewhere. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=see_link\">",
"      \"Patient information: Postmenopausal hormone therapy (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Thus, estrogen is not recommended for the treatment or prevention of osteoporosis in postmenopausal women. However, some postmenopausal women continue to use estrogen, including women with persistent menopausal symptoms and those who cannot tolerate other types of osteoporosis treatment, and those women are usually protected against bone loss and so do not need to consider additional drugs to prevent bone loss.",
"    </p>",
"    <p>",
"     Estrogen may be an appropriate treatment for prevention of osteoporosis in young women whose ovaries do not make estrogen. This treatment may be given as a skin patch or orally, such as a birth control pill. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=see_link\">",
"      \"Patient information: Absent or irregular periods (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Calcitonin",
"     </span>",
"     &nbsp;&mdash;&nbsp;Calcitonin is a hormone produced by the thyroid gland that, together with parathyroid hormone, helps to regulate calcium concentrations in the body. Synthetic calcitonin is sometimes recommended as a treatment for osteoporosis. Calcitonin may be administered via nasal spray or injection (subcutaneous salmon calcitonin). Nasal administration is typically preferred due to ease of use and because the injections tend to cause more nausea and flushing. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43173?source=see_link\">",
"      \"Calcitonin in the prevention and treatment of osteoporosis\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Other drugs are usually recommended in preference to calcitonin because it is not clear if calcitonin improves bone other than the spine. However, due to its pain-relieving (analgesic) effects, calcitonin may be suggested as a first-line therapy for those who have a sudden, intense (acute) onset of pain due to vertebral fractures. The treatment regimen is typically changed once the acute pain subsides or if the pain fails to subside over a prolonged period (eg, four weeks).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Parathyroid hormone (PTH)",
"     </span>",
"     &nbsp;&mdash;&nbsp;PTH is produced by the parathyroid glands and stimulates both bone resorption and new bone formation. Intermittent administration stimulates formation more than resorption. Clinical trials suggest that PTH therapy is effective in both the prevention and treatment of osteoporosis in postmenopausal women and in men.",
"    </p>",
"    <p>",
"     A PTH preparation called Forteo&reg;, given by daily injection, is approved for the treatment of severe osteoporosis for two years. It is more effective at building spine bone density and reducing spine fracture risk than any other treatment. Because it requires a daily injection and is expensive, it is usually reserved for patients with severe hip or spine osteoporosis (T score &lt;-2.5",
"     <strong>",
"      and",
"     </strong>",
"     an osteoporosis-related fracture). It is not recommended for premenopausal women.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H2226558\">",
"     <span class=\"h2\">",
"      Denosumab",
"     </span>",
"     &nbsp;&mdash;&nbsp;Denosumab (Prolia&reg;) is an antibody directed against a factor (RANKL) involved in the formation of cells that break down bone. Denosumab improves bone mineral density and reduces fracture in postmenopausal women with osteoporosis. It is administered as an injection under the skin once every six months. Although denosumab is generally well tolerated, side effects can include skin infections (cellulitis) and eczema. A mild transient lowering of blood calcium levels has also been reported, but this is not usually a problem in patients with good kidney function, who are taking enough calcium and vitamin D.",
"    </p>",
"    <p>",
"     Because it is a new drug and there are no long-term safety data, denosumab is usually reserved for patients who are intolerant of or unresponsive to oral",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     intravenous bisphosphonates. Denosumab should not be given to patients with low blood calcium until it is corrected.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h1\">",
"      MONITORING RESPONSE TO TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Testing may be recommended to monitor a person's response to osteoporosis therapy. This may include measurement of bone mineral density (DXA scan) or laboratory tests that indicate bone turnover (ie, rate of new bone formation and breakdown). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=see_link\">",
"      \"Patient information: Bone density testing (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H26\">",
"     <span class=\"h1\">",
"      SUMMARY",
"     </span>",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Osteoporosis causes bones to become abnormally thin, weakened, and easily broken. This condition can be treated and prevented with diet, exercise, and not smoking.",
"      </li>",
"      <li>",
"       Calcium and vitamin D can prevent and treat thinning bones. The main dietary sources of calcium include milk and other dairy products, such as cottage cheese, yogurt, or hard cheese, and green vegetables, such as kale and broccoli (",
"       <a class=\"graphic graphic_table graphicRef67824 \" href=\"UTD.htm?28/58/29611\">",
"        table 1",
"       </a>",
"       ). Milk is a primary source of dietary vitamin D, containing approximately 100 international units per 8 oz (236 mL).",
"      </li>",
"      <li>",
"       Calcium and vitamin D can also be taken as a supplement (eg, in a pill) (",
"       <a class=\"graphic graphic_table graphicRef70454 \" href=\"UTD.htm?36/37/37468\">",
"        table 2",
"       </a>",
"       ). A total of at least 1000 mg of calcium per day (total diet plus supplement) is recommended for premenopausal women and men. Women after menopause should consume 1200 mg calcium per day (total diet plus supplement). Experts also recommend 800 international units (IU) of vitamin D each day for men over 70 years and postmenopausal women, and 600 international units daily for younger men and premenopausal women.",
"      </li>",
"      <li>",
"       Exercise can help to prevent and treat thinning bones. Exercise should be done for at least 30 minutes three times per week. Any weight-bearing exercise regimen is appropriate (eg, walking).",
"      </li>",
"      <li>",
"       Smoking cigarettes can cause bones to become thinner and weaker. Stopping smoking can reduce this risk.",
"      </li>",
"      <li>",
"       Falling can cause fractures in the elderly. Preventing falls can lower the risk of fractures.",
"      </li>",
"      <li>",
"       Some medications can cause bone thinning. Such medications include glucocorticoid medications (eg, prednisone), heparin, and certain antiepileptic drugs (eg, phenytoin, carbamazepine, primidone, phenobarbital, and valproate). Patients should ask their healthcare provider about the possibility that these medications should be replaced or the dose lowered. (See",
"       <a class=\"local\" href=\"#H11\">",
"        'Medications'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       There are several medications that help",
"       <strong>",
"        prevent",
"       </strong>",
"       osteoporosis in women after menopause. We think alendronate (Fosamax&reg;), risedronate (Actonel&reg;), or raloxifene (Evista&reg;) are the best medications for prevention. (See",
"       <a class=\"local\" href=\"#H15\">",
"        'Bisphosphonates'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Alendronate (Fosamax&reg;) or risedronate (Actonel&reg;) are recommended to",
"       <strong>",
"        treat",
"       </strong>",
"       women after menopause who have osteoporosis. (See",
"       <a class=\"local\" href=\"#H15\">",
"        'Bisphosphonates'",
"       </a>",
"       above.) Zoledronic acid (Reclast&reg;) or raloxifene (Evista&reg;) may be suggested for patients who cannot tolerate oral bisphosphonates, or who have difficulty taking the medication, including an inability to sit upright for 30 to 60 minutes.",
"      </li>",
"      <li>",
"       Denosumab (Prolia&reg;) improves bone density and reduces fracture in postmenopausal women with osteoporosis. It is another option for patients who are intolerant of or unresponsive to oral",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       intravenous bisphosphonates. (See",
"       <a class=\"local\" href=\"#H2226558\">",
"        'Denosumab'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Parathyroid hormone (Forteo&reg;) is another medication that can be used to treat osteoporosis. We recommend this medication for men or postmenopausal women with severe hip or spine osteoporosis. (See",
"       <a class=\"local\" href=\"#H24\">",
"        'Parathyroid hormone (PTH)'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Hormone replacement (eg, estrogen, progesterone) is not usually recommended to prevent osteoporosis in women after menopause. Hormone therapy is recommended for young women whose ovaries do not make estrogen normally. (See",
"       <a class=\"local\" href=\"#H22\">",
"        'Estrogen/progestin therapy'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Testing may be recommended to monitor how the bones respond to osteoporosis treatment. This may include a bone density scan (DXA) or laboratory tests. (See",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=see_link\">",
"        \"Patient information: Bone density testing (Beyond the Basics)\"",
"       </a>",
"       .)",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H27\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H271\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11168151\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/58/35746?source=see_link\">",
"      Patient information: Osteoporosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?39/27/40370?source=see_link\">",
"      Patient information: Menopause (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/12/36034?source=see_link\">",
"      Patient information: Calcium and vitamin D for bone health (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?10/45/10962?source=see_link\">",
"      Patient information: Vitamin D deficiency (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/6/23650?source=see_link\">",
"      Patient information: Bone density testing (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/39/20083?source=see_link\">",
"      Patient information: Exercise (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/6/2147?source=see_link\">",
"      Patient information: Primary hyperparathyroidism (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/53/27475?source=see_link\">",
"      Patient information: Paraplegia and quadriplegia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/46/23266?source=see_link\">",
"      Patient information: Aseptic necrosis of the hip (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?14/33/14867?source=see_link\">",
"      Patient information: Hip fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/63/27635?source=see_link\">",
"      Patient information: Vertebral compression fracture (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/41/6803?source=see_link\">",
"      Patient information: Medicines for osteoporosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/23/16754?source=see_link\">",
"      Patient information: Monoclonal gammopathy of undetermined significance (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11168168\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/29/1491?source=see_link\">",
"      Patient information: Bone density testing (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/60/23491?source=see_link\">",
"      Patient information: Calcium and vitamin D for bone health (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?32/4/32835?source=see_link\">",
"      Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/16/32001?source=see_link\">",
"      Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/42/7844?source=see_link\">",
"      Patient information: Exercise (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/31/499?source=see_link\">",
"      Patient information: Medications for the prevention of breast cancer (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=see_link\">",
"      Patient information: Absent or irregular periods (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H29\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/10/43173?source=see_link\">",
"      Calcitonin in the prevention and treatment of osteoporosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/56/12170?source=see_link\">",
"      Calcium and vitamin D supplementation in osteoporosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36213?source=see_link\">",
"      Clinical manifestations, diagnosis, and evaluation of osteoporosis in men",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11128?source=see_link\">",
"      Diagnosis and evaluation of osteoporosis in postmenopausal women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/35/42553?source=see_link\">",
"      Evaluation and treatment of premenopausal osteoporosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/54/30569?source=see_link\">",
"      Metabolic bone disease in inflammatory bowel disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/8/29830?source=see_link\">",
"      Metabolic bone disease in primary biliary cirrhosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/52/39754?source=see_link\">",
"      Overview of the management of osteoporosis in postmenopausal women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/53/3929?source=see_link\">",
"      Pathogenesis of osteoporosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/26/17831?source=see_link\">",
"      Postmenopausal hormone therapy in the prevention and treatment of osteoporosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/28/40393?source=see_link\">",
"      Screening for osteoporosis",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/58/31657?source=see_link\">",
"      Treatment of osteoporosis in men",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44487?source=see_link\">",
"      Use of biochemical markers of bone turnover in osteoporosis",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"      www.nlm.nih.gov/medlineplus/healthtopics.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Osteoporosis and Related Bone Diseases National Resource Center",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (800) 624-BONE (2663)",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;TTY: (202) 466-4315",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.osteo.org/\">",
"      www.osteo.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Osteoporosis Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Phone: (202) 223-2226",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nof.org/\">",
"      www.nof.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Women's Health Resource Center (NWHRC)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Toll-free: (877) 986-9472",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.healthywomen.org/\">",
"      www.healthywomen.org",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Osteoporosis Society of Canada",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;Phone: (416) 696-2663 x 294",
"     <br/>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.osteoporosis.ca/\">",
"      www.osteoporosis.ca/",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       The Hormone Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hormone.org/public/osteoporosis.cfm\">",
"      www.hormone.org/public/osteoporosis.cfm",
"     </a>",
"     , available in English, Spanish, French, Italian, German, and Portuguese)",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?24/49/25366/abstract/1-6\">",
"      1-6",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?24/49/25366?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25366/abstract/1\">",
"      Lyles KW, Col&oacute;n-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25366/abstract/2\">",
"      Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25366/abstract/3\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002; 288:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25366/abstract/4\">",
"      Fulton JP. New guidelines for the prevention and treatment of osteoporosis. National Osteoporosis Foundation. Med Health R I 1999; 82:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25366/abstract/5\">",
"      Gregg EW, Cauley JA, Seeley DG, et al. Physical activity and osteoporotic fracture risk in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med 1998; 129:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25366/abstract/6\">",
"      NIH Consensus conference. Optimal calcium intake. NIH Consensus Development Panel on Optimal Calcium Intake. JAMA 1994; 272:1942.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f24_49_25366=[""].join("\n");
var outline_f24_49_25366=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           OSTEOPOROSIS OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           OSTEOPOROSIS PREVENTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           OSTEOPOROSIS MEDICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25\">",
"           MONITORING RESPONSE TO TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H26\">",
"           SUMMARY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H27\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?28/58/29611\" title=\"table 1\">",
"           Foods with calcium PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?36/37/37468\" title=\"table 2\">",
"           Calcium supplements PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?30/26/31147\" title=\"table 3\">",
"           Bone density definitions PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f24_49_25367="Insulin detemir: Drug information";
var content_f24_49_25367=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Insulin detemir: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/8/6277?source=see_link\">",
"    see \"Insulin detemir: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/41/18070?source=see_link\">",
"    see \"Insulin detemir: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F2110562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Levemir&reg;;",
"     </li>",
"     <li>",
"      Levemir&reg; FlexPen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F2186123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Levemir&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F2110565\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Insulin, Intermediate- to Long-Acting",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F2110330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Insulin detemir is an intermediate-acting insulin administered by SubQ injection. When compared to insulin NPH, insulin detemir has slower, more prolonged absorption; duration of activity is dose-dependent. Insulin detemir may be given once or twice daily when used as the basal insulin component of therapy. Changing the basal insulin component from another insulin to insulin detemir can be done on a unit-to-unit basis. Insulin requirements vary dramatically between patients and dictate frequent monitoring and close medical supervision.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      General insulin dosing:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Diabetes mellitus, type 1:",
"     </b>",
"     SubQ:",
"     <b>",
"      Note:",
"     </b>",
"     Multiple daily doses are utilized and guided by blood glucose monitoring. Combinations of insulin formulations are commonly used. The daily doses presented below are expressed as the",
"     <b>",
"      total units/kg/day of all insulin formulations combined.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Usual maintenance range:",
"     </b>",
"     0.5-1 units/kg/day in divided doses. An estimate of anticipated needs may be based on body weight and/or activity factors as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Adolescents: May require &le;1.2 units/kg/day during growth spurts",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Nonobese: 0.4-0.6 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;\">",
"     Obese: 0.8-1.2 units/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Division of daily insulin requirement (\"conventional therapy\"):",
"     </b>",
"     Generally, 50% to 75% of the total daily dose (TDD) is given as an intermediate-acting (eg, insulin detemir) or a long-acting form of insulin (in 1-2 daily injections). The remaining portion of the TDD is then divided and administered before or at mealtimes (depending on the formulation) as a rapid-acting or short-acting form of insulin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Division of daily insulin requirement (\"intensive therapy\"):",
"     </b>",
"     Basal insulin delivery with 1 or 2 doses of intermediate-acting (eg, insulin detemir) or long-acting insulin formulations superimposed with doses of short- or rapid-acting insulin formulations 3 or more times daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Adjustment of dose:",
"     </b>",
"     Dosage must be titrated to achieve glucose control and avoid hypoglycemia. Adjust dose to maintain premeal and bedtime glucose in target range. Since combinations of agents are frequently used, dosage adjustment must address the individual component of the insulin regimen which most directly influences the blood glucose value in question, based on the known onset and duration of the insulin component. Treatment and monitoring regimens must be individualized. Also see Additional Information or Pharmacotherapy Pearls.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Insulin detemir-specific dosing:",
"     </b>",
"     Manufacturer recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Diabetes mellitus, type 1:",
"     </b>",
"     SubQ: Initial dose: Approximately one-third of the total daily insulin requirement administered in 1-2 divided doses. A rapid- or short-acting insulin should be used to complete the balance (~2/3) of the total daily insulin requirement.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Conversion from insulin glargine or NPH insulin:",
"     </b>",
"     May be substituted on an equivalent unit-per-unit basis; in one Type 2 diabetes clinical trial, higher doses of insulin detemir were required than insulin NPH.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Diabetes mellitus, type 2:",
"     </b>",
"     SubQ: Initial:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Inadequately controlled on oral antidiabetic agents:",
"     </b>",
"     10 units (or 0.1-0.2 units/kg) once daily in the evening; may also administer total daily dose in 2 divided doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Inadequately controlled on GLP-1 receptor agonist:",
"     </b>",
"     10 units once daily in the evening.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     <b>",
"      Conversion from insulin glargine or NPH insulin:",
"     </b>",
"     May be substituted on an equivalent unit-per-unit basis; in one Type 2 diabetes clinical trial, higher doses of insulin detemir were required than insulin NPH.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F2871771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/41/18070?source=see_link\">",
"      see \"Insulin detemir: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Diabetes mellitus, type 1:",
"     </b>",
"     Children &ge;2 years and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F2307962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F2110331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F8103745\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; insulin requirements may be reduced due to changes in insulin clearance or metabolism; monitor blood glucose closely.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2104225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levemir&reg;: 100 units/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Levemir&reg; FlexPen&reg;: 100 units/mL (3 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F2110321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2110194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Do",
"     <b>",
"      not",
"     </b>",
"     administer I.M or I.V.; for SubQ administration only:  Do not use if solution is viscous or cloudy; use only if clear and colorless with no visible particles.  Insulin detemir should be administered once or twice daily. When given once daily, administer with the evening meal or at bedtime.  When given twice daily, administer the evening dose with the evening meal, at bedtime, or 12 hours following the morning dose. Cold injections should be avoided. SubQ administration is usually made into the thighs, arms, or abdomen; rotate injection sites. Do not dilute or mix insulin detemir with any other insulin formulation or solution;",
"     <b>",
"      not",
"     </b>",
"     recommended for use in external SubQ insulin infusion pump.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F2110190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Insulin aspart, insulin glargine, insulin glulisine, insulin lispro, insulin NPH, insulin regular.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2110567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of type 1 diabetes mellitus (insulin dependent, IDDM) and type 2 diabetes mellitus (noninsulin dependent, NIDDM) to improve glycemic control",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F2110182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"       <b>",
"        <i>",
"         Due to the number of insulin preparations, it is essential to identify/clarify the type of insulin to be used.",
"        </i>",
"       </b>",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Insulin detemir is a clear solution, but it is NOT intended for I.V. or I.M. administration.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Cross-contamination may occur if insulin pens are shared among multiple patients. Steps should be taken to prohibit sharing of insulin pens.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F2110187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Primarily symptoms of hypoglycemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiovascular: Pallor, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fatigue, headache, hypothermia, loss of consciousness, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Redness, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Hunger, nausea, numbness of mouth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Atrophy or hypertrophy of SubQ fat tissue; edema, itching, pain or warmth at injection site; stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Muscle weakness, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Transient presbyopia or blurred vision",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, diaphoresis, local and/or systemic hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2110185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to insulin detemir or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2110571\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Allergic reactions, including anaphylaxis, may occur with insulin products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemia: The most common adverse effect of insulin is hypoglycemia. The timing of hypoglycemia differs among various insulin formulations. Hypoglycemia may result from increased work or exercise without eating; use of long-acting insulin preparations (eg, insulin detemir, insulin glargine) may delay recovery from hypoglycemia. Profound and prolonged episodes of hypoglycemia may result in convulsions, unconsciousness, temporary or permanent brain damage or even death. Insulin requirements may be altered during illness, emotional disturbances or other stressors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypokalemia: Insulin (especially I.V. insulin) causes a shift of potassium from the extracellular space to the intracellular space, possibly producing hypokalemia. If left untreated, hypokalemia may result in respiratory paralysis, ventricular arrhythmia and even death. Use with caution in patients at risk for hypokalemia (eg, loop diuretic use). Monitor serum potassium and supplement potassium when necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetic ketoacidosis (DKA): Should not be used in patients with DKA; use of an I.V. rapid acting or short acting insulin is preferred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment. Dosage requirements may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment. Dosage requirements may be reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Administration: Insulin detemir, although a clear solution, is",
"     <b>",
"      NOT",
"     </b>",
"     intended for I.V. or I.M. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Diabetes mellitus: The general objective of exogenous insulin therapy is to approximate the physiologic pattern of insulin secretion which is characterized by two distinct phases. Phase 1 insulin secretion suppresses hepatic glucose production and phase 2 insulin secretion occurs in response to carbohydrate ingestion; therefore, exogenous insulin therapy may consist of basal insulin (eg, intermediate- or long-acting insulin [eg, insulin detemir] via continuous subcutaneous insulin infusion [CSII]) and/or preprandial insulin (eg, short- or rapid-acting insulin) (see Related Information: Insulin Products). Patients with type 1 diabetes do not produce endogenous insulin; therefore, these patients require both basal and preprandial insulin administration. Patients with type 2 diabetes retain some beta-cell function in the early stages of their disease; however, as the disease progresses, phase 1 insulin secretion may become completely impaired and phase 2 insulin secretion becomes delayed and/or inadequate in response to meals. Therefore, patients with type 2 diabetes may be treated with oral antidiabetic agents, basal insulin, and/or preprandial insulin depending on the stage of disease and current glycemic control. Since treatment regimens often consist of multiple agents, dosage adjustments must address the specific phase of insulin release that is primarily contributing to the patient&rsquo;s impaired glycemic control. Treatment and monitoring regimens must be individualized.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dosage adjustments: The duration of action of insulin detemir is dose-dependent; consider this factor during dosage adjustment and titration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F2110324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F2110323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents (Thiazolidinedione): Insulin may enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: May enhance the hypoglycemic effect of Insulin.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate CALCIUM Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Edetate Disodium: May enhance the hypoglycemic effect of Insulin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Insulin may enhance the hyperglycemic effect of Quinolone Antibiotics. Insulin may enhance the hypoglycemic effect of Quinolone Antibiotics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F2110326\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: Use caution with ethanol; may increase risk of hypoglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Use caution with alfalfa, aloe, bilberry, bitter melon, burdock, celery, damiana, fenugreek, garcinia, garlic, ginger, ginseng (American), gymnema, marshmallow, stinging nettle; may increase risk of hypoglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F2110568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F2110569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose-related adverse events were observed in animal reproduction studies. Limited information is available related to the use of insulin detemir in pregnancy. Maternal hyperglycemia can be associated with adverse effects in the fetus, including macrosomia, neonatal hyperglycemia, and hyperbilirubinemia; the risk of congenital malformations is increased when the Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     is &gt;1% above the normal range. Insulin requirements tend to fall during the first trimester of pregnancy and increase in the later trimesters, peaking at 28-32 weeks of gestation. Following delivery, insulin requirements decrease rapidly. Diabetes can also be associated with adverse effects in the mother. Poorly treated diabetes may cause end-organ damage that may in turn negatively affect obstetric outcomes. Physiologic glucose levels should be maintained prior to and during pregnancy to decrease the risk of adverse events in the fetus and the mother. Insulin is the drug of choice for the control of diabetes mellitus during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F2110322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F2110184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if insulin detemir distributes into breast milk. Endogenous insulin can be found in breast milk. Plasma glucose concentrations in the mother affect glucose concentrations in breast milk. The gastrointestinal tract destroys insulin when administered orally; therefore, insulin is not expected to be absorbed intact by the breast-feeding infant. All types of insulin are safe for use while breast-feeding. Although use of insulin detemir is compatible with breast-feeding, the manufacturer recommends that caution be used when insulin detemir is used by nursing women. Due to increased calorie expenditure, women with diabetes may require less insulin while nursing.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F2110193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Individualized medical nutrition therapy (MNT) based on ADA recommendations is an integral part of therapy.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F3422163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Levemir FlexPen Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/mL (3 mL): $54.47",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Levemir Subcutaneous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 units/mL (10 mL): $162.14",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2110332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diabetes mellitus: Plasma glucose, electrolytes, Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     , lipid profile, renal function",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F2110580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Therapeutic, serum insulin (fasting): 5-20 &mu;IU/mL (SI: 35-145 pmol/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Glucose, fasting:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Newborns: 60-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 60-110 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Elderly: 100-180 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes mellitus (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak postprandial capillary plasma glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Insulina Levemir (AR);",
"     </li>",
"     <li>",
"      Levemir (AT, AU, BE, BG, BR, CH, CN, CZ, DE, DK, FI, FR, GB, GR, HN, ID, IE, IL, IT, KP, MX, MY, NL, NO, PH, PT, RU, SE, SG, TH, TR, TW, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2110327\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Insulin acts via specific membrane-bound receptors on target tissues to regulate metabolism of carbohydrate, protein, and fats. Target organs for insulin include the liver, skeletal muscle, and adipose tissue.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Within the liver, insulin stimulates hepatic glycogen synthesis. Insulin promotes hepatic synthesis of fatty acids, which are released into the circulation as lipoproteins. Skeletal muscle effects of insulin include increased protein synthesis and increased glycogen synthesis. Within adipose tissue, insulin stimulates the processing of circulating lipoproteins to provide free fatty acids, facilitating triglyceride synthesis and storage by adipocytes; also directly inhibits the hydrolysis of triglycerides. In addition, insulin stimulates the cellular uptake of amino acids and increases cellular permeability to several ions, including potassium, magnesium, and phosphate. By activating sodium-potassium ATPases, insulin promotes the intracellular movement of potassium.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Normally secreted by the pancreas, insulin products are manufactured for pharmacologic use through recombinant DNA technology using either",
"     <i>",
"      E. coli",
"     </i>",
"     or",
"     <i>",
"      Saccharomyces cerevisiae",
"     </i>",
"     . Insulins are categorized based on the onset, peak, and duration of effect (eg, rapid-, short-, intermediate-, and long-acting insulin). Insulin detemir is an intermediate- to long-acting insulin analog.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2110581\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Rate of absorption, onset, and duration of activity may be affected by site of injection, exercise, presence of lipodystrophy, local blood supply, and/or temperature.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 3-4 hours",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:2em;\">",
"     Peak effect: 3-9 hours (Plank, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Dose dependent: 6-23 hours;",
"     <b>",
"      Note:",
"     </b>",
"     Duration is dose-dependent. At lower dosages (0.1-0.2 units/kg), mean duration is variable (5.7-12.1 hours). At 0.4 units/kg, the mean duration was 19.9 hours. At high dosages (&ge;0.8 units/kg) the duration is longer and less variable (mean of 22-23 hours) (Plank, 2005).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 0.1 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;98% (albumin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: 60%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 5-7 hours (dose-dependent)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak, plasma: 6-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/49/25367/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/49/25367/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, \"Canadian Diabetes Association 2008 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada,\"",
"      <i>",
"       Can J Diabetes",
"      </i>",
"      , 20078, 32(Suppl 1):1-201.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Danne T, Lupke K, Walte K, et al, &ldquo;Insulin Detemir is Characterized by a Consistent Pharmacokinetic Profile Across Age-Groups in Children, Adolescents, and Adults With Type 1 Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2003, 26(11):3087-92.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/49/25367/abstract-text/14578244/pubmed\" id=\"14578244\" target=\"_blank\">",
"        14578244",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Davies M, Storms F, Shutler S, et al, &ldquo;Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2005, 28(6):1282-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/49/25367/abstract-text/15920040/pubmed\" id=\"15920040\" target=\"_blank\">",
"        15920040",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heise T, Nosek L, Ronn BB, et al , &ldquo;Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes,&rdquo;",
"      <i>",
"       Diabetes",
"      </i>",
"      , 2004, 53(6):1614-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/49/25367/abstract-text/15161770/pubmed\" id=\"15161770\" target=\"_blank\">",
"        15161770",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hermansen K, Davies M, Derezinski T, et al, &ldquo;A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2006, 29(6):1269-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/49/25367/abstract-text/16732007/pubmed\" id=\"16732007\" target=\"_blank\">",
"        16732007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Home P, Bartley P, Russell-Jones D, et al, &ldquo;Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2004, 27(5):1081-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/49/25367/abstract-text/15111525/pubmed\" id=\"15111525\" target=\"_blank\">",
"        15111525",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kirkman M, Briscoe VJ, Clark N, et al, \"Diabetes in Older Adults: A Consensus Report,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012; doi: 10.1111/jgs.12035.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/49/25367/abstract-text/23106132/pubmed\" id=\"23106132\" target=\"_blank\">",
"        23106132",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Le-Floch JP, Levy M, Mosnier-Pudar H, et al, &ldquo;Comparison of Once- Versus Twice-Daily Administration of Insulin Detemir, Used With Mealtime Insulin Aspart, in Basal-Bolus Therapy for Type 1 Diabetes: Assessment of Detemir Administration in a Progressive Treat-to-Target trial (ADAPT),&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2009, 32(1):32-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/49/25367/abstract-text/8945928/pubmed\" id=\"8945928\" target=\"_blank\">",
"        8945928",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Philis-Tsimikas A, Charpentier G, Glauson P, et al, &ldquo;Comparison of Once-daily Insulin Detemir With NPH Insulin Added to a Regimen of Oral Antidiabetic Drugs in Poorly Controlled Type 2 Diabetes,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2006, 28(10):1569-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/49/25367/abstract-text/17157113/pubmed\" id=\"17157113\" target=\"_blank\">",
"        17157113",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Plank J, Bodenlenz M, Sinner F, et al, &ldquo;A Double-Blind, Randomized, Dose-Response Study Investigating the Pharmacodynamic and Pharmacokinetic Properties of the Long-Acting Insulin Analog Detemir,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2005, 28(5):1107-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/49/25367/abstract-text/15855574/pubmed\" id=\"15855574\" target=\"_blank\">",
"        15855574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Porcellati F, Rossetti P, Busciantella NR, et al, &ldquo;Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: A Double-Blind, Randomized,Crossover Study,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2007, 30(10):2447-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/49/25367/abstract-text/17623819/pubmed\" id=\"17623819\" target=\"_blank\">",
"        17623819",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/49/25367/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rodbard HW, Jellinger PS, Davidson JA, et al, &ldquo;Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on Type 2 Diabetes Mellitus: An Algorithm for Glycemic Control,&rdquo;",
"      <i>",
"       Endocr Pract",
"      </i>",
"      , 2009, 15(6):540-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/49/25367/abstract-text/19858063/pubmed\" id=\"19858063\" target=\"_blank\">",
"        19858063",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Russell-Jones D, Simpson R, Hylleberg B, et al, &ldquo;Effects of QD insulin Detemir or Neutral Protamine Hagedorn on Blood Glucose Control in Patients With Type 1 Diabetes Mellitus Using a Basal-Bolus Regimen,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2004, 26(5):724-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/49/25367/abstract-text/15220016/pubmed\" id=\"15220016\" target=\"_blank\">",
"        15220016",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silverstein J, Klingensmith G, Copeland K, et al, &ldquo;Care of Children and Adolescents With Type 1 Diabetes: A Statement of the American Diabetes Association,&rdquo;",
"      <i>",
"       Diabetes Care,",
"      </i>",
"      2005, 28(1):186-212.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/49/25367/abstract-text/15616254/pubmed\" id=\"15616254\" target=\"_blank\">",
"        15616254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9022 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-65E6C3AFCD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_49_25367=[""].join("\n");
var outline_f24_49_25367=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110562\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2186123\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110565\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110330\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2871771\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2307962\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110331\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8103745\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2104225\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110321\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110194\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110190\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110567\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110182\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110187\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110185\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110571\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110324\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110323\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110326\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110568\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110569\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110322\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110184\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110193\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3422163\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110332\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110580\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869458\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110327\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2110581\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9022\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9022|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/8/6277?source=related_link\">",
"      Insulin detemir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/41/18070?source=related_link\">",
"      Insulin detemir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_49_25368="Solar lentigo back";
var content_f24_49_25368=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86484%7EDERM%2F61452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86484%7EDERM%2F61452&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Solar lentigines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Solar lentigines presenting as brown macules on the dorsum of the hand",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigC5pcZku0x2r1Pw3ZERKQPmxgV5t4dQPfDPSvaNDt/KsY5CvGCTk8e1ZzOuhpEq3wUSyOVAWNdi49fX86zndjC6rhF6bs4yO5q3qjAtHADkj5n/oKyb5w4wCfKX5cDox9PpWdjqvZGfeSC6ZYoQREvJOMFjWhplmiAOQDnr9fQetQwW5c9AQBk4GATW1pFuso3O2FUcH0FDBRtqVnEm4mLCHGCR/LPrSLalx8oMjDkqo/mas3LmSVLe3+6DjPr6102l2cMUA3kAAZJPVjWXNqbqJx76VcMB8qIp5zyTQNCOd8rM/PQLivSrTSpbpC0Me1ccF+uPpWla+FkYq0vzPjkGpdRmigup5pa6TAkYEce5j1XGaLrwoNQTBt1jHXIXnNewxaLDBEECqAfQDNST6cqRkptxjjihTZMoJ7Hzdrfh6/0pmMTtLF3HXFZMWoPFJtmZkf34r6B1HSDcbt8KFj29a878ReFYwzkoEHJGBmtI1e5lKgnsczbaqJADJK8jehNXbfUgpBJPzdqzF0ONZsM5UHoy5qy2kXVvjyZBIh5O5SP1rTmTMHGUS69y8obgjPbk1E1wVG0Oc4w3HQelV4lu4/lEB5GcA8GrVpCXdRLAw7ZVc0mxqLejIzM8gMcY5PTA/SrNrob3DD7VJt9VArd0/TGlkRU/ebjg7RjFdTb6QlqSLll3dfJX+p7VnKRtGHRHGxeHrcfIhYL9OT+VbdloEQCrHBzjOSefyFdZBYyvu8iNGP+yPlHtWvZWSpzdeU8naJOWPHfHSpUm9jVUdNThW8NiaHYzKCf9iuU1rwJMG8y2P7z+8oxXupsJpYg5gWGPpiNe/ux61lXdmInB35X3PNLnsxOndHz48s+nv9l1GF1cH5Wxw1b2i6kZrdbcMvmE7Ax9K7Hxp4egv7V8MC2OAeteRsJtA1AfaQWiB4YGuiEubRnJOk4e8evOjxQKFOQBzxWPq1oZuI1A+XIGeSapaL4kFw0UdtcGRGH3W5Nb0CRu80jzLFjOCSBiqlF30IjNWueV6/YhJNyjnPWpdKZLmHyJgoccH3rpPEa2s0LLJdW7HJAI4NcJLN9jucJIp2nKuKvldjOUle5oan4eSQ8Dax6MveuX1HS7mxciWNig/jA4rudO1MXMQEmCRWqqxXUBhmA3Y4J7iglwUtjyKiuh8Q6C9kzT2w32+eQP4a56qMJRcXZhRRRQSFFFFMBaWk7UUgCkpaSmAUUUtACUUUUAFFFFIAooooAKKKKACiiigDZ8M/8fbdM5Uc/WvcpI9mkxlTlCF57cV4T4bYDVYUbo7AfrXuOpXSLpiqASsaevXis57nVRehzsQN5c3DrnBPGB1x0rPvdq3TRKcJF8oHqe9aVpc/2ZpX2grlz9wdyapaTZPLIZLgHb99h/jWb0OpPUsWxMdmUVQXYdT0xVvSsvAXC7m6Bew/+vVa4lAiKquZZQQieg9TW9p1t9ltY0CbpMcDpk+/oKhs0Q7TbMWnmz3BUyngKR69gK6fQLBXZZJVLMevtWDp0D3Gob5iTt/Ku20IbLgg46cVi2dMYm5ZIFCkD2x7VrRwjaHwQCOo7n0o0y3RgxkYBFAJzV8W7TuH27I8YVRSsVdIzdkhG47gvYVVltm2kOxPoK25n8rCk/Kwwc9qpq6Sgoqnd6j/ABp8o7mHdwFlbaWyvUg1iX9sBGQ0QOR0x0rr5IpEJIKgnpxxWPf2krDcMn1BGDRaw0kzzXU9JRXZx8qk5GRkVShs3yqFsr1x2ru7+0/d4KtnPQmsiW3WOUBlbjrgc1N2hSgmVtN063I2ToCT0IwMVqW+ixYwXhAHI2jI/HFTwDyuDJhT935a3dMd8LmQSAnmPbgZ7VqpXMfZ8ruYCaY2/wAuJpnOfuxJj9a1rTT2tHBlto0GPlaZt5z7Adf1rchkiG6RAdw+9kfdq/ZWs1womjtAzN/y0nbIA9Qvb8aTXY00S1MSDT5512hpI4SeSAFLfh2rQs7KSGNVhRIUUkl8ZJ/E1aiScljBKzKB8wHCgfWmwqrk7i2VPO/rUJstFi3hjZD5ju7Y4yc1nX9ig6IMZwPSt3T181yIH3ADdvI4/CqN2rCbCNuKnDNjiqa0uRH4mctf2ETIpK4boeK8z8beG4pt48vGcnGM169fWrS5DsRz2FYms2SPb5UDAAH40RbTFOK6nyvcWtxpl+YySoU8GtKGaSaPLStu6jLHk12XjDRwZBJhV5PX+tZFhorO+5V2xrjf32Z7n2/wrqjNtHn1KCT02MuLTLi7I2oGY+hLk1MfC8rKco2PdcCu003RAbhULosg6bGADfjXTafbCHguGUcbeSc/hUSmy4UY9jyAeHbm2O+KSRT2+Xg1Il5dWrf6THkD+ICvZ7jTrW42jypI2HU7QVH5c1zWr+HkkLAFJD/CydPzqVVktzR0I9NDkormG7jIODuHK9jXIa1oghmLwfLGx+76V0mp6FdafKWiPPb0NVYL2O4b7PdqY26bT6/Wtoyvqjmq00tGcZNayxclSV9RVeu3n0l9u6E7164HJrA1HTXV2KqA3p0rRHJKFtjHopSCDg9aSmZi0UlFACiikpaYCUUUUAFFFFABRRRSAKKKKACiiigAooooAns5Tb3cUoOCjhv1r1e71AT6UhzjzAoB/nXkNdXo9893BbW38SHaT/n2pNGtKVmdcJDOIpZhiBOIh/Wr8czOxgtEMsjkDHYD3qta2cupyoIYy1vFiOMdN7f4CuxsNLg0HTWlnObhume5/wAKxkzsh5mJFpjWMqb/AN7cOPmb0/8ArV0TIQBEi/veM/4Vn6bG8ztcyN9843MK2Wfy49sRDMfvOeo96xkzqUb6Edo32aJkC5Yk5b3rpdBjV/mYlmcdycVzkUByFjBYHr7Cup0SNY7eQK3zlcAmsjrS0OisUaR0VXxzxg8YrcitHaARSSsXxxg1jaYvkKDk/KPWteOdki8zqwHJB5/KtIqxE/IgazQyqGztHyOx5JqUJFGoYbQvqOOKhNygkwR8+MkYySabJJIEf924UDv0pXQ+Vvckv4jsD7hjoD61lygBFExIAAOfWprt2MWC7MO+O1ZUjEbAzE442k9cVMmUo2M/U5nL4IBB6fSs6e3eULIwO/0x1Fat/PbosaTOqs2BjPQ+lQtuLB4QXjHHPbFZtlEEMKzwkSqSF7GrkEY81DHLjoMdxVAXscW5jlTz8jd63dNjjkjd3O09QcirRjJ2NG3tYGgUMrNIox6g1dKXIRFJZ4cfKpIXbj1A7VQinDIctg9W2ADIxj8aupIB5ZcooT/nox59sVfQlXZK10PJMaKgVedkQwB9Say7a7F7OEuJQqI2BtHBNLfOZQ5eMRx88gcms23s0aYFLg4X5grDGKybNYpJHU2snly+VHMSxGGYjKqO9RyOpL5YhAeMDGahAlW2EkY+XpuA6E1Gm0Hyix+QAnP860fYlK+pFgSToDkAng56cZNZOqwDZkAjBBP6iteZ1BZpBg7TjH0rNvZvOR9o5K5Ax6UkJ67Hn3iPTRKLmMjJZS4OPT/61c9YHy1WXG1dvlSkDJAHAPuMV2euwiQqkWS4UHjqT3FZthYJ5fzggyKcnrz0H9Qa1izGpHTUs2MSLOLa7iiYE4jkUjBzyAc/hit+2tQsht5Lfy5Oqk9MelZtrbJaN9hvoUkU/wCpkPQg9Bu/xrZshb25SK5EigYCsXJx+NDFDQLhAqbbhNicgPGvB+orN+wA7zsHl5+6O3vXWC0wP9DY7W6hhkH8KrmGJWUTgxyYwRnis2jVNWOC13RlI+VQM9BXm2v+H13sdpz1B7/Svb9XjhAZZCSenJORXIalZxeYVHO7p7f/AK6pNp6EON0eMSyajpEgzmWHtnmtGDWtM1RBDfxKrHgOBgiu1utKSfzIHjweqEj9K4rVPDOyQvGhxkqa6I1DjqUbPQjfw/ZzFntZo5VPRW+8Kw9T0AwjfAxHqj9a3F0xgdtoGt34HzPlWPsfWo2uZon2XkbjHXHIrZTj1OaVFvocS6sjFWGCKbXZSadZ34OOH65HUVg3mkyRE+SfMA7YwafmjJwaMuilIIJBGDSUiAooopgFFFFABRRRSAKKWkoAKKKKACiiigArrPh/pNzqmqCKAMFOCz9lFcxbRGadEHc19D/DPRYtP0mKcoFnfkmonK2hvRhd3Or0PQ7XTrQYVc28ZGT3OOtc1qbNq18ScraRjaCeMgd62tcvXkdoLZsrjMpB7elc9rd1Goht4DySNwA7VzydzvjGzHmWPzNsa4QYCKP51etIecsdwzk+9ZiBDHvY/OTj610ukRxrCu5eW7E9aiSudMDR0e3Mx3sAu45x7dK6WO0QvHhRsj6n3xVfTbdAFwo3k9cdBWubdVUgNJwfug9ag0uQJmN2SMlj3z0x/wDqp4nDuEZicHJUfyqZrIqrebMAW5+7UQs0iBYSBWPOBmr16DvfUrtM28rgYHQAU9pnAIOTn3wPrULK6zPsZWI4POKh3ku0UjGIkdWBOfoazehqrNGkWLxk4JOMduKxdShmMMmzO8/dB61fiXzIx5bHbnJKrxT4Idsuy2WVmb+8oP60k7ibtqeYLbTw69Da3IZ5XfcVJzx616Da2jRwBQPcnpg1oR6CXullnhVp87Qdwyg/xqzcWyWVntZvmVgCrE5FNQaMp1U9EchqWnpKu4R5PX60aext7dIyhC8ZK85NbkgSUnbEq5PBzWbd2j/vFjyEI/Ck421Ic76Mux3At5VchiCvXHFaJ8towVKy3D9Aegrk7drtLhYgQNpzknIOBW/DO0Rhljb5Pp1Pr7VUXdFbWNeS2MVqomZllxkEkd6zIrUvdmS4J2A5wP4qsfaRsEuDITyGyT/kVY0pzdvvmnXk8bR6UNDi2tWWI5kjWBtu5QxLKeen+RVIyiQ+cBlpXOR6Yq1q1vBA0s6PlYhsyT3Pp61mzXBgD5ztRAqDvkmhvoEbPVEd5KGufLV22hTz2qjNuYBQD16jGTTZpo8AoW3lvuk/pUccryIoUkMc4zU3Ka0MvU4nk2OuFKN0J96rW8LJM6RcHJkiyc4PcfjWm+42b5TLhywJoFvzHcjcADiQD06A/wAquL1M5EmlhX06WCZMJuPyyAYB/wAKrRqbQmG4LSRowIDZyEJ4YeoFXpo5L62kCYWdSNy7fvAZ/I+9YeqOsLQTBz8hKvE315H61o/hOdP3js7OfdEESQuFGY2yMbah1AxtImQm7GeetZWm7o3aSyOVyCEJ4IwOasvcsZVYqCWBO305rNs3iiHUo98gWVgR/CawLi08wyBuvUDGMd+DWveT7yApwVB4IquJxuQSgZ3YBx0pxY5JpGMbRZsqN3nbcY9SORVO905ZrXzNi7c4k9Yz7/zrTBaG9aSNiHDZwO/1qzdxoy+YjMI3HzqOwq46GDVziY7INL5bqomU/LkfLIOwPvSaho8Fwq7kMVuxI6ZMTd/ciup1DTlWaNmO9CNu/GOnc1Fbwnc9nen93IP3chH8XYH69Kak+pDilqedXvhqWzvDHjacA4U5DA9waqrpTH93JH87c8DBFd6VEU0tpIQkq5MW4dT/AHc9vap4okvNiyxiOdAQMcbv8ntWkWS1zLU8e8T+HRHbie3X5hn6sPf3riyCCQete86nZSfvVljZlY/KMd/avIPFWn/YtRcxg+WxP4HvWylc4a1Ll1MSiiimYBRRRTAKKKKQBRRRQAUUUUAFFFORd7hR1JoA2vC1uH1S3eQfJuz+Ar3+wufI0/MR+UDsO3rXhmhp5d5bsDhQSvHfivTdPvSLYRRkg9CfSsaiud1FWNaW+SG1kmQZYnr6sayoDgPNId0r/wAz2qG5YKjqwIYtiNR2qzCF+VYznZ/PuayaudSaNHTU3uTKQdgrqdJw2xipU9RkViWpgLxLEuQoG6uiicRKdm3ANZSumdENUdVpjbwpbPPcVqrjzWYnDDgA96wbG5xGgj27W6kjrWrNdF4t8QJbGNppXLsyzdO8jFRlVX5vof8ACsuV2SX5uVA6E1cgmMib2BV8c5XAqF0G0kYPX7pOf1qt0UtNzPB+Yom5nb+EVXad4l2bWJHXvmrcQjCNIytjOQO5rRsrKO7Yi5ilOFzgdcVPK27Fuagrle0tDcWykfucDnH3fxzVy1n+wyozktj5eO9SXGxVaG3QKcYzk+vemxslvCzzJhkXADDIJq4xVzmnV0NKO4e7ljWL5AH+YtxjNSapb2iRLuYM3X533Z61yN74mCwOoRQxP3gMc1jXOszzri3YtK2Bknj8KuU4rcwVKc3daHUpcWq3JGMlBtxjG41YuIRPFz8j9hjtXG6ZdTgyE/NKesjHp64FbsF82zIdVOO5ycd81mpoudJrYbqelnzi0ab1/wBk4/Gj5fsccTqoALcAc46VM2piUN5UhLbSu4DjB4rKYsJ8yqCOgGfbrV6dBRlJaSJob2B4ABIqsBhlzwMe9aGlzNBEXijHmSPtizzgdzXKnS7me/PlNizQliI+ATjqa6uwmFvDGWXMigCEZzgdAT6kmudu71OpbaGjq8pKJbxN5iq2+Rm7tWPLEZS+SWHQkn056fjV6XGShkwzcMByVA61UhbyYsYO0g4J+vGabetgStHQwdRISWIoArbyF46D3p1iwcx5Ugg4BGRntmjUozcSodv8WCenGaS3mQMYocZRsZYUDb0saLtA5ljXA2MN30NQs2y6kiUcAAgdAc1HO5jlbCq3mYwe/T1/KqIeWS5EoJBVccd+1NMycTZLKrKcOj4CFsds1xfi6KVbmS5BIG4eaq9P/wBVdmt0HQI6+Xn5R3yKzPEUMc9sdpAk2lSccEdjXQtYnO3yyuM8MTNPYRyYAKEZ4+8uOD+hq1eRyFlOW+dsg9cdzXL+EL0w3r2UjgAgqC3AArs7nbbwxOmCgGAMdPWsXqjpizP2b8yk4YkAA44P+FULuVCdzgHc3GKS/vTO4CYJzk471M1pGY0Z14XBx3yaSTRctrsgtolBJb5imc56mp5ipUkNlGA4A7jjNNu0eL5o2ChlHUdaXTLd0Y4fJ64xWu6sYdbk8EJjt2iPKqAef4lP/wBesm+WS1tyqoZYTnMZPKn1BrpSyRzRkL8v8Qx09araqkcFqZM5DHIP8qEROSRwN/cR3hyz/wCkJ0yOT6ZrXtSl7aL5oxPHhXI7j1rm9WCpqKMQUVjtYiui0lZUcJKuCe/Y/WjYI6oZco2wpcEkDhZMZI+teVfEOwKiQkfMnzZ9a9pv41aBolADgZK+g9q818W2wdJI2Gcg/lVxlYipDmTPGqKkmTy5nT+6xFR10nkPQKKKKYBRRRQAUUUUgCiiigAq/p8PDysMYHy+5qfRNJkv5dzAiBep9fatu9sxDsVFAQEACpbsb0qbfvMbbK8bWqIcEndk12th+6hVUG52+Y1yS7TfQJ3VSa6qxnUMuz5mbpj+VZyOmnuXpYyD58soDgZB7fSqFvetGcAje5JPtntV24DPAFkKu7fdjHb61mWEQgunmuBkjoM8Vkzddzs9HQKylZMuV3EmtqwuEE8glPB6gVxFtqq72dMhM7a2YLlWkBRjuI5zUtG1OR3Gn3aLNtDAgfdBFdDbspBbIY46djXAWDl5dyEAKBk56Gujtr3awji3HnPI6VkzoWpvz3pjjERDEk+mQP8AComuYvMSOPknkZ71Wil+1SYj+UAAemPWrUMVvbhVRSTz856g01cbaRqafYJc3O5sMV/vDgepFagVI7ho4MAMgBYHjrWdayfuShdSe/bAp+p3YSLZDMrNwQCMMP8A61aWSVzklJydiPUrmKy2n5d6/MCOcmuT1LWHujIsJGP1FWZXmuX3yfLEQR8x+99BUP8AZzmZNwCp3RVwSO+TWUpt7bG8KaWsjmHF1c3fkrHgdyTk4H8q1Lawlh2NKvmFjgFTgfie/wCFbT2PmQ4gjVF3dMdcdyasW6BU/fsH2jGNveo5bG7atoVnRVCbYkC7QCSveoogtwMz7FgUgAIOtabpG0KmZdkZ5yD972FOguImfyoVVCoJ2r2NWvMwlsZC24WYmKPeMZ28jH1PrU81u+N5xvb8OP6VYaO4WYusgdAMMNvT3HrSTwkxuyuWwvcYrSKMJ9xNongRIBshiXDOf4j3P58VPANlq8u4m4blM9RjjNUtNtpftQidh5AwXw3H0Bq1qQlkMkiAbQAQgOMjsPrUytY1g7aCfbY7a0ZHO8xnL4OefrUcd+t0HkRegwobjmuXd5rPsWBPznqK6DS2a+05nCj0PbmsY+8dEklqRXrDC5IVYhnBPUn/ACazbOUGLc3yDlxx1qzexztDJG2Mkj5v0FZE0BVY1w5DYQc/nWqMn2OgSe33o8snyodoHHPFJojR3kVzLGRtD7eeDx7fiK5bxBdNDNbWzDZbKRh+/P8AOjSvtry+fbljbAltoJG7Oe3rii2pDXY6eUAXSfMcIDjHTPpUqOJ7ZlHzMPxyay5p3EETznbJgnkfpVOe+uYJ1T/Vq3foB/kVpBoyqQujEuIja6ujvuwxwc9RzXXXtzKLdVMgKY+Tnqe9cbq8gkuo3V92WwQDW/bu09v5bNnC8e4x1pOybRdN7EFgkkl67IOSOQ3f61toA0WwEq4PPHOPSs2zP2WBXUHzmOGY9PpVqe6WK3J5AI/HmlHUqrLWxDqEu+eNUOPm4Ppita1h8qJDngsciuatJfMlaRyMD7ueM11NrcxzqgGGIAGB0zVLuZS0SRcaBGUCEgsOmeQR71zGtXXmgwf6tP4Sx6Gtq8ultVCQnIzwTz+Fcpeq+oMzOQCOhFW1ZWMbOTMScJc3BVMuVPJI6j1rptLlXZtJBcjahPpVO1gj2qrBUwMEY+8a1YooVGWG3jIWlc2UUkUNWYRwnyz8/wDs9q4DX5PPdjIpV+4PTNdpqt0yyEOdydjjFcrrcKyRE7QQc8/1oW4M8a1iPy9SnX/azVKtDXTnVbj2OKz66lseNP4mFFLSVRItJRRSAKKKKACtTQtLfUrkLyIh94isxQWYAdTxXqnhLSvs1qmcKCMkmplKxtRp8712Lem6XFFHGiIVReAorN122HnORyE6eldcsqLFsgAwR1rK1S0ZNPaQj5nycmsTuaOFiBl1ZnZiiKoGe/Su40aDzkAhAjXrvPWvP7+cWl1G5BKsfmA9u9dPoWpTSqqxkiNu5GKqVzGno2jq7a3SElnIL569zUN7bDG4ANI1XYLjT7REMymZmGArdcitOxjjeBp2+WRuVjHPFZWOqLOIntCoBiLAdyOxo06/kSZY5SflJH0rsb6xjGf3YaRxniuT1TT3gnMqEgjjpxS3HezOnsL8iUOGBB4P0rqtNud42jGME896810OVmkKSNyCF612VkzxMjJzjnA7CocdTeEjrI5ntURhwe49Ktm6XIcYCt1A7VRtZhIuW2sGXkHrWXeX8NvujcNuA6dKq1iZttm9caqtmC7N+7xwTyawbzxNIrl4lGQeA/U+59PpWZPK12VXPztwoPb8PWpobaSwhcvCokbpIwzj6VnNvY1pxS33O20KWXUoIpbpfJc4G5sDA9QO3FbLwIJJFVmEJ5UZ3NIa5nw/FOlu0lwGEZAz5mQzH1PoPat63ZnwArt8xJcnGR6ewFJDkrMSFDJOUCBEU8qOc1faNDKGnToOBjkCo08uONm8wrJjMi9vYZ/KmXTqu4AuRjLA/wCPWjYV7lfVrdirOqseOFB56cZPT8Kp2ttIssqpC0eVBaYYw3sK0rN2beTjYvyxqe5/qanitbm4mxGQij5i+7OB9expNXHeysykgZSFC8HjbjoajuZZGCx43jPc8E1YuIVVJGd5FCcE9Bz2+tMjUvsaI4jU5zjj8upqldMxlG+pXS7ZGPmpuRFyFXjzHPqfQVKsyFcMSNo+f/YPoKsoBKrNKVCZOCx6/hWDqD3MHnfYgjqD8xHLZPAx61ty8xnfldibUbO1kCJEwEhxuUH+H3rStljhgWOAERhsngCuMivblWlDx7ONrc5Jxz+Fb2n3gNp5kyurAgAD0qHDlZvfmRUvSFvZWkdm28BRnknmqTEMEkdQTuAH1z0q/qMIe+kkyQ7A7dvYVR/dDywjbCHXGTxnPNKKHLuizqmhJcyi4gRXkj6RuTj0z+VJHZtplt5fms+FwuOi8f561v2katE0uc54HP61BqEQEGHX5yMnPfPc1Vklcyi7uxzd5HGbQSbmZk+bjJGf6ms2eKW409d+DGCcBhyD16/hW1ZxMm4NuLE46YGDRcWm20nc/MAeFXOcn+YqYajqOxwuqEQF5JI9u0jaMbcDHb9K0PDFy00cdzMxBY7V9Pr71NfWK6gYIbqFsISWG7t6VJBp6Q4gQYhHKgelDjdiVrGvf3KpEgRvlOSDjnNYlxdSTbx1QDHWn6vOqRxgY3g/KM9KWFVS1LuBkjv0PpVtN6EJpambqdteXVvALQBIicOM4JFX/DFlfwSLJMZUh3Zye56c1b0u5DLGduVyTj6V0ccUtwwC4WI8FicfkKFDqKUr6FG/jkmU7Ix7kHPNV3tkMRIUJJj8/eujismgU7SPLU5AJ5I96z9RlUIWRlEg5HsPSh73HDsY0NoocF2JXptqWW2k3lQcqOBzzVWKRvNLA98n2q+JQy9OR055NI0ehg3iqWKyRlSB35zWBripbWbliCoGQCeRXW3OHGZFxgdD1rgPH2oxxWsipgFQQxFXFamNSVkeP6jIJb6dx0Lmq1OY7mJPUnNNrqPIbu7i0lFFAhaSiigAooooAt6WofUbcHpvFev2zYssJ16D6V45ZSeTdxSHorA16xplyGtEbPRetZVDtwuzNTTMMTuOSOMVd1xR9iQEDOOayNMm3yvIvG48jNat4RPHlGyy/r7VkmdcjzXU7dFu0kkXMa5BBFdHYSWv2ZQUAwPlZat3elxXEUg6ttOQe5rirxbnSXiXcVhcjg/WtbXRzN8rudBLePFcbn++x2qD2Fd1pMzmBVi+ZyvzNt4Fed6NbtqurW8J3ADLlsjn2r1m2s47S1iWIYcfwgVnJGtOWpKgbyFDLiUfxH0rE1m2WaGTBwOob3reid2XymHAzz1wKzLxdyuIwNuPzqLrobNdzitILLqbA98Y5rvLTbAu0NuYjPWuLvrRra5VgcY6V0+nk3cCgH5wvUd6mQR3Ol02cszlF5HcDg1na9Ym4vhNDFJ935zzhT/Wp9G+QNGdwJ6c4rp2tWubFYm/cCTIDKam91Y6EuVnJ6LIk+1LdRJP08yQfoD2/CuknJgGyMie6IAUN8xU+g9PqaWx0WO2VERySBtDHr+JpkmlS29+ohk3OxwR6j8/501puJ2b90saG8tnhdSRpJpGLkDJVfatn7Q4MkuSydXx0/3VFRLbT/Jao3mOhyxB6DHc9quWwEsUkedoB/g6fQf41Nrsb0Rxj+IpZ7shlMIjfJUc8fWtq0u3vIQCcs3ztjnA9Pbp0ql/wjqRaks9u4dFO59+cD6Y6/jWzb2yWlorBczOCwGOevp6+1JXT1NLx0sWLQtC+xB84GDgbsZ5rQkLQQeS0rp5gztB+Y+2f8arWWEiyFVXZQoVDk5PrVySwdCZI0JOMnHPzevNFm9jNyTZJHGr2Z3Ehe4fox/mar3jW9pG9w7LtTAJxxn2FRSz3UMWCyxSDn5Rnk84zUU4iv1linTdFtG5CPbqfWqe1iOWz12KjyictLDH8nRW659/asa5u71A7ooRYwQuFxz/AFrpU/dW620aBEAAGxeQOwyapS2s0k7FrYsCdq4O5qIycdilFPcwbFlmBNzFskZuSV5atCSMMJGt8Abd/wAx+7g9PrgmtH+yg0pj2sNvJXrj8e9VdRg8iAtlUAOAmcZ59OprRVOb4jKUbaxMXUZJF3xHcJAuDx2NZm+MwICBwQv4e9atw73O9mG5SCxbGMmuNv7p4NRTBXbuB4oaVroSm27M9A0xpIo38uRlIxgHkdDzitBUmltg0oVnBx8p/M1gx3TRSWjKgCTLksegroYXdlKjEa7RwTnqM/yqGraFJ31IbVfMcn5V3NlR3B6VJqcX2eNiFVWx8xzyef1psWPNZxhgpAI3cn3puvRLNYysrsGUb0B7exrSCM610zlZlCXjM30ORx1/SqupSNbIrKcliQGz+lKLqS5ixGhZud2fUCsHVbsjKOSFA+apemqGn0IFczXJmlbOD0zwK3vkZRFngDnP+FcGLmVppDG7eQegIrs/CzySyL5i71TAL4ySKcd7EzNzRtLLtuTIH8PHFddDCkasgADRjJ3fxe2KitWCxKiIGZ8nGOR+FWFvvJmiQ4YOucepFXtoSrvUi1G5EkKhsqMcgLt5rl9Ybc5ZCUGAMsOlberTK7vLGxHB+Q965m5vRKhGeO4x3rKT6G8dFoUVcxybA2WPB47VdQsy4Xahzj3qrGC8hkUKPT1pk92Y13twOuT3NOwNkOrXgtFdi/JHAJrxfxvqTTStGWyWNdr4q1F3SQjhD368V5HqNwbm6dz0zgfStqcepxYmdlbuVaKKK3PPCiiigB4jkMfmBGMe7buxxn0z61PfwpbvHEEuI5lTE6TLtKvk8AdcYx1561vW7W2q+G7Gw/tSCwltJJHeK43BJdx4cFQfmA+XB7Diqniu9hu7iyjhuTePbWywyXRBHnMGY555IAIUE84WgDCooooAWu48JamZoBA5BZRjHrXDVa0+6ezuVlQkYPNTJXRrRqckrnpNpK0d0AnTNb8bFn9COtcla3W5kuAcg10NhN5jEMeozmsLHpcwuqXAihRgAMNzzjNcPrtw1/dRwSNiJBxXZyBJpGXqi8A+pri/E8aQaorwqVHGR71pFnNUVzb8AR+TrqxMWVSABXtE+wOFVhyOWNeG6LdmK4huo8hwcYx2r0231F5o0KH53IrOWprTN5VKJthRiHHJqS4sdtuDIAR6DrVzR9jR7GJdgOSO1WL6322pZSTk5AzUWsaqV3Y871qBZLslMcfLk54qfS43tkVd4GRgmrmoQj7UQFBLdqm+z/IQQvPIJ7VnzGyWpd05SX81WTAOTXY2kqSoAxI6YBHQ1xlgjQl9oGc54710mmunkJmE5qdjotdGnNFKvmHcqxng7iAfrU1iq+VtjDSS4+aRhj8c1DCJJh+8CxgE4B5LCtK0gAjy4WIHseM0LUmySEjSMQtCiuzElmbJAJx0PrV9IYIbVGupsMOdqrgdOgH9TVT/AEfhYXeRl6tj5R7CmQbopBJcKjoDiOP+971WxDV1oO3iZ9zxhIg/7uNO/ufU981FMEjXzwWAc7PmPPWrkkUQcST/ACzy8gNwAPUAf1qCQZmimVjt2skZAwMdzg+tNuy1EkgtLmK2eN51Mig7Y0C4+p9TVtrzEg82ORQW4ycDb6DvmqP2dFAlDYf+/wBT+daOmwpNcMwcZxjJOaXM1oDjF6lF2aaf9wqnbluTjBqW1jDQ5kKR5/jHVj+NXNRgRT5kZB57jqfpWdJHvijMu5VLAkt8ufwoTu7BbTQswxeXuxKChBGfvHHrzUSuIpBFZsZGJALsOKhM5knZRxH03Y4GD2rYt4oYVdiPMGB1wCTVJa6CbtuZrwTC0YPMVUZyydW/GsK9t48EZBkI3YLcr9T6/wCNbmpOJUWPcxwNyqDjHoKxbhpLRQkxG5xnaP8APFTJK5UdVqYt3MYLcu8TEPwAM/5xXEPbPfaxG5RlVfmCgH5fT9a9A1CFp0kkmJQIuxHft+FczbTf2d5gG9mJBAUYJHb8K0v0MZJXutzojEk1rDEWwI4s/d5+lb0cZihCTbScBj3bAHr7CuVsdVihULesiiU4A9/c10STrMjBHJfHPPC8DiqaT1MuZx0K9ndxfbXRMZzncO/tTbq4N2rlWYA8c8YrA1bdDLJ8pRj/AHTjv2pIrmQ2hYEK7dvQdqyi7M2mlJXRi6uz218sse4DkNtHX3Fc3q8+xpHdvlGCMng5rqb8yTLskjbJPBArnNesEWykUqS2Mknse1aWTWhipNPUx7a7R3VFbBA4B9K9M+HUWy0zKmFZsKT/AI+leP6S+LnEmAUGPc1674a1AWtpCJs4cYUgdumTU7O5bd9D0K0gEqbGGFydsmecelQ39n5I3BFk2HIYE8j3qXSbrG5lbAAByRnA9qtX0sR2hJgyEYGODj6VotUZtu5zNztlQmNzlsk8421yGsMqS7U3MT1OO9dBrUq29zmMkxse3rXOXCmS7LufvDp1x6VEkjaLuWdPYm2YNGVYdcLzWTr0u2Eq4wB/ePIraVzDGrqCrlcsK4/xRqJaZgcbRzTWoNnAeML8xxNCr5L8VxFaWu3Zur9yPurwKza6YqyPJrT5phRRRVGQUUVJbyCKeORo1kCMGKP0bB6H2oA7fRTqI8LWR0K50+1kEkv2gSywpJIcja3z84A4x/jXOeJzqJ1CM6vcQT3Hlja0Mkbjbk8ZTjOc+9XP+EktP+hb0b/vmT/4usnVb2O/uFlisrayUKF8u3DBTyeeSeef0oAo0UUUAFFFFAHR+Hr0lTC7dOldTDcNEfTI7V53ZS+VcK3PpXZ28vmQxnd04xWU49TuozvGx0Vixjg4+YGuT8RnfMJD1DE10UDM0XyZGBWFrUSywO5JJBzj0pIuWqItPQq6swypHIrsba6dNhRyBjmuQ0nd5XKhjjGPWumghLQfu1+VeGzSkVA9I8N6xGGwWAJUZBrpXbz/AC/LAYr82QePpXmFhiSBcAK+cZzXV6bqbw24Vwpf7p75rNlpW2LuqWatMsgYbumB61QnieNG2csTk89KvTSrcKjF9ozkCknZYEJfJG3rispI6IEOl5R13HCk554ro7J41OPn8vGdp5Nc011HDDDcH5k3DPHIra0y4EsLvC7FuzY6Vm0dC1N4IgffExHOckc/hVxYg2ZJJDIw5AJzVCGRpUVDG2cfePFW4PvELIFXGGYjpTSBliHLHapVEHUfrk1O0cQhYpJKzKAd0Y7j+lVFtEDDZJK/Oc/wk9uO9WsyyDZzu7ndjA9/SrXmZy8gl2sytIAzsQS7feI9vQUksAjlYliAEyRkk0jMpA2glRnLHnP+NVbu6Yxhl2AkHJB6GpfmJXGSSb5UUHCnkitWC4eGMiMYcgDAXoPf1rBt/nlXk47kHGTWsdzoIzGd/RcYA9//ANdK9y7IuT3BYtsULJwxLcn8BXKTeI40u5IpwJJA+EdPmwv07VutK4EkRaMsoOEHQH3rhPsEy3IbcAzk5ZOVHP8A+ui9rFqCd0ztEvbGF1aaVG3/ADLhd3am6frVtelfLkYhePLGFJI4zkdq5m5whBldtrjG3qcZ4x7UaFbIJZXu9weM4Qg9Ae9NybJ9mtzupjFsRkBNxkE44x9PU1g38HmSM4B4JODya1rEobdQhKr13nk1n6tcBlCqNqLkE9D7c0N3RHLbY4rxLeXMNoywOWcuCd3p/kVgeF5Z7x2+2PvkLYIHG72o8cXbQS+SsZYdjyfyqp4Numi1WKSQ7yvygYzk+v4Vad7GfKdB4g8LahqMam1CCGPhwD936VN4esrvTJAl2rSKMYBY/MfrXe2BVmx5kaRnBKlslj64p93axAbkYgHG9wuSRQ7J3JvdcrOSvmW6kCvFHu7c8j2FQrpjKVyobdggA9Fq5f2t4heWG3LfN92Q8n8Kr6beXQP+lfcAIPy7ePTNUkpO7IalFabFm6EVuVifsuWbv9BXM3lql0rhUDDPBNdFfstyoSBgc/M3HQ9gKx7aEpM8R3HJJwTzWhm9UeUeILNtN1F3iDIN2Bx2rodD1OaWzjZss0fHyjHf5Qa0vF9vFdSxxsgVwduD61naZajTLiK3Xa6XDeUNxxz60uXoVF6np3hLVV1BwkkQWZVDsM/KwHUVv6heW9kmVAUlvkUAcegrlfCkN3o8f2e8R/Lb50cKPkJ7E9xVTxddTRM6qwVT9wr7+9C0Vglq9Ct4q1qFJBGmCDzgDHNZdleCXBB+Xv7VztyJJLlWnJYg4bJ7Vo6a5E5SNcqehBqLts0SSR0V9PH5L7W3FQT9a8n8bap5Jk2ZDPwAa7TWL/bA3zAHGMDrXkHim8Nzf7d2QnWtaauzCvU5ImKTk5PWkooroPLCiiigAooooAliglmKiKJ3LMEUKpOW9B71b1GCG0RLeS0vLe/QfvhOwAzk9E2ggYx1J7103h7V7e30OGSM3RvNNjuGSCOIshkkGFmLDgbQe/8AdGKxPE95FcyWEMMk05tbZYnnlUq0jbmboecDcAM9hQBiUUUUAFFFFADlOGBrotHuVdwjnGeMiubq9ptx5UyZ7HNJq6NaU+VnoVqDDuHVcVj6jjZIp5HUf4VofaPMjXacZHIqne4aMtjnHIFZJnbuijodyWPzbf7p9q620dkTaxJA5PvXD6ZlLjcwPORwK7m1USRAMrKQODUyHBaHSabGhiD52k84NaGGCLJGAQvc1iafcYRY5VJ2dwf0rU0+5gkdrdncMec+lZtGmpqafKzvlhxnBHpW5sIQiRSUx9awhutgCiAk8bieRW7BN58MZLLkDGRxmlfobIqzCHyf3cK4I+YY4/Kn6ezIGSLKRsdvParyQLuO5twJ6Y/Oi5kjg2qFDE9FA6isXqbxkXbcsiKDPkdST6fWp1vJFIW3ga4DfxAcVlwzRbgZyS2d23qorYtCZBzOAG6Bcj8KLFPzJ7Ce8kAEixqxPQk/rjpV5vNJZWuFOOMIvAqn5bxqhWWMg9RzWslor25C3CoD/eIA/wD1VpHzM5vqjNeKQ7dkjuR07ZPoBUbQOweIqXc/wr0X2JrQZHhUKhWUKMjYfl+uT1+lR5mcZnXPH3VHGPpUzSCMihp8KG7J3B1j4O7iNfoOpraN2iqgj7DBYqMn/CqRHlb/ACyFLEZA5IFTiPCq4+YYBYKuFz2oSG7N6kmGlYu5GCMcqP51X1Kxhkt8pErvF8wCsCfzrSI+QAx/Lt5DHr71ZtY4yv7sDOOy9KXoNytqclpmlQ3zBpt6dt7DG3HbNaVtpdvZFwJDI+dudvX/AD61vSSB8pkIqjA2jJNUpC6gEhlDHqOtNLQnnbZjajeLAGEFuwbOfm7L7Vmz3P2qAygbFUhsk5z7V0F7Gs0LqygMT3OePrXNX0VvFuTzMgEknnmpvrqXpY5fX3WeZQyjj16n3qr4N0Mtqs94ZNqhhsB5C+vFRaxdbNUgjjUHdkEkdBXZeFVZvLjIUhhuwB0Hv71pBJswm2jrLe2aUYMKsYxknIDE9gPWo7m2dcs+0LGcld3GfT3rT0+HyY3e6BUkfKMEvWRqt2wkYZ3MRtUY+6Pp60Tj1Jg9bFAIZpCZQD834k1TvtLhJaRN6HJyOSM1PbTbZF2qS2cD606VmRwXOCeRjrQlpqVJWOZkRo2ClZCvYgE/0qncEBHmAYHHMhyBjsBXWrbyXLIFG0rkZzjdn3rG8Q2UsEMiy4aMAncewrVbHNLc8+vZzfXLMow6sMH1/wDr1QcXmpatHFbwkpanIKjBz9a2LC2DrJGDjb8wauq0+zWHSo5ICi72LucfMD6fQVNy1Y1tODxWq/bHeS4cktnO0L2xXFeJcpflZZDsHQD+Gukm1Y744IyJNoAye9Y2r2sVy0k1wree2ATnAGP50N3BKz1OW4mASEMWJ5HvWz5XlwqVADDGar2FqEfep3uDj8PSrGqXRhVvLIU+9IrpY4zxjP8AZzK6EcAgj0ryqZzJKzseWOa7Pxzdna0e7Jc4/wAa4iummrI87EzvKwUUUVocwUUUUwCiiikB3vhadLjQktLa/trYiC6S4gmmEPmu6kRsckBh0Htj3rB8XTRPNYQLcx3dxbWqwz3EZ3K7AsQAf4tqlVz3xWtpguE8LWUmlaLZ6lK0sgnka0E8kZyNqEdQCOcn19queILaGfTrwXGlWNlLbWMU8jW8YjMFwz48s467l52nkfgaYzz6iiikIKKKKACnIdrA02igDq9JuldFA7DvV+7I8ltp698VyWnzFJAv5V0UUrDZI/MRNZSjZnbTnzRDTIC8hQg7gc8V2lqGg8pWGTjrnNczaMBqKtF91xjNdBJFIGVYzvHtxis3qbwZqw4jldgB059TVmygJv45FKuzHPHb61jWFx51y8OcSg8g8ZFdLo7R87FYMec9xUFt6m44xhAvB4x61dGBFGXU/h2rNZyp3lQVA55rWsYp7yJZCyhe3+fpSfkaR03LglQKskWCM8DFMu7nG541UM3zYbHNJLbqioryMd393HWnrYhUQhhIGXkE5I5qGjaDRh3dzIyEhtuQDkdQfStfQdQ2ERXEm9icDBGaF06Jp8v97PJ960bDSYrZ98eCxHUdh+NZ6m109DobYk4whx9ecfU1M0WYwyIMDg/xH8/8KgtN/lKkhB9C3P51KwnJ+affzwo6VpqZNEsoxKjSqMfwDu3tUb3RkYQttXHIVR0pkxhjJV2E7gfdBPy+1UHmaMFzIsaZ4A4JHuaJaIlRuy3bttY9iD8zNzj2ArdtWRbYMwUq/diMk/TtXJGSWS5h8pN+7+Fe/vWvbCe4ZXjjGYxlsk/L7YqosJxNsTBslwzg8dAB7VH5zRROkG1g33jmqTvNIu1ZPNcHAU/Kq++e5/xpgVv+WsmwEcYUkk0nIcYq2pfJdEyWQseBhOnvmqslwE+V8Fye3zE/SoVKw/68OzZ4y2f0qRdxjH72JC3O2MZYD39Km7Y7WYkm4/wlP94c4rjPEci2MyvKc7zjA6nmuu3uVJjZdpP32XnP1rjfEsBeVGclyT1A7VD7lx31MVrJbm5N04XzEX92nPA+ldR4ZdrVELBRKQN2R09K562dWiJIGcngHtXUaVEYotz/ADNxknknNbRtuc9TfU7BLmONFwu0EfNhs7vauf1BC8rMm4EtnLHv7D0rUjzKD8jLjltwzgduK5vxBqVvZyMJZF83B2gk9ewqZ3CEbbESXHlXDxnbgkBmxkrUFy85kwA0hbpgYJz0GK5+21Oe5nLO43dAT3bPp6VqTai8Y226P9o5EjdcHpxST01NmrHQaSksdk8kqMjIcnJ3VieLb2FreVGDbmAOcZrc00NHZOZ5SbjZ8x6D/wCvXHeJZ/LhMBTCngPjGRXQn7pxSSlO5haR+8mKIMqcZwOT7100kaRPLCjRgMoYZPHToPrWN4bjNtGX24jc7RKeak8S3e1gsLAovzNt6t681nd2uVa7GpaPc3B3ZUD5hgUslzAkzxGMO+OGPP41QtNanWXykiAEigBifyq0EUSR3DnLuu0j601sVbuRGJbdjhgyt1GO9ct4iuI41aP+IMTnNdpeRqLEsSu/nCgc15V4nuliW6G/c+cg96qKuyJSSRxfii6E96FHAXmsSpJ5DLM7sckmo66UrHlTlzO4UUUUyQooopgFFFFIDuvC1np0NjYtPa3U93ex3Dq8dy0SqYwSI/l6k45+orE8WRWqPYT6bbPa2d3bCcRvKzsW3MrFie+QcH0x71c017TTtD0+4vL3VMyzvNHHZsqrC6fLklv4j1+mKy/E2ox6pqIuYpr2YeWFLXZUsCM8DaAAMY4+tMDIooopAFFFFABRRRQAqkqcjrXXaWEk0aMgnfvww9q5CtrQ7oqPKJ6HOCetKSujWk7SOjgXYRwuO+K27WdBErA4UdT7ViIxyXUnay5x6Gp7d/Nt54S20YwfesWdyJdKuWi1pt53CQkZA7V3mkosUmdy5964LRtOuL1/MRSgX7p9cV3dqmbRZJ9yspyefSsm+hodVCiNFgohQrksRgmnWl7HZzFTwMA49axdE1qLUYn2cRxHbljjPvVmKe3uGdXKlwOM9Me1EWr6DcX1OjguEvDlk+Qc5btV21tnaPchx6ntj0rCsHtwMK7bRzwa6Cxvo/JAjcqAcYA6mlNGkHYqT2Exvo5I5CsRPzAd607KBY0wqDA45JNWY5JWX90u8E9PSiPzcEOGGOowODWLjqdClcsr9mCAS4wo/vEVYtJLbIAheRsZOD1H1qkkUhlJjgJkPAZuc1PGt8+2Ew7mB52Lx+NEXqJrTclSWS4dlBhs4c9hkn6etStp9tNIFtg7SAZaUjjPsP8AGj7DMISr20m4jkk4A9wBVfEiN5QBVmbHlgHJ+vrWiempna7912Lc8GnW27YSZ2GAVPXHcnrVJlEYLxxu5JwsYJUH3J71NhI5FFyuHxnIYbv/AK1R3dxIdxkjDLjK85+nJ60NjSew+wmF1Kyrgyr2Iwo9gP61Ld3Oy58vzOFG1jFzjjselUEEjor7XWDoFRQMnuc+tSJi7IWK1EeTgKrZIA654pN6FRVmS+VbyiRhHNHFt5YkAk+xpnmpMiwxrKUVeDnv74q3FYtNcR7FMsBO0AcDI7c1euW+z2rFl8gKpx8vJ+g/rQo3XYHNepmqgWJiSyBRyRyAPfP8qwNYMNwyWyMTKeTxnitk3tj5e9nMzHkg5OP8TWFrl4LGOOV8AMcRx9GbPf2pNWQ47mFNb+XKXZSIYztVu7V0Gm7SYjufJYFj0qrpk8V8Y5LjDRgbh15I7cd60Y4YS4Cg7d3XODmnDRXMpvWzN8NDDa/uWYSYyG3dPqa8n8ZxSzaiyecjCP55CnT6Htn/ABr0OadILN4piiqylVkIyR7V5ldnbuhmSVyzFl3ck/Qd+O9Ko20VSutTJt77bOghY7kbABNdL4S1d5pGidXMm773B3DNYF9pNwYU+xqVMpC7lXj8foK7Pwnoi6a6tcyNNKB80mOntRHawTtudE0OIQzfPt/g3HGfevPPFOpKmoA3DCQkhQmOK9M1eeG3tgEXIYZwvf8A+vXh+ryJda8WDbnVsYY8Ef54raTtojlpu7uzroIpZoEB4+XO0fyqpc6XczZTzFVIuSSOR7VvaLZ3ElsifKCRuJxwBWjJZpBg7WYdD6/5NLlT1NFK2hw+n2R2yPcM6kN0x1FXL5wjRiNMAdCTmtXWYUgUmL/VE5JA5HpWPd3CzRrGqlmIxk0ttB76mVq2ovBBK5K7SvBzzXk3ii6eRZmJPzsBXoGvERsYpmBIXKAngGvK/EUwa58sHODuNbU49TlxE7RMeiiitzzhaSiigApRSUUAFFFSW7rFPHI8ayqrBijZwwB6HFAHbaJd3SeF7SLStW0vT5BLIZ4p5EDynPyudwPQcYrnfE8l3Jfxtf31pey+UAJLZlZQMng7QBnr+dXP+Eh07n/imNL/AO+5v/i6ydWvIb64WS3sbexQJtMcBYqTk8/MSc8/pTAo0UUtIBKKKKACiilpgJTkYowZTgjoabRSA6bSL3zYwMncOGHrV15lWUkHBJwa5mwaWFhMoIQnbu7ZrYeQyRl/4qznGx2U6nMj1bwygNmuAMkZLdcitPU7CS4R1hmKRlDhAvBNYPgi6SWxVcc8DHvXfQtuUblwMelYS10OpOxwHhhUt76SAo8MjLl1f1roWsmSYvBjA/WruqaXb3jK+MSBt25Rzmp2ARQFBDYxwOtRtozXd3K1pIIZiXXLEAYIzkYpdWvJt8YtWAHJwHwAaLVFN3J5jqTk7Qar3GkXX2l22Ep97ipnfl0Li0panQaJqszxhZ5ghUDndwa1p9VNosLeY0m9sHHO30rh4x5JBXBKcsDXWaZAL+Dy3DbTjBzWKd9Op0pJas6W3kuBh3LBSMgen41Zt726JZIpgOONo5NMEbrCEUkYXH3scUxrZBDtj4c9ctgAe5rbYzVnuWzNeyRATXZ3n/lnHySe3+e1UVgktbhXv5niXknMnzD8eprTg322ns9nPaWq4y0krHc3rtrMGnCeRJpr5ZQwyxzg59getXbQiLV7F+C90y32fZrGS5df4mPJP8zVXUNRvbu5Z1iSCJuEVvnK+uPersNvaW5SVlF04GAhckH8BjAqZ5ViTMSrHI43ExKARn09KT5vQnS+1zLIvLSMeYxWbGfLIOcHvntVbTU1OGaQuoTc25VfuPpWp5E87RTIj5Yk5uH3EgdyPamXC+TE8gMbSkkktg/kPwqLNlqXR9SdLy9hXeI1HO/cHBbOMZxmq8xurrzGa3uZt2Nxk6+/HpWO2seTIjgfMSRg8VqRakZYkklkUQ9TGXOf/wBVC16lcvLqkVkMiy4+zqiJ26Z+vtXG63HeXGq/aLyREVm444UdBgV3Qkjug8qwkk/LFEi9T9famjTQodtQiiRk5GAGIbp+dDhcFV5XcwdCtxZRFQG5JbB7gelbM9zG9sA4SKdyMDnIHr9aZdvDAisi54x8xyQBVDzVnWRXGSTnOcdKq3KrMxb5ncz/ABBZXE08Yhn+Ynpgnb71mSaU1tdxy3F0XWI8g9vf/wCtXUQGGNPMb5znbuH8XtWFqkj3Vwv7s534Ct3qeVGqk/hLsT7otwVVj58sAYzitLRA9uX3gFWPDMcD6VnwFSBtzJJ2QD7vPYV0MsYktUDR7HwFMnf8vWqinuYzstDD8WSNFZtEzhWfkY4AHrXnWm6Vby6i0ksq79wGMZLc/lXZ+KvLhsSqs7Tqc7mOQetc5oFv59wu45OcluwqrdCIKyud3aMoi2x5Z4wAQo6iiW9aRGbyPmXhRjhjVbTUOdnyCUAjJOA1GoyCzjDxyFpMfMAMYJ9aq7YrWM6dJHtnEw2kdc8VzN4yx2+0AccZHUitaa+M4dsHgcr6muf1ucJGJJAI1I4U9aAvY5XWyZ5JtxwIge/tXlWouZL2Zj/er0bWJyPMOcb1weOteZyndK5Hcmt6a0OHEyuMooorQ5QooooAKKKKACpIGRJo2lj8yNWBZN23cO4z2qOigDudL0231W0NzYeEneDJG9tS2AkdcbsZx3rB8WWJ0/UY4Tpw09jEGMP2kTnknkkdMjHH0PetDSdVhh07TGuYLsxWrzWsjIuY2jmVs4P98ZJx3wKpeLWiS6tLKJLkPZW4gkkuYvKkc7mblcnAAYAewFAzBooooEFFFFABSikopgKaSilpASJNIiFFY7M529q2rJ1mtjn7wHUH+dYFXLCcxsVP3D96h6mlOVmerfD5SLQKRyD17Zr0m0lDgITyRyfavLPAXmLFIFyVJzmvQbGTy48M/A4CnrXLLc9KGqRryoFTBBZRzx3phkQ27bflk6g+lVzMeVR857k9ah3+TNhm3IPTqfaspPU3S0HqjmcfODzuNb1nI09qVIDP09PzrAt2ZmkCocKcDPFaFnfLFPxHvCrj2NVDbUmV3qi3ZaWpctPA7FjzjgD2rchikto/kswijpl+1JHIJNvksNp+bJ61dDPLklWyvTjIx61m48rZrGTe5TuYbyZCTMsaHA+XlsVNZ2DOuUzME+8ZZDz+lWBHJcBlcKSpyTjGant0YsiA4X0BwKEtS3LQp3FjtCyNZL5nTex3Y/CmRW8cg2PKwdm/hTBA9iRW4sMPlhriRlJzsRR1NOdTDCvmKjccDeQx9x1rTkZDqaFC001oElM00iRt945GcVdtIvOt0azt22A4Z5DhifUe/vVLM9x++jtwYkYEeYchjn171qya7DFZwxzRxo5b5lEgP06UoxREm99yO8ja2ikAiIkKFUVTnb7n/Gsq9sjBaRguDJsBwpzVu+1OOXeII5J5mHVFOMDsPaqxuJZL4utvIR33EAH24qJNX3NIJmXaaWJ7s+am5cHORjFa8ejwQiF87sqSyscbAB2NQyHVHmzbwRQrLkAlsn1qNLVwxkvFafa2ChI2k+gHelHlRq79zQF48wA02FIrXOFkfv8A7v8AjVHUbqJFCTMDK7bQvYH1xVm5e5nZTMpjjQfKiDOB6Csq/WIymRoGc7SFYvjH1FNz10MVTuzI1PUonvFitizhF2mQL3+v1pVLqQzkEsOVAwPrUum2vlTrNcxb1jG1RnCgVceadpn8m3hjDnOBkgDtR8Vmx6J2RiX2pmxbaFxDEvIbqWNUzqUeqIBbYRsYZj1X1/wqh4l0vVhdyGZSUf5y/XcPb0rE0ssJyY3kS4ZwhUj5SP8APelzW0LaVrnfx7V09PKwkikkqDy3vW9ZzyLpa+YOGXacjpVS3iWC1RpWWSZfm3KM5NUJ9TuVieRlSNAeMt1/CrjozlmubY5vxWHubpIoi2R29PrUuiGOFCso27Qc+tZ0lxJqOoytbn5Vblveul07Tw6KJpCzMeoAA9KI/FdDS01Llq0TxGRpMSD7mDz9ajv2EhyisXxgY54rTS0igi/eRBAw4Gc5PrWbexuI2gLGMSDgg9a0XZktrocxdRyWzmaEq3+z2Brg/FtzK06s8h8onHHY+lejGCK1jkTcWVW5yec15f8AECUG7gjjHDkscCrijFy1Oc1q8UW1wxcbsYUVxVamuSP9p8s5CAcZ71l1ukcFSV2FFFFMzCiiigApaSigApeppKkglkgmjmhcpJGwdWHUEHINAHQ272Wp+H7GyuNS/s+S0eQlZYnaOXcQd2UB+YdOR0xzVXxReQXM1lDbTSXKWlssBuZFKmUhmOcHnA3bRnnArd0m/ex8P21xdeJNTsjcyyMlvbwBwcHl87x1P65qPxTpq3sJvk1u51KeO1W4X7RDsLQF9uVO48qxIIOO+M0DOLooooEFFLRTsAlFFFABS0lLQAlKpwc0lFID1f4azxzabskZhsOMg8iu6S2O3KykjGRg9PrXknwxvo4NUaGVgA4yuema9dllSKLKhdxx9MVzzjZ3PRozukMjnhDeU75k6j1qYGOOMysQG+v6VyesXEttfecXRgMbWxgjj9at+HNSlvrkpc/Nk5HfbWDtsdttLkq6wq3hjBdW34KE4GK6iKX/AEZOOMBveuV8TaU0t2JbIqZGI3r0BGfXtxW9otvJ5KRzvuI4LLz+FJScSrJo6vRLgx+X5uRjpnkCugluZFiiS3l+b+LbjgeorjC/7wKssnAwABwa1LC7jhQBDO5PJJA6/Wq5lLQjks7nWOYhEqsrllX72MZ9frWPdXrwzqFLFM9cVUjvFnBVZJgQeAv+Nc1qt/K98bY2t0wUjcFbJqZtRNoRvodrJ4hVYIoUd5ZAem7APt9KdbW2q3xFxHfQQ25P71FG9yPTJ7Vm6Xb+RB9oj0I7CMF5pDWv/wAJQ1qIkfThC0YwjW7jA+o6mmpp/EyJrpBGrNpFrBCj3YuLnOB5TPg/XHQCp4NP05UM32aFHkOyJVX7npn/ABrK/wCEm+025CIqRYzJyC7eualtNbgukb7PbO7LyCikZPpn/CrcoXM4xqJamjc6bHC6ySTCLaPnROcL6mqyxXE1vJ9jcBO77ep9qprdK8mLkSlmx8gB29ec9z+NbUYSJGhiYSDAIIbgk89aiylsa6xtd6mQYLwKEWRmzz8wwKyNbkvrGePfMY2I3ALlsCt69uGiUuzhCvBAHWqF3pqzWyXcrhbqTOA3PGfTtUuNk0i4uzTkUIbm8uBFby3UiSSLkDbgY9TzxVswWlopd5Gnk6bnPFP0qwlWRnlnVs8KxyRg9zT5bUQPJKjKx+98wzk/0HtSjcJOKdjLaC4udRL4LqxAGQQkY/2R3NSxGQ3LoFwo/unIq8rysQzvllXOPeqdld+S809wfLQ5+7/EfQVpbzMZPsWLi0LgC5YlSNwTOWx2+lZdvodsA8pgUKxIYk/dGev1q/DqSOC8Kb4+rt2Ht9aqXd79pTy2kC9gmcKAPU9zQ7LVijzdCs29JDHbzGREOF80cgVQ1OeJA4kBUHjHB5qO5MYkdjchTnBCf41ng2s8nl3M3lRkFjIctt/CkncJIj0q0aS+AgUiMnc2DwBXX2ts4jPygIRyp4PtXOaVqEcEaiJXMjEjeo6itq61CWOHatsQX5LMQMjHSqVkTdli6uXt32y/PHjjnn/69Z9xcRyM6s4dDyOeRWNqT3NzNmSZEQYAWP0/Gs9opxcsIZXPHVzgGhPXYlxua+owxxwyuCGVkzmvKvFEZuLsTudu35QvoK6jVb3UIjJG2xTjAPc157rF1MJiJ5d/cAVrG/QykrbmP4mjhki3xrmSP7xX0NcxWnrAmicByVWTnbnrisyujoedP4mFFFFBAUUUUAFFFFABRRRQB2WgssehQHW30v8As8yP9lW8ikd93G4r5ZBC5xnJxmq3iO/v7V54ZPsTwXtvGsM1shCC3DEhI8/dXcOQRnI5qnZ6rp8mmQWOsWU0y2xYwy28wjdQxyVOQQRnJ/E03xPNJM2nMLZbWy+yj7JEJN5Ee9xlj/eLBienWgDEooopgFFLRQAlFFFABRRRQAtJRRSAtabcG1vYphn5T2r2XTNRF7poVfmVlHA5xXiFdV4a1Oe2jXyZmAB5U8j8KmUbo3oTs7HeS281yyKTviHygn196saLpcguzvVkyD8wNU4NRdhGJgoLn/WKeD+FdloqrPF8xUMOhB4NcrhqenGpoRGySOQbSx6DDcityzjCARrGEZlycVRZ/L3B0wxPBxxVmzdXxu3Db1weTWUlZmqu1c37eBHeIqgLBeOMZFWZrZ0jxgYbHBFV7ZkUrLscgD04q4upKGx5ZkKnuP8APSqTS3Bp9CW3ax3EwqIeAfLzkE+x7VqQW6TRB1VN7/x46e1c8l2qSSOkKhmOckZFaWmX8EjgXDiPb/D29wapNPQzacdja+zXYiCMqiNj8oHIbHeshi8UrbX2OCQxI61pvcSW+ZhcB16IFbt9BWXeGS6kLRxOykDdtUmoloOKZatbF71Ms6KqjIVQDxnuf6UgsvKScC72AHg7inPsBVWz0+6SUDdIkBb7o+83pgV0dnaBNheCQsq5Jk5z9KFaXQfwvcyYbCAqxi1HytuOrlskVZa2v1WLyru3lOMncu05/ka14Y7aeDzPJVZm4AxtI+vpUt5IbVhJtiTC4VsZX8+1U4WVx+1lc5G4Go21x5tzaTM4GQcAge9U7rU5/P3z2koIH8bAAmuo1LVix3Q3Rmkx8xUZC/nxWPcyteuiyPCqYJLFMc+57/hUNJPc2hJtXkjNub3UbpkKxoIwCQqnGPpUkV26RhLuSVD1ACbhn196lW6tYY2RpJJWXkBF689Ko3+pSPGRGoTA7fNj25pLTW4229EiOS5aRHy0mRzuCkY9sVFDFHPE3nTCGMZA3qeaWO4ubwBAnyKOAB396U6TeIGl3BVA4DnP/wCqmlclytvoWdNgt7K22b/3YO5ARxn6Y5qPVXurhAlukcO8FvNYDgeoXtUDXckKQx3EQI3ZKhsg0XN1HINykEL6Z4FUrWsRq3dmFLp/kQmS7nkmUZye3Wqmn2sVzeHIyC2dg9K6U/v7ckxARAjlztGazfLSC4YxlQw5DL29vehRitiJ3Zp2ctvFdLbuqqf4B1z60l9dWiFjgYwcjsKw0WR9WW7Ebbl+XngHIq4L62WKZLi2jkdsHcSSU+lXczUbblT7Xb4bbGZJx93jgVBdXMrQArCWl/iA421NDIJ3+W32g/xYx+tPu0aNMI6kHqQOn0pRY5WOE8SanPHGTNCQqp17tXI2Eb3s73bx57Jnt7123iKE3SmIdO7sMVxk7fYpAsLnaDgit4Pqc9S72OZ8WxFL5C7ZZl5HpWFW34oST7WryA5I61iVsefP4mFFFFBIUUUUAFFLSUAFSQeV58f2jf5O4b9mN23POM98VHUttBJc3MUEK7pZXCIvqScCgDex4S9de/KGqviW+srx7CPTFuVt7S2EANxt3sd7tn5eP4/0qzLo+jW0jQXWvf6Qh2v5FozopHUbiRn6gVm6zprabNEBNHcW88YlhnjyFkQkjODyCCCCD3FAGfRRRTAKKKKACiiigAooooAKWgUUgEq3p919lmyw3RtwwqpRQB6Hpc5lgR4WEiA5A7it/TdXaF2WRWV92PT8a848NzzLcFIXKk9q7a3vJkkAuUUsvA3CsJxPRoTuj0Cz1KC5T5zjnHJyK0bV4wMbwGzkZFcfp9yjf6tQGz0JrpdPvIVKmQ/8BNc7jd6nYpaHSW17F5RHnH5eAOnNT20kTOHjkLN0wKx0jhncBWRc849T61rRJuhHkEqQcj0ot1NVaxpW4YKz7BwMHvk+9SpvhYFeQeT6U6x80R5GWbv2zUwIEhRohntubihMykrlm0kndHa2nVFB2lTGMg1ZjfUY3KudxA6KRn8qpWU5SdtsQU4+U8HP/wBelEjwyb7hvKTOdznAq3sZampbamLOQeZBJuUEqMjjPXn1pkniCcgrDauzk8B2GB+VU31ppQUtbeaUAY3JGTu98mqSXs1vGdtuEff3BJPpSlJdzSnC+rRsQy6rfugEcUIU7i7c5x29qsyadauGlvbiadkPzmRv0UDisqHXr8lBtGf7qITipbrVLxUeZrbzlycRlCpzUucGtdTRxmnpoaaTW62W+KFI0HGMZHPeqskomgWMx4VDnBJ61iw67fSszHSVhjHOWJIFVG1S6JI2g+5O1R/9aoc09ilTktzbH2dLgHyskqSueAKzbmGCSctGpV9vzEkcj6VFZy3b7zIqyBvlUK+AV9M1AzX6yOUhijQcrhst9M0c19hpPuW7OOZCZI1RT6AdPqaCTPKWncgnoBwBWW15fqzxBV+Yg4UnAOKz7g30rMZFzKflVmbCgetPm0sS4PdnQGe0hlIcqxA5LHOKzby9smfAQbzwrIa5+6sLt3Co6ZJ5O7IzWhpGjtEGeUq7dcEnH/1qV23ZIfIkrtizhpMN8uwHoTz6UyW5jgjPlQyeYeQCMVr/AGmaOKMGC1jRF2jA5ArOuJ72RiwKMD9zHFXtsQrspu13cy+bIoRC3CDjBq+totrDhQJJD/Cfl5/nTIors484/Nn+E4I/OtO1S1ifPkncRhneTJB9apPTUykncoJaTmJtxREXnheB7Vjam5SNtjgkjj5entXV3FwFjdUcMvfaMmuO1m4kRGKQncRn5hxTbJ1ueeeK7i8hfYZCUJwT0xWZY2zS7WCBqn8UyvcNtJBlY8gDoM1Z0SZI7YA49Cc1rEym7M5zxpDi1VpQA6kYxXF12/j6cOiqCOoriK2jscFX4gooopmYUUUUAFFFFABUtrJLDcxS25KzI4ZCo5DA8Y/GoqfG7RurxsyOpDKynBBHcGgDppb+3uZGmvPCyPcucu0TyxqzdztBwPoMVka7fT31zGZ7dLWOKMRwwIhVY0BJwM8nkk5PUk11V1c+NtUS3uoItZiJiVXaOR1WUjjeF4wSMZx1PPeuR1efUZr1hrEl093EPLIuSxdR1x83I6/rQBRooopgFFFFAC0lFFABRRRQAoooFFIBKKWkoAsWM7W91HIpwQetekaRcQ6pEVlIjuVXgt0cV5fXU+F7qGYLBdNtaM/K/tSkro3oSs7HcCJ7NUlQkqvLKece/wBK1JFknSOSJATuDErz0rM33UVoHz58HIWQdfxqjpt60Vy+7zInI5U1zzij0acmekaZcpcpGNoEufXBromV4tPYI/zKO4ziuD0bUd0aFirkDr0rrLWc3Fs/mkpjkZznFZWsbKWpqaff3nkDPBbkEnr71p2uobUEVzDuTq2e59zWRDGBbK0bKwGBuPRRV9IvIgT5HKNwAOpNFmVeMjRmW0mkjeeB/KHTZheo71bt7NJGXbHtVFyqOoYsfU5/lVGGFECeaDuboM5Cmta1hRmy8sgXv81WkmzCenUuQT3sMMm1QHJAxsxj2qtFE1y7faDIsZ5ARQM//rqwyxJEmy6nTzOpLDGPeqbTWcKtv1C4yvGFHynilNPqFN32NkWiwkGaY4UY4wCfrVz/AIl8MWwyoxIzjIJrjXmtjEzE3koz1UgUyS3vJYQ0UE0YYdZWFSp+Ro6V92amp6hp9vcMGKE/wsT/AJ5rFnvrGWdVZTs27myevPA/nVOPSru7ucTSLMUGFXd8qn14q9FpQtotp8jBbLPjJJqW5PZGijBdSC8vDlDbwAKenXgVNALq4Az5cQPVm6n8KskxICCgfGcs3YUFv3RZlQKwwAWpRUt2EpRSskVbjT4kZt00jHu2cflVK0s7eWV5RnZGdoB5FTNMCdoc7R97v+tV0vLS2keKW4CjhtoOSauJLbLLMsMgRolcDptX+dMlurmSILBCqKP71QHUklUJa27jdxuIPA71VQ3M8r73EceOBnoKG+gJN62HrdQxP/pCB5MYzu/X6VSk1eJ1AhQjB7DPHpWlbaUqsTGrSf7TcZ/xqWfSMxbwI45OxAqEmtirrqY8F0LjBmWYDPCqMCtjTpbeN1ZLXzGAwd/09KqKPJbytpbn+Hv71bt57cvvOVfuG4x24rSOu5lNrsOuZmKlcQoAeV9K5nWbqEBllZT9OwpvisStf+ZFK7Ice1Vrm3iCAOxZ9oznmhtp6E8qPNfFEu+VxbJuwT82OtZunMUtSc7jj8q7TXbSF4N68MR6Vw8sEltIVHKsemelawZjUXY5rxJM8lyqt90c1jV0Gv25WMyEHr1rn66FsedU+IKWkooICilpKACiiigAqzp1wtrqFrcSRiVIZVkZD0YAg4qtVrSzbjUrQ3ozaiZPN/3MjP6ZoA39QttO1K+mvR4lQea5ci5il81cnODgEEj2NUfFF9BeTWUdtNLcra2ywG5lXa0xDMc464GQozzhRW1qWq+Zq0+m+IzbTadKcwT2yofsyn7jxlf4cYyh7e9Z/jSBbX+xbdZoJ/KsFUyQOHRv3shBBHsRQBzVFFLTASilpKACiiigAooooAKWgUUAJRS0UAJVvTWYXShTgn9aqUoJBBBwR3pDTs7np/h29cW6xgjy2+8DyD/hXUSW9ncROzwoCR93pg+xrz7wjqB3KQm5u6/59a9CtpLe9ZduIUH8Pv6Y+tYzPSpyuriafpitDiG4BmX5fLYcj8qtNd3NrEY5DLFK42hl+ZRU0tj5USsv7xT8wkU4ZTVOykZrhzcKZIOu1hg5HesZHTBXOm8O3txHGIA32gEgtgck111veSBE/cPvzkgsMVymnSWkpzGXSXPQHpXSWMLY8wybmX5WyP51CukaNJ7l9bt5WKbUVhzuJ4FVrhJ5cbrxAp6qi5JHpVqC1ty5MkIcMOSGPFaEVvZwqHJ2AgADOM1STZLstjGRYUUsZbiUk9GH+NPh2ebiOwV1/wCmkpP44rTF0iu0axtO+OFzkfnTpr7VWGw6XZIhGA0qjp9avlRN5dCCHUL+BT5aQRjsEXk1SvLi9uRHE7t5hPI9B7Voia8SFkjlsUGCziJWc8fTNVrRNRkVp7qcWkBG0O0WMgc9z3pNFJoRBcRWxDyJCo+6oHNVXW5JEZuUBALqWGAKtPa2sjDbd3NxcZztWPP/AOqootCSWRZrwSrk5O5tzY6YqPIpNLUw9T1Sa2aOFZUdiMkIM59s02G31nUQGt9sUJGd8p/kK7cQ6VbxoMGNlB+ZlBxismV1eTEHmyo3AZQAPzpcr6samn8KOeGkXIiYy3HmL/cAxk9/z5oiim+14hs4EU5HEWf5810jwhIi7GFAgOSXJ5rOvLiMrGfN2kv96Pvx6UW5dBp83QayC3hH2ySby27KAB/+qnRywRJmKBWZT1LE8e9WZ52vVEaxybVHHQc0yKwmii3sVWLr97n8u9G+wl5jxNJhTFCgUjqWPNPN3ckACEMhOMhulSDbDFl5wF74Xr+FUroq0X7iNymemepp7ENdiG7muNzbY4k9GJ3GseKS4kufLnfODwwHGa2PJmnCAR+UByTjrVG/s2jnTy7kewA6U7XIvbRjLnTnedWkn3DuCMVRu7ZdpMm1wDgelVNRa7s5VkOZ1fPU5INSfbm2K8lv9B1H5Uly3sPUxNYgMqSPnHAAx2FcDfOI7gFzuPau71m788PGjqhHOB2FcPqNvsOWVg/UnHWtYmMjM1WESWrqRlSv61w5GCQe1egxBZbZgxywBOK4O6XZcSLjGGNbxOCsiGiiiqMAooooAKKKKAClAJOByaSrui3Edpq9lcTjMUUyO/0DAmgC2+jRwOYb7Uba2uwOYSrvsPoxUEA+o5x3rPvrSaxuWguFAcYIKkMGBGQQRwQRyDXWzQPHqOlu15LDLbABViheQzfMTviKgh9+c8kckg8Vi+KXQXNtAqqskERWRFORGWkdxHn/AGQwH1yO1AGJRRRTAWkoooQBRRRQAUUUUAFFFFACiiiikAGkoooA3PCjsL4qDxwa9HsifLjfJyWxRRWdQ7sNsbUsskOPLcj5gD75Fa6ok9tF5iLkjqBg0UVzs7YjXhFuu5GbI45q7ZXlxnIlYHAPFFFYSep2WTiaUk0yW6uszgucHmp7a7nljUyys5XgFuaKKd3qFkTLPcSTbPtEiID0TA9vSrlrafaZH+0TzymN9oLtn0oorNyfNa5aiuW9jdTTkjst6zXA4L4D7Rn8MVS06zjvrgG5eVxuHBckfrRRW61aRzPS7NaV/skG23VU5PIrmtQuJX+YscsSDj6Zooqq+miJpK7L+gWsd1Epny5GOvOa0dVcwxAoeuPw59qKKml8Nx1fjsYrsLlMzKrYPTtWxa6fb/uJGTc7N1bnHHaiiqWsiW7RHXcEa8KuOagGnw7QxaTOM9aKKT3Ji9CqUAldeoXOMgen/wBeqsdzJ5shJUhAMKVGKKKBvY0S7eYRnAx2rN1o7SgAHzEZ4oorZ7HP9oy7iCNRuCjOcVTnwIzhR1FFFZ9SznNVtYZFZmjG4HANcXrWYbgxqSy4/i5ooqo7kyMCQ4LFfl+lclqpzfyn1NFFdETir7FOiiiqOYKKKKACiiigAooooAtQahe28DQwXdxFC3WNJWVT9QDVWiigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple brown macules are present on the dorsal hand.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_49_25368=[""].join("\n");
var outline_f24_49_25368=null;
var title_f24_49_25369="Placenta accreta";
var content_f24_49_25369=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F60800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F60800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Placenta accreta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 362px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A) Villi have implanted in scar tissue (arrows) which replaced the endometrium in an area of thinned myometrium. Placenta accretas often occur at the site of prior cesarian sections. Panel B) Note the layer of dense pink fibrinoid covering the scar (arrow). The presence of fibrinoid material between villi and myometrial tissue does not exclude a diagnosis of placenta accreta. Panel C) Villi are immediately adjacent to underlying myometrium without any intervening decidua. Panel D) Villi in direct contact with myometrium (arrow). Note the implantation site trophoblast (arrowhead) which can be mistaken for decidua.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Miriam D Post, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_49_25369=[""].join("\n");
var outline_f24_49_25369=null;
var title_f24_49_25370="Chelation therapy for iron overload states";
var content_f24_49_25370=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chelation therapy for iron overload states",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/49/25370/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/49/25370/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/49/25370/contributors\">",
"     Bruce R Bacon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/49/25370/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/49/25370/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/49/25370/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/49/25370/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/49/25370/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 27, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phlebotomy cannot be used to remove iron in transfusion-dependent subjects (eg, beta thalassemia major, sickle cell anemia), or in the rare patient with congestive failure and an unstable hemodynamic status (eg, hemochromatosis with severe cardiac involvement) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/1\">",
"     1",
"    </a>",
"    ]. Thus, if treatment for iron overload is deemed necessary, one must use an iron chelator.",
"   </p>",
"   <p>",
"    The use of chelating agents for the treatment of iron overload states will be discussed here [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/2\">",
"     2",
"    </a>",
"    ]. Overviews of the causes and diagnosis of iron overload are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33748?source=see_link\">",
"     \"Hepatic iron concentration and hepatic iron index in the diagnosis of iron overload and hereditary hemochromatosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Decisions to begin treatment with iron chelation require clinical judgment, since both the prognosis of the underlying disease and the potential benefit of chelation must be taken into account [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/3\">",
"     3",
"    </a>",
"    ]. The level of evidence to guide the clinician in initiating chelation therapy is quite variable, as shown by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with myelodysplastic syndrome (MDS) and refractory anemia &ge;70 years of age may have a life expectancy similar to that of an age- and sex-matched normal population, with reduced survival for those who are transfusion-dependent. Although such patients might be candidates for chelation therapy, it has yet to be proven that such treatment improves organ function, reduces morbidity, or prolongs survival. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link&amp;anchor=H2104230#H2104230\">",
"       \"Management of the complications of the myelodysplastic syndromes\", section on 'Iron overload'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There are few relevant clinical trials to define the impact of iron chelation on the clinical course of patients with sickle cell anemia [",
"      <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Institution of vigorous chelation therapy early in childhood has been responsible for a marked improvement in survival of patients with beta thalassemia major and is considered the standard of care in this disorder. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Use in thalassemia'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2407611\">",
"    <span class=\"h2\">",
"     Goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of iron chelation therapy is to reduce the increased body burden of iron, especially iron within labile compartments in plasma as well as in various cells within the body. By decreasing iron in these pools, one hopes to minimize the production of reactive oxygen species, thus reducing damage to critical organs such as the liver, heart, and other organs, resulting in reduced morbidity and improved survival [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'Iron toxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=see_link&amp;anchor=H13#H13\">",
"     \"Pathophysiology of beta thalassemia\", section on 'Non-transferrin bound iron'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2407618\">",
"    <span class=\"h3\">",
"     Beta thalassemia major",
"    </span>",
"    &nbsp;&mdash;&nbsp;Goals for the initiation, maintenance, and intensification of chelation in patients with beta thalassemia major have been proposed, and include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/2,5,6\">",
"     2,5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Initiation",
"      </strong>",
"      &mdash; Current practice is to initiate chelation therapy after the first 10 to 25 transfusions have been given,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      at a time when the serum ferritin is greater than 1000",
"      <span class=\"nowrap\">",
"       mcg/L,",
"      </span>",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      when liver iron concentration (LIC) is greater than 3 to 7 mg",
"      <span class=\"nowrap\">",
"       Fe/g",
"      </span>",
"      dry weight. This may occur as early as two years of age. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link&amp;anchor=H6#H6\">",
"       \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'Routine iron studies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Dosing",
"      </strong>",
"      &mdash; Dosing should be tailored to achieve serum ferritin levels &lt;1000",
"      <span class=\"nowrap\">",
"       mcg/L,",
"      </span>",
"      LIC &lt;7 mg",
"      <span class=\"nowrap\">",
"       Fe/g",
"      </span>",
"      dry weight, and a cardiac T2* by MRI &gt;20 milliseconds.",
"     </li>",
"     <li>",
"      <strong>",
"       Intensification of treatment",
"      </strong>",
"      &mdash; A LIC &gt;15 mg",
"      <span class=\"nowrap\">",
"       Fe/g,",
"      </span>",
"      serum ferritin &gt;2500, a cardiac T2* MRI &lt;20 milliseconds, or a fall in the left ventricular ejection fraction (LVEF) because of cardiac siderosis, cardiac failure, or arrhythmia indicates inadequate chelation, requiring intensification of treatment. This may include revision of the dose or frequency of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      infusions, switching to another chelator, or employing combined therapy with two chelating agents. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7802?source=see_link&amp;anchor=H17#H17\">",
"       \"Treatment of beta thalassemia\", section on 'Cardiac monitoring'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Amelioration of iron loading",
"      </strong>",
"      &mdash; The iron intake from blood transfusions can be reduced by performing splenectomy if transfusion requirements are unusually high (eg, &gt;200 to 220 mL packed red blood",
"      <span class=\"nowrap\">",
"       cells/kg",
"      </span>",
"      per year). However, we are reluctant to recommend splenectomy before the age of six years because of the risk of overwhelming sepsis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7802?source=see_link&amp;anchor=H18#H18\">",
"       \"Treatment of beta thalassemia\", section on 'Splenectomy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     DEFEROXAMINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     Deferoxamine",
"    </a>",
"    (DFO, Desferal) is a clinically approved and effective iron chelator for long-term therapy in patients with beta thalassemia and other iron overload states [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. DFO is a relatively specific and nontoxic iron chelating agent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/9,10\">",
"     9,10",
"    </a>",
"    ], which has also been utilized for the diagnosis or treatment of aluminum-induced toxicity associated with chronic kidney disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=see_link&amp;anchor=H13#H13\">",
"     \"Aluminum toxicity in end-stage renal disease\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although DFO is absorbed orally, the pharmacokinetics of intermittent oral doses are unfavorable for effective iron chelation. Continuous intravenous or subcutaneous infusion is therefore necessary. Previous regimens that attempted intermittent intramuscular administration have proved unworkable.",
"   </p>",
"   <p>",
"    In the circulation and tissues, DFO binds iron and the iron bound form is excreted efficiently in the urine and bile [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The key mechanisms involved in iron chelation by DFO are [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      DFO is a hexadentate iron-chelating molecule, meaning that one molecule of DFO can bind one iron atom (",
"      <a class=\"graphic graphic_figure graphicRef77704 \" href=\"UTD.htm?38/40/39565\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Iron derived from senescent red cells is released by macrophages of the reticuloendothelial system, chelated by DFO, and immediately excreted in the urine.",
"     </li>",
"     <li>",
"      Iron-free DFO is internalized by hepatic parenchymal cells, interacts with the chelatable intracellular iron pool, binds iron, and is excreted in bile.",
"     </li>",
"     <li>",
"      DFO is able to remove iron directly from myocardial cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, DFO has a relatively short half-life in the body, but the release of iron for chelation from tissue iron stores is continuous. As a result, it has been necessary to develop continuous infusion protocols designed to achieve iron excretion rates of at least 115",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in patients who were previously iron overloaded [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/7,9,10,12-14\">",
"     7,9,10,12-14",
"    </a>",
"    ]. If patients are treated concomitantly with ascorbic acid, an agent that increases tissue iron turnover into the plasma, up to 300",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of iron can be excreted in the presence of large doses of continuous intravenous DFO.",
"   </p>",
"   <p>",
"    For typical chelation regimens, approximately 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    is placed into a small battery-driven pump, which is then adjusted to deliver the infusion subcutaneously over 8 to 12 hours each night. To avoid visual or auditory loss, no more than 2.5 g of deferoxamine should be used with each infusion (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Side effects'",
"    </a>",
"    below). The cost of the pump, tubing, medication, and accessory materials at Stanford is approximately $45,000 per year (",
"    <a class=\"graphic graphic_table graphicRef78454 \" href=\"UTD.htm?15/0/15372\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Nightly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    infusion should result in 20 to 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (600 to 1500",
"    <span class=\"nowrap\">",
"     mg/month)",
"    </span>",
"    of iron loss in the urine and stool [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/15\">",
"     15",
"    </a>",
"    ]. It can therefore minimize further iron accumulation and may even reduce iron stores if the transfusion rate can be kept under four units of red cells (800 mg of iron) per month.",
"   </p>",
"   <p>",
"    An alternative approach in patients who already have severe iron overload (eg, cardiac arrhythmias, left ventricular dysfunction) or do not tolerate subcutaneous therapy is continuous 24-hour",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    infusion via an indwelling intravenous catheter. This approach was successfully used in 17 high-risk patients with beta-thalassemia who were treated for one to five years; the infection and thrombosis rates were 1.2 and 0.5 per 1000 catheter days, respectively, and there was no treatment-related mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Use in thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Current regimens for DFO treatment in transfusion-dependent beta thalassemia call for a nightly 10 to 12 hour continuous subcutaneous infusion of about 2 g of DFO using a small battery-driven pump [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/12\">",
"     12",
"    </a>",
"    ]. An adequate dose of DFO can usually be injected through a 25-gauge butterfly needle, thus minimizing discomfort. Local irritation and hives at the injection site are occasional complications, but these are usually transient or can be controlled by reducing the dose or rate of infusion. In order to be effective, DFO should be administered about 250 nights each year.",
"   </p>",
"   <p>",
"    Some centers begin continuous DFO infusions at age five to six years, while some begin these infusions even earlier [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/5\">",
"     5",
"    </a>",
"    ], although the effects of earlier initiation on growth and development are uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/9,10,12,13,17\">",
"     9,10,12,13,17",
"    </a>",
"    ]. Starting chelation early appears to delay cardiac symptoms and, perhaps, prolong survival. Iron excretion is improved if vitamin C supplies are adequate, but ascorbic acid should be administered with great caution, since the increased release of iron can damage tissues unless DFO is continuously present. It is best to establish the optimal dose regimen of DFO before instituting supplementary ascorbic acid therapy.",
"   </p>",
"   <p>",
"    Serum ferritin levels should be monitored and therapy should be maintained or increased until levels fall substantially. Based on studies of iron-associated disease in patients with hereditary hemochromatosis, one should attempt to reduce the ferritin level to less than 1000",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    Three to five years of therapy are often required to obtain this level.",
"   </p>",
"   <p>",
"    There is increasing evidence that the use of this regimen, or even more aggressive regimens, will delay the onset of, or actually reverse, cardiac hemosiderosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Ultra intense regimens of &gt;15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per hour of intravenous DFO have been reported to reverse early cardiac hemosiderosis, while more conventional doses (eg, 43",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day averaged out over a mean of three years) improved left ventricular ejection fraction (LVEF) and prevented death in a group of patients followed with annual determination of LVEF [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/18\">",
"     18",
"    </a>",
"    ]. A retrospective analysis of a patient database has indicated that the 2.6 to 3.1 percent improvements in LVEF observed in randomized trials of iron chelation have been associated with risk reductions of 26 to 46 percent for the development of heart failure over a 12 month period [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of available studies in patients with transfusion- dependent thalassemia has concluded that iron chelators significantly reduced myocardial iron content by about 24 percent (95% CI 17-30 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/21\">",
"     21",
"    </a>",
"    ]. There was no significant difference between the amount of iron reduced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    . LVEF was not significantly changed by chelation, although this meta-analysis indicated that a publication bias existed for LVEF, but not for myocardial iron.",
"   </p>",
"   <p>",
"    Although DFO therapy is effective and relatively nontoxic, it is extremely expensive and cumbersome to use, and compliance with prolonged infusion regimens is difficult, particularly when children reach adolescence. Furthermore, complications related to iron overload still occur and the long-term effects of DFO remain a concern. In a long-term follow-up of 97 children with beta thalassemia major, 36 developed cardiac disease and 18 died [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/22\">",
"     22",
"    </a>",
"    ]. Only the proportion of serum ferritin measurements that were below 2500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    were of prognostic value for cardiac disease. Patients in whom less than one-third of serum ferritin values exceeded 2500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    had estimated 10- and 15-year rates of survival without cardiac disease of 100 and 91 percent.",
"   </p>",
"   <p>",
"    Long-term studies indicate that full compliance with iron chelation therapy has been accomplished in only about 50 to 80 percent of patients, with overall survival to age 30 of about 55 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. This compares with survivals of 25 percent prior to the advent of iron chelation as standard treatment (",
"    <a class=\"graphic graphic_figure graphicRef75362 \" href=\"UTD.htm?3/36/3662\">",
"     figure 2",
"    </a>",
"    ). The Torino data indicate survivals to age 30 of 88 and 10 percent for those able (60 percent of patients) or unable (40 percent) to adhere fully to a chelation program, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/25\">",
"     25",
"    </a>",
"    ]. Clearly, present chelation programs are burdensome and inconvenient, and alternative, more tolerable approaches are required [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For these reasons, a vigorous search for less burdensome modes of DFO administration continues in many centers throughout the world. Starch-conjugated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    , a long-acting preparation capable of inducing increased iron excretion for as long as one week following a single 60-minute intravenous injection, is in clinical trials [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    include visual and auditory neurotoxicity with chronic therapy, and acute complications such as abdominal",
"    <span class=\"nowrap\">",
"     discomfort/pain,",
"    </span>",
"    diarrhea, nausea, vomiting, hypotension, and anaphylaxis. In one report of 89 patients receiving nightly subcutaneous deferoxamine for transfusional iron overload, 13 presented with the acute onset of visual loss",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deafness [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/28\">",
"     28",
"    </a>",
"    ]. Detailed ophthalmologic, audiologic, and evoked-potential studies uncovered abnormalities caused by neurotoxicity in another 27 patients. Thus, patients treated with deferoxamine should be referred to ophthalmology and otorhinolaryngology for baseline and yearly examinations.",
"   </p>",
"   <p>",
"    Visual loss and ototoxicity following the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    are directly related to the dose of deferoxamine and inversely related to the degree of iron overload. This risk can be minimized by adjusting the daily dose of deferoxamine to the patient's serum ferritin concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fortunately, DFO is well tolerated by most patients. Chronic administration of 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of DFO has been associated with the development of cataracts in animals, but not in thalassemic patients. However, decreasing visual and auditory acuity has been associated with prolonged use; fortunately, much of this toxicity appears to be reversible upon discontinuing DFO. Long-term monitoring of auditory and visual function is clearly indicated. High-dose DFO therapy has also been associated with aggravation of pulmonary disease, including pulmonary hypertension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Risk of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     Deferoxamine",
"    </a>",
"    administration may be associated with an increased risk of infection with mucormycosis (zygomycosis), Yersinia, and Vibrio vulnificus. The presumed reason for the susceptibility to these infections is that the deferoxamine-iron chelate, called feroxamine, is a siderophore for these species; the resulting increase in iron uptake stimulates their growth, possibly leading to clinical infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. This complication may not be seen with the other iron chelators",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    , which do not act as siderophores [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link&amp;anchor=H4#H4\">",
"     \"Mucormycosis (zygomycosis)\", section on 'Deferoxamine and iron overload'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44710?source=see_link&amp;anchor=H6#H6\">",
"     \"Vibrio vulnificus infections\", section on 'Iron'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Use in myelodysplastic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of iron chelation therapy in the myelodysplastic syndrome is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link&amp;anchor=H2104230#H2104230\">",
"     \"Management of the complications of the myelodysplastic syndromes\", section on 'Iron overload'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Use in sickle cell disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of iron chelation therapy in sickle cell disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H28#H28\">",
"     \"Overview of the management of sickle cell disease\", section on 'Excessive iron stores'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H16\">",
"     'Use in sickle cell anemia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Use in acute iron poisoning",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of iron chelation therapy in acute iron poisoning is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2970?source=see_link&amp;anchor=H30#H30\">",
"     \"Acute iron poisoning\", section on 'Deferoxamine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DEFERIPRONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;An orally effective iron chelator,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    (Ferriprox), has been tested in patients with thalassemia and sickle cell anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. Deferiprone is a bidentate chelating agent, which means that three molecules are required in order to bind one atom of iron (",
"    <a class=\"graphic graphic_figure graphicRef77704 \" href=\"UTD.htm?38/40/39565\">",
"     figure 1",
"    </a>",
"    ). It is in regular use in much of the world but was not approved by the FDA for use in the United States until 2011.",
"   </p>",
"   <p>",
"    One series evaluated 26 patients who were unable to take or were not compliant with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    ; the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    for a mean of 39 months was associated with stable iron stores as evidenced by no significant change in serum ferritin or urine iron excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/34\">",
"     34",
"    </a>",
"    ]. However, 8 of 17 patients tested had hepatic iron levels above 15",
"    <span class=\"nowrap\">",
"     mg/g,",
"    </span>",
"    a level at which hepatic and cardiac injury are likely to occur. The major side effects were joint symptoms, gastrointestinal complaints (particularly nausea), and neutropenia or agranulocytosis. In a multicenter study, the incidence of agranulocytosis (absolute neutrophil count [ANC]",
"    <span class=\"nowrap\">",
"     &lt;500/microL)",
"    </span>",
"    and neutropenia (ANC 500 to",
"    <span class=\"nowrap\">",
"     1500/microL)",
"    </span>",
"    was 0.6 and 5.4 per 100 patient-years; all resolved after drug discontinuation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similar limitation in efficacy was noted in another report in which 19 patients with thalassemia major treated continuously with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    for a mean of 4.6 years were compared with 20 patients treated with parenteral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    ; multiple liver biopsies were performed in some of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/35\">",
"     35",
"    </a>",
"    ]. In 7 of 18 subjects deferiprone was associated with hepatic iron concentrations in the range associated with increased risk of cardiac disease and early death. However, many of the liver biopsy specimens were subsequently judged to be suboptimal and many of these patients were infected with hepatitis C. Accordingly, it was not possible to separate the effect of hepatic iron deposition versus that of hepatitis C on hepatic fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/36/43591?source=see_link&amp;anchor=H11#H11\">",
"     \"Long-term management of the thalassemic patient after hematopoietic cell transplantation\", section on 'Chronic hepatitis and liver fibrosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The study cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/35\">",
"     35",
"    </a>",
"    ] raised the serious concern that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    might enhance the propensity for hepatic and perhaps cardiac fibrosis in patients with beta-thalassemia major, and resulted in considerable debate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/36,39\">",
"     36,39",
"    </a>",
"    ]. This issue is of considerable clinical importance since some patients cannot take or refuse to take",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    ; its high cost and complex administration make it virtually unavailable in third world countries. Deferiprone is thus a potentially useful alternative for these patients, especially for those in whom current chelation therapy with deferoxamine has been inadequate, or where deferoxamine and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    are not available [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19247545\">",
"    <span class=\"h2\">",
"     Dosing and side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common adverse events included increased hepatic enzymes, gastrointestinal discomfort, and arthralgia. Incidences of neutropenia and agranulocytosis were 2.1 and 0.4 events per 100 patient-years, respectively; both were reversible upon interruption of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/41\">",
"     41",
"    </a>",
"    ]. Similar rates of neutropenia (2.8) and agranulocytosis (0.2) were found in a second long-term study involving 187 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/37\">",
"     37",
"    </a>",
"    ], although a report from the United States FDA indicated that agranulocytosis occurred in 1.7 percent of patients in clinical trials. Ten fatal cases of agranulocytosis have been reported with this agent, one with Diamond-Blackfan anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/42\">",
"     42",
"    </a>",
"    ] and nine with thalassemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gastrointestinal symptoms (eg, nausea, vomiting, abdominal pain) were more common in the group of patients taking both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    (38 versus 24 percent), but were generally mild in severity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/44\">",
"     44",
"    </a>",
"    ]. There was one episode of agranulocytosis and two episodes of neutropenia in the combined treatment group.",
"   </p>",
"   <p>",
"    A potential problem with the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    was raised by cell culture studies in iron-loaded liver cells that showed potentiation of oxidative DNA damage by the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/45\">",
"     45",
"    </a>",
"    ]. This occurs when the concentration of the chelator is low relative to the iron concentration. The clinical implications of this in vitro observation are not known. Despite these concerns, deferiprone continues to be tested in clinical trials, particularly in developing countries where there are no alternatives, given the cost and complexity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    administration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommended initial oral dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    is 25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    taken three times per day (initial total daily dose 75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day), and the maximum recommended total daily dose is 99 to 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/47\">",
"     47",
"    </a>",
"    ]. Absolute neutrophil counts must be performed regularly while the patient is receiving this medication to monitor for evolving",
"    <span class=\"nowrap\">",
"     neutropenia/agranulocytosis.",
"    </span>",
"    Periodic measurement of the serum ferritin should be used to adjust dosing. If the serum ferritin decreases consistently to &lt;500",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    <span class=\"nowrap\">",
"     (mcg/L),",
"    </span>",
"    temporary interruption of treatment may be necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19247476\">",
"    <span class=\"h2\">",
"     Comparison with deferoxamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    does not appear to adequately control the total iron burden in some patients with thalassemia, the following clinical trials appear to support the relative safety and utility of deferiprone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/36,41,44,48-53\">",
"     36,41,44,48-53",
"    </a>",
"    ], and suggest that deferiprone may be superior in removing myocardial iron compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/44,50,52,53\">",
"     44,50,52,53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest series treated 532 patients with transfusion-dependent thalassemia major [",
"      <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/41\">",
"       41",
"      </a>",
"      ]. For the 151 patients completing three years of therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"       deferiprone",
"      </a>",
"      , mean ferritin levels at the start of treatment, and at 12, 24, and 36 months were 2579, 2671, 2472, and 2320",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      respectively. Ferritin decrease was significant at all three time points for those with initial ferritin values &gt;4000",
"      <span class=\"nowrap\">",
"       ng/mL,",
"      </span>",
"      while those with initial values of 2000 to 4000",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      showed a significant decrease after 24 months. Overall, 20 percent of subjects showed a worsening of ferritin during the first 12 months of treatment.",
"     </li>",
"     <li>",
"      A randomized trial compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"       deferiprone",
"      </a>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      in 144 patients with thalassemia major and serum ferritin between 1500 and 3000",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/49\">",
"       49",
"      </a>",
"      ]. After one year of treatment, there were no differences in reduction of serum ferritin, reduction of liver or myocardial iron by an indirect magnetic resonance imaging technique, or liver iron concentration by biopsy.",
"     </li>",
"     <li>",
"      In a small comparative study of 15 subjects receiving chelation with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"       deferiprone",
"      </a>",
"      alone for &gt;3 years, and 30 matched controls treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      , the deferiprone-treated group had significantly higher estimated liver iron concentration (magnetic resonance imaging), but significantly lower estimated myocardial iron concentration, associated with a greater left ventricular ejection fraction [",
"      <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In 56",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"       deferiprone",
"      </a>",
"      -treated patients, serial liver biopsies disclosed no evidence for progression of liver fibrosis during long-term therapy (median time of treatment 3.5 years) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is evidence that compliance with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    (79 to 80 percent) is higher than that for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    (59 to 78 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/24\">",
"     24",
"    </a>",
"    ]. However, the efficacy and safety of deferiprone remain controversial, so that routine use cannot be recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/39,54\">",
"     39,54",
"    </a>",
"    ]. While at least one retrospective analysis has shown superior efficacy for deferiprone over deferoxamine [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/48\">",
"     48",
"    </a>",
"    ], a Cochrane analysis of the available literature has concluded that deferiprone is indicated for the treatment of iron overload in thalassemia when deferoxamine is contraindicated or inadequate [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19247636\">",
"    <span class=\"h2\">",
"     Comparison with deferoxamine and deferasirox",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no prospective randomized trials comparing the three available iron chelating agents for the",
"    <strong>",
"     initial",
"    </strong>",
"    <span class=\"nowrap\">",
"     treatment/prevention",
"    </span>",
"    of iron overload in subjects with thalassemia major. However, results are available from the first 550 subjects enrolled in the Myocardial Iron Overload in Thalassemia network, dealing with a retrospective analysis of selected patients who had been receiving only one of the three agents for longer than one year (24, 42, and 89 treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    , respectively). The three groups were not entirely comparable, with the main difference being the duration of active treatment which was 2 &plusmn; 1, 4 &plusmn; 4, and 24 &plusmn; 10 years for those in the deferasirox, deferiprone, and deferoxamine treatment groups, respectively. Observations include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/56\">",
"     56",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The global heart T2* value was significantly higher, meaning less cardiac iron overload, in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"       deferiprone",
"      </a>",
"      group than in the two other groups.",
"     </li>",
"     <li>",
"      Left ventricular ejection fractions were significantly greater in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"       deferiprone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      groups than in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"       deferasirox",
"      </a>",
"      group.",
"     </li>",
"     <li>",
"      Liver iron concentrations were significantly lower in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      group than in the two other groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Preliminary results are available from the same authors on a prospective evaluation of 193 patients with thalassemia major who had received only one of the three chelating agents between two MRI scans of the liver and heart [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/57\">",
"     57",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among those with no significant myocardial iron overload at baseline (ie, global heart T2* &ge;20 milliseconds), there were no significant differences in all three groups in the ability to maintain the patients without significant iron overload.",
"     </li>",
"     <li>",
"      Among those with myocardial iron overload at baseline (ie, global heart T2* &lt;20 milliseconds), there was a significant improvement in the global heart T2* in all three groups, with the greatest improvement being in those treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"       deferiprone",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      In patients with liver iron overload at baseline (liver T2* &lt;5.1 milliseconds) the change in liver T2* was not different among the three treatment groups. Similarly, changes in mean serum ferritin levels were not significantly different among treatment groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these studies suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    was significantly more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    in improving myocardial siderosis, only a randomized, prospective study comparing the three available agents can definitively answer the question concerning the optimal way to avoid clinically significant cardiac and hepatic iron overload in thalassemia major.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Deferiprone plus deferoxamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether alternative dosing schedules of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    or combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    (given at the time of blood transfusion) would be more effective has not been extensively studied [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/44,58-61\">",
"     44,58-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One report evaluated the effects of increasing the dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"       deferiprone",
"      </a>",
"      and combined therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      in 13 transfusion-dependent patients who were inadequately chelated by the usual deferiprone dose of 75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day [",
"      <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/59\">",
"       59",
"      </a>",
"      ]. Both raising the daily dose of deferiprone to 83 to 100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      and combination therapy with deferoxamine lowered the serum ferritin in all patients.",
"     </li>",
"     <li>",
"      Combined treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      (40 to 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      SQ at least five nights per week) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"       deferiprone",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day PO) was compared with treatment with deferoxamine plus placebo in a randomized study which included 65 subjects with thalassemia major and mild to moderate myocardial iron loading, as judged by myocardial T2* cardiovascular magnetic resonance [",
"      <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/44\">",
"       44",
"      </a>",
"      ]. Following 12 months of treatment, there were significant improvements in the combined treatment group compared with the deferoxamine alone group in myocardial T2*, absolute left ventricular ejection fraction, absolute endothelial function, liver T2*, and serum ferritin levels.",
"     </li>",
"     <li>",
"      A multicenter randomized open-label trial assessed the long-term effectiveness of sequential",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"       deferiprone",
"      </a>",
"      -",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"       deferoxamine",
"      </a>",
"      (DFP-DFO: DFP 75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day orally for 4",
"      <span class=\"nowrap\">",
"       days/week",
"      </span>",
"      plus DFO 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day by subcutaneous infusion for the remaining 3",
"      <span class=\"nowrap\">",
"       days/week)",
"      </span>",
"      versus deferiprone alone (DFP 75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day for 7",
"      <span class=\"nowrap\">",
"       days/week)",
"      </span>",
"      in 213 patients with thalassemia major [",
"      <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/61\">",
"       61",
"      </a>",
"      ]. The decrease in serum ferritin during the five-year treatment period was significantly greater for the DFP-DFO treatment arm than for the DFP arm.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, there were no overall differences between treatment arms for T2* MRI signals of the heart and liver, overall survival, adverse events, or costs, suggesting the value of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    alone in countries in which subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    is unavailable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Use in severe cardiac complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with iron overload states usually treated with phlebotomy (eg, hereditary hemochromatosis) may not tolerate such treatment if they suffer from severe congestive failure with an unstable hemodynamic status. Similarly, transfusion-dependent patients with severe cardiac involvement may require more aggressive therapy than the use of a single iron chelating agent alone.",
"   </p>",
"   <p>",
"    It is in such cases that combined treatment with intravenous or subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    plus oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    has been instituted. Such combination therapy, as discussed above, has been shown to be more effective than single agent iron chelation for those with mild to moderate degrees of hepatic and cardiac iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/44,59,61\">",
"     44,59,61",
"    </a>",
"    ]. Combination therapy also takes advantage of the fact that available iron chelators appear to remove iron from ferritin via different mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combination therapy also been effective in smaller studies in unstable patients with severe degrees of cardiac siderosis and impaired left ventricular function [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/1,63\">",
"     1,63",
"    </a>",
"    ]. As an example, one study in 52 patients with beta thalassemia major employed \"very intensive\" combined chelation therapy consisting of DFO 20 to 60",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day by subcutaneous infusion plus DFP 75 to 100",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in three divided doses. Results included [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/64\">",
"     64",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients' iron load normalized, as judged by cardiac and hepatic magnetic resonance imaging findings. Baseline and post-treatment ferritins (mean &plusmn; SD) were 3422 &plusmn; 882 and 97 &plusmn; 25, respectively, indicating",
"      <strong>",
"       full",
"      </strong>",
"      normalization of ferritin levels with this dosing regimen.",
"     </li>",
"     <li>",
"      Symptoms reversed in all 12 patients receiving treatment for cardiac dysfunction, enabling 9 of the 12 to discontinue heart medications.",
"     </li>",
"     <li>",
"      Glucose metabolism was normalized in 44 percent of the 39 patients with baseline abnormal glucose metabolism.",
"     </li>",
"     <li>",
"      A high percentage of those with hypothyroidism or hypogonadism improved. Of the 19 females who were hypogonadal on DFO monotherapy, six were able to conceive.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DEFERASIROX",
"    </span>",
"    &nbsp;&mdash;&nbsp;Utility and safety of the orally active iron chelator",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    (Exjade) have been shown in short-term pharmacokinetic studies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/65,66\">",
"     65,66",
"    </a>",
"    ], as well as in nonrandomized and randomized, trials in patients with thalassemia major, thalassemia intermedia, and other transfusional iron overload states (eg, sickle cell disease, myelodysplastic syndrome, Diamond-Blackfan anemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/67-70\">",
"     67-70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     Deferasirox",
"    </a>",
"    is a tridentate chelating agent, which means that two molecules are required to bind one iron atom (",
"    <a class=\"graphic graphic_figure graphicRef77704 \" href=\"UTD.htm?38/40/39565\">",
"     figure 1",
"    </a>",
"    ). It has a high affinity for iron and a much lower affinity for copper and zinc. This agent is commercially available in the United States. Multiple randomized phase III studies comparing this agent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    are in progress. The recommended starting dose in children, adults, and the elderly is 20",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day with a maximum approved dose of 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, since raised to 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day by the United States FDA [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Use in transfusion-dependent beta thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Results from a randomized phase III trial in 586 regularly-transfused patients with beta thalassemia indicate that chronic use of this agent, via a single oral dose of 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, induced decreases in liver iron concentration (LIC) in most patients, similar to that achieved with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    (DFO, &ge;50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day), with minimal short-term toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/69,73,74\">",
"     69,73,74",
"    </a>",
"    ]. Specific results of this trial included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/69\">",
"     69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For both DFO and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"       deferasirox",
"      </a>",
"      , iron excretion increased linearly with increasing dose. At the rate of iron intake seen in the patients with beta thalassemia (0.4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day), negative iron balance was achieved in approximately 50 percent of patients at a deferasirox dose of 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day or 40",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day of DFO.",
"     </li>",
"     <li>",
"      Doses of 5 and 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"       deferasirox",
"      </a>",
"      were too low to maintain or reduce absolute LIC or to achieve negative iron balance at any level of transfusional iron intake [",
"      <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/69,74\">",
"       69,74",
"      </a>",
"      ]. Differences in bioavailability may have explained inadequate responses to this agent in some of these patients [",
"      <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/75\">",
"       75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A four-year extension study was made available to all subjects who completed the initial one-year trial [",
"      <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/76\">",
"       76",
"      </a>",
"      ]. In those with four or more years of exposure to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"       deferasirox",
"      </a>",
"      , mean liver iron concentration and serum ferritin levels decreased significantly. Adverse events (increased creatinine, abdominal pain, nausea) were generally mild to moderate, transient, and reduced in frequency over time. No adverse effect was observed on pediatric growth or adolescent sexual development.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As a part of a larger EPIC trial in patients with various transfusion-dependent anemias [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/77\">",
"     77",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    was employed in a one-year prospective, open-label, multicenter study of 192 patients with beta thalassemia and iron overload (serum ferritin &gt;2500",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    LIC &gt;10 mg",
"    <span class=\"nowrap\">",
"     Fe/g",
"    </span>",
"    dry weight, &gt;50 transfused blood units, and a left ventricular ejection fraction (LVEF) &ge;56 percent). Results included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/78\">",
"     78",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the 114 patients with cardiac siderosis (ie, MRI myocardial T2* from 5 to 20 milliseconds, cardiac iron reduction arm), treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"       deferasirox",
"      </a>",
"      for one year at a mean dose of 32.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day resulted in a significant improvement in myocardial T2* from 11.2 to 12.9 milliseconds, with no significant change in LVEF.",
"     </li>",
"     <li>",
"      In the 78 patients with iron overload whose myocardial T2* was &ge;20 milliseconds (prevention arm), treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"       deferasirox",
"      </a>",
"      for one year at a mean dose of 27.6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day resulted in no significant worsening or improvement in myocardial T2*. LVEF increased from 67.7 to 69.6 percent.",
"     </li>",
"     <li>",
"      Ferritin values after one year of treatment increased in 17 and 20 percent of subjects in the cardiac iron reduction and prevention arms, respectively.",
"     </li>",
"     <li>",
"      Seventy-one patients in the EPIC cardiac substudy continued chelation therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"       deferasirox",
"      </a>",
"      into the third year [",
"      <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/79\">",
"       79",
"      </a>",
"      ]. In those with baseline T2* values of 10 to &lt;20 milliseconds, 68.1 percent normalized (ie, T2* &gt;20 milliseconds), while 50 percent of those with baseline T2* in the range of &gt;5 to &lt;10 milliseconds improved to 10 to &lt;20 milliseconds. There was no significant variation in left ventricular ejection fraction over the three years. Only one serious cardiac adverse event was noted during this interval (atrial fibrillation in a patients with improved cardiac T2*, decreasing liver iron concentration and decreasing serum ferritin level).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a separate study, 28 patients with abnormal T2* and LVEF were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    at initial doses of 30 to 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/80\">",
"     80",
"    </a>",
"    ]. Cardiac iron improved 24 percent in patients having LIC in the lower 2 quartiles, but worsened by 8.7 percent in those having LIC in the upper 2 quartiles. LVEF was unchanged at all time points.",
"   </p>",
"   <p>",
"    These results show only marginal clinical benefit, especially given the current cost of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    (approximately",
"    <span class=\"nowrap\">",
"     $80,000/year",
"    </span>",
"    at these maximal doses). We await the results of the phase III trial comparing deferasirox with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    in these patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15375128\">",
"    <span class=\"h2\">",
"     Use in transfusion-independent thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although subjects with thalassemia intermedia may be either transfusion-independent or require only infrequent transfusions, they have increased absorption of dietary iron, and may ultimately develop signs and symptoms of iron overload. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=see_link&amp;anchor=H23#H23\">",
"     \"Clinical manifestations and diagnosis of the thalassemias\", section on 'Beta thalassemia intermedia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The randomized, double-blind, placebo-controlled THALASSA trial assessed the efficacy and safety of two different doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    taken over a one-year period in 166 subjects with non-transfusion-dependent thalassemia. Eligible subjects were &ge;10 years of age, had serum ferritin levels &gt;300",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    MRI-measured liver iron concentrations (LIC) &ge;5 mg",
"    <span class=\"nowrap\">",
"     Fe/g",
"    </span>",
"    dry liver weight, and had not received transfusions within six months or iron chelation within one month before study entry. Results included the following [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/81\">",
"     81",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An absolute reduction in LIC of &ge;3 mg",
"      <span class=\"nowrap\">",
"       Fe/g",
"      </span>",
"      dry liver weight between baseline and 52 weeks, the primary study endpoint, was reached in 11, 33, and 56 percent of those treated with placebo,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"       deferasirox",
"      </a>",
"      at a starting dose of 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, and deferasirox at a starting dose of 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, respectively.",
"     </li>",
"     <li>",
"      At one year, the mean change from baseline in LIC was -1.95 and -3.80 mg",
"      <span class=\"nowrap\">",
"       Fe/g",
"      </span>",
"      for those receiving the 5 or 10",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day doses, respectively. In the extension study, reported in abstract form, 133 subjects received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"       deferasirox",
"      </a>",
"      at doses of 10 to 20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day. The mean absolute change in LIC from baseline to month 24 for those enrolled in this extension study was -7.1 mg",
"      <span class=\"nowrap\">",
"       Fe/g",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/82\">",
"       82",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The median change in serum ferritin from baseline to 52 weeks, one of the secondary study endpoints, was +81, -102, and -202 for the placebo and the two",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"       deferasirox",
"      </a>",
"      -treated groups, respectively.",
"     </li>",
"     <li>",
"      Investigator-assessed drug-related adverse events were reported in 24 percent of the patients, were similar among the three treatment groups, of mild to moderate severity, and resolved without discontinuing treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although this use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    has been approved by the FDA for subjects &gt;10 years of age with non-transfusion-dependent thalassemia and a LIC &ge;5, the results reported thus far may not be clinically relevant. However, it seems reasonable to consider deferasirox therapy for those patients with liver iron levels above 10",
"    <span class=\"nowrap\">",
"     mg/g,",
"    </span>",
"    as they are approaching the 15",
"    <span class=\"nowrap\">",
"     mg/g",
"    </span>",
"    threshold for increased risk of cardiac disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2809410\">",
"    <span class=\"h2\">",
"     Deferiprone plus deferasirox",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are only a few reports on the combined use of the two orally active iron chelating agents",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. Impressive results were obtained in a 34-year-old patient with beta thalassemia major, a life-long transfusion requirement, and severe iron overload (cardiac MRI T2* 9.36 ms, serum ferritin &gt;2800",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    who was treated with the combination of deferiprone (75",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    plus deferasirox (30",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    after having suboptimal response to treatment with deferiprone alone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/83\">",
"     83",
"    </a>",
"    ]. After 12 months of combined therapy, her cardiac T2* returned to within the normal range at 21.1 ms, and her serum ferritin was markedly improved at 397",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    No renal or hepatic abnormalities or episodes of neutropenia were noted on repeat testing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13075577\">",
"    <span class=\"h2\">",
"     Deferoxamine plus deferasirox",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 34-day iron balance study in six thalassemic patients indicated that supplementing the daily use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) with two to three days of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    per week (40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) placed all patients into net negative iron balance, whereas four of the six remained in positive iron balance when treated with deferasirox alone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Use in sickle cell anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized open label phase II trial evaluated safety and tolerability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    in comparison with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    in 195 patients with sickle cell disease who had received at least 20 units of packed red cells and had a serum creatinine equal to or less than the upper limit of normal, and a serum ferritin &ge;1000",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/67\">",
"     67",
"    </a>",
"    ]. Doses of deferasirox of 10, 20, and 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day PO resulted in statistically significant and progressive reductions in liver iron concentration from baseline following 52 weeks of treatment. Over a one-year period, similar dose-dependent reductions in liver iron concentration were observed with deferasirox and deferoxamine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8346483\">",
"    <span class=\"h2\">",
"     Use in aplastic anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective one-year Evaluation of Patients&rsquo; Iron Chelation with Exjade (EPIC) study evaluated the efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    in 116 patients with aplastic anemia and transfusional iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/86\">",
"     86",
"    </a>",
"    ]. Results included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Median serum ferritin decreased significantly from 3254",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      at baseline to 1854",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      at one year. Decreases occurred in both chelation-na&iuml;ve and previously chelated subjects.",
"     </li>",
"     <li>",
"      Decreases in mean alanine aminotransferase levels at one year correlated significantly with reduction in serum ferritin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most common drug-related adverse events were nausea (22 percent) and diarrhea (16 percent). Serum creatinine increases above the upper limit of normal occurred in 25 percent; concomitant use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    had a significant adverse impact on serum creatinine levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse events observed more commonly following",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    included abdominal pain, nausea, vomiting, diarrhea, back pain, and skin rash; gastrointestinal adverse events were generally transient in nature, lasting not more than one week. Discontinuation rates of deferasirox and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    were both 11 percent in this study.",
"   </p>",
"   <p>",
"    Of importance, patients with baseline serum creatinine above the upper limit of normal were excluded from clinical trials. Post-marketing reports include cases of acute renal failure, cytopenias (eg, agranulocytosis, neutropenia, thrombocytopenia), hepatic failure, and gastrointestinal hemorrhage, some of which were fatal [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. Leukocytoclastic vasculitis, urticaria, hypersensitivity reactions, including anaphylaxis and angioedema, and ocular disturbances have also been reported. These reactions were more frequently observed in patients with advanced age, high risk myelodysplastic syndromes, underlying renal or hepatic impairment, or low platelet counts.",
"   </p>",
"   <p>",
"    Serum creatinine levels should be monitored in patients at increased risk of complications (eg, preexisting renal disease, elderly, presence of co-morbid conditions, use of medications decreasing renal function such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/86,89\">",
"     86,89",
"    </a>",
"    ]. Serum transaminases, bilirubin, and blood counts should also be monitored regularly and treatment should be interrupted in patients who develop unexplained cytopenia or alterations in tests of liver function [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acquired proximal renal tubular dysfunction (acquired Fanconi syndrome) has been described as a complication of treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/19/2360?source=see_link\">",
"     deferasirox",
"    </a>",
"    (eg, severe degrees of metabolic acidosis, hypokalemia, and hypophosphatemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. Cessation of deferasirox and initiation of replacement therapy resulted in prompt normalization of electrolyte imbalances in all of the four cases in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/90\">",
"     90",
"    </a>",
"    ]. Accordingly, it is reasonable to check for this complication in patients treated with this agent.",
"   </p>",
"   <p>",
"    The estimated annual cost for treatment with this agent in the United States in a 60 kg adult is $39,000 and $58,500 for doses of 20 or 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, respectively (",
"    <a class=\"graphic graphic_table graphicRef78454 \" href=\"UTD.htm?15/0/15372\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OTHER CHELATORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A potential alternative to these agents is the hexadentate phenolic aminocarboxylate iron chelator HBED [",
"    <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. Another potential chelator is ascorbic acid (vitamin C). Ascorbic acid can mobilize iron but may do so too quickly and cause iron toxicity. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Deferoxamine'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/14/7394?source=see_link\">",
"       \"Patient information: Thalassemia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/41/2709?source=see_link\">",
"       \"Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     General indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron chelation is a supportive treatment modality employed to reverse or reduce the adverse effects of iron deposition in critical organs (eg, heart, liver) in patients with iron overload who cannot be treated with therapeutic phlebotomy. Such patients include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Transfusion-dependent subjects (eg, thalassemia, sickle cell anemia, myelodysplastic syndrome)",
"     </li>",
"     <li>",
"      Possible use of iron chelation in non-transfusion dependent thalassemic patients who have evidence for serious degrees of iron overload (see",
"      <a class=\"local\" href=\"#H15375128\">",
"       'Use in transfusion-independent thalassemia'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Non-anemic patients with iron overload who cannot tolerate therapeutic phlebotomy (eg, hemochromatosis with severe cardiac involvement",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an unstable hemodynamic status) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/49/25370/abstract/1\">",
"       1",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Treatment of specific disorders",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Transfusion-dependent thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend iron chelation therapy in transfusion-dependent patients with thalassemia (",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    ). This treatment has been shown to significantly reduce tissue iron overload and prolong overall survival in such patients (",
"    <a class=\"graphic graphic_figure graphicRef75362 \" href=\"UTD.htm?3/36/3662\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Use in thalassemia'",
"    </a>",
"    above.) The most commonly employed chelating agent for such patients is subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     deferoxamine",
"    </a>",
"    , either alone or in combination with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/18/3365?source=see_link\">",
"     deferiprone",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Chelation therapy is generally held when the ferritin level falls to &lt;500",
"    <span class=\"nowrap\">",
"     mcg/L.",
"    </span>",
"    Its efficacy in removing iron from the liver and heart can be confirmed using MRI imaging techniques. (See",
"    <a class=\"local\" href=\"#H19247636\">",
"     'Comparison with deferoxamine and deferasirox'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Sickle cell disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with sickle cell disease who have had at least one year of chronic transfusion therapy and have a serum ferritin concentration &gt;1000",
"    <span class=\"nowrap\">",
"     mcg/L",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a liver iron concentration of at least 3000",
"    <span class=\"nowrap\">",
"     mcg/g",
"    </span>",
"    dry weight, we suggest the addition of iron chelation to the treatment regimen (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A clinical benefit in terms of overall survival from iron chelation in this setting has not been demonstrated and the optimal agent to use is unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H28#H28\">",
"     \"Overview of the management of sickle cell disease\", section on 'Excessive iron stores'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Myelodysplastic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with myelodysplastic syndrome who have received at least 20 to 30 red cell transfusions and have a serum ferritin concentration &gt;1000",
"    <span class=\"nowrap\">",
"     mcg/L,",
"    </span>",
"    the use of an iron chelating agent can be considered. However, a clinical benefit from iron chelation in terms of overall survival in this setting has not been demonstrated and the optimal agent to use is unclear. This subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=see_link&amp;anchor=H2104230#H2104230\">",
"     \"Management of the complications of the myelodysplastic syndromes\", section on 'Iron overload'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/1\">",
"      Fabio G, Minonzio F, Delbini P, et al. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). Blood 2007; 109:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/2\">",
"      Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood 2012; 120:3657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/3\">",
"      Maggio A. Light and shadows in the iron chelation treatment of haematological diseases. Br J Haematol 2007; 138:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/4\">",
"      Glickstein H, El RB, Link G, et al. Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences. Blood 2006; 108:3195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/5\">",
"      Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood 2011; 118:3479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/6\">",
"      Fernandes JL. Iron chelation therapy in the management of transfusion-related cardiac iron overload. Transfusion 2012; 52:2256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/7\">",
"      Adams JG 3rd, Coleman MB. Structural hemoglobin variants that produce the phenotype of thalassemia. Semin Hematol 1990; 27:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/8\">",
"      Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997; 89:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/9\">",
"      Beris P. Introduction: management of thalassemia. Semin Hematol 1995; 32:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/10\">",
"      Cao A, Galanello R, Rosatelli MC, et al. Clinical experience of management of thalassemia: the Sardinian experience. Semin Hematol 1996; 33:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/11\">",
"      Hershko C, Konijn AM, Nick HP, et al. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood 2001; 97:1115.",
"     </a>",
"    </li>",
"    <li>",
"     Forget BG, Pearson HA. Hemoglobin synthesis and the thalassemias. In: Basic Principles and Practice, 3rd ed, Hoffman R, Benz EJ Jr, Shattil SJ, et al. (Eds), Churchill Livingstone, New York 2000. p.1525.",
"    </li>",
"    <li>",
"     Schwartz E, Benz EJ Jr. Thalassemia syndromes. In: Smith's Blood Diseases of Infancy and Childhood, 6th ed, Miller DR, Baehner RL (Eds), CV Mosby, St. Louis 1989. p.428.",
"    </li>",
"    <li>",
"     Weatherall DJ. The thalessemias. In: Molecular Basis of Blood Diseases, 2nd ed, Stamatoyannopoulos G, Nienhuis AW, Majerus PW (Eds), WB Saunders, Philadelphia 1994. p.157.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/15\">",
"      Schafer AI, Rabinowe S, Le Boff MS, et al. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload. Arch Intern Med 1985; 145:1217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/16\">",
"      Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk beta-thalassemia. Blood 2000; 95:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/17\">",
"      Fosburg MT, Nathan DG. Treatment of Cooley's anemia. Blood 1990; 76:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/18\">",
"      Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004; 104:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/19\">",
"      Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol 2004; 127:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/20\">",
"      Pennell DJ, Carpenter JP, Roughton M, Cabantchik Z. On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure. J Cardiovasc Magn Reson 2011; 13:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/21\">",
"      Mamtani M, Kulkarni H. Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis. Br J Haematol 2008; 141:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/22\">",
"      Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/23\">",
"      Modell B, Khan M, Darlison M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia Register. Lancet 2000; 355:2051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/24\">",
"      Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 2007; 47:1919.",
"     </a>",
"    </li>",
"    <li>",
"     Piga A, Longo F, Consolati A, et al. Mortality and morbidity in thalassaemia with conventional treatment. In: Bone Marrow Transplant 19 (suppl 2), Proceedings of the third international conference on bone marrow transplantation in thalassaemia, 1997. p.11.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/26\">",
"      Payne KA, Desrosiers MP, Caro JJ, et al. Clinical and economic burden of infused iron chelation therapy in the United States. Transfusion 2007; 47:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/27\">",
"      Harmatz P, Grady RW, Dragsten P, et al. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator. Br J Haematol 2007; 138:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/28\">",
"      Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med 1986; 314:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/29\">",
"      Porter JB, Jaswon MS, Huehns ER, et al. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol 1989; 73:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/30\">",
"      Boelaert JR, de Locht M, Van Cutsem J, et al. Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies. J Clin Invest 1993; 91:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/31\">",
"      Green NS. Yersinia infections in patients with homozygous beta-thalassemia associated with iron overload and its treatment. Pediatr Hematol Oncol 1992; 9:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/32\">",
"      Bunce PE, Mishra S, Gold WL. Iron-clad diagnosis. Am J Med 2008; 121:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/33\">",
"      Neupane GP, Kim DM. Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificus. Transfusion 2009; 49:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/34\">",
"      Hoffbrand AV, AL-Refaie F, Davis B, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998; 91:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/35\">",
"      Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med 1998; 339:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/36\">",
"      Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood 2003; 102:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/37\">",
"      Cohen AR, Galanello R, Piga A, et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003; 102:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/38\">",
"      Cohen AR, Galanello R, Piga A, et al. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol 2000; 108:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/39\">",
"      Kowdley KV, Kaplan MM. Iron-chelation therapy with oral deferiprone--toxicity or lack of efficacy? N Engl J Med 1998; 339:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/40\">",
"      Viprakasit V, Nuchprayoon I, Chuansumrit A, et al. Deferiprone (GPO-L-ONE(&reg;) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand. Am J Hematol 2013; 88:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/41\">",
"      Ceci A, Baiardi P, Felisi M, et al. The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patients. Br J Haematol 2002; 118:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/42\">",
"      Henter JI, Karl&eacute;n J. Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood 2007; 109:5157.",
"     </a>",
"    </li>",
"    <li>",
"     www.cooleysanemia.org/bodies/body309.php (Accessed on June 27, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/44\">",
"      Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115:1876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/45\">",
"      Cragg L, Hebbel RP, Miller W, et al. The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells. Blood 1998; 92:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/46\">",
"      Pootrakul P, Sirankapracha P, Sankote J, et al. Clinical trial of deferiprone iron chelation therapy in beta-thalassaemia/haemoglobin E patients in Thailand. Br J Haematol 2003; 122:305.",
"     </a>",
"    </li>",
"    <li>",
"     Prescribing information for deferiprone: file://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021825lbl.pdf (Accessed on October 17, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/48\">",
"      Piga A, Gaglioti C, Fogliacco E, Tricta F. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/49\">",
"      Maggio A, D'Amico G, Morabito A, et al. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial. Blood Cells Mol Dis 2002; 28:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/50\">",
"      Anderson LJ, Wonke B, Prescott E, et al. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Lancet 2002; 360:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/51\">",
"      Wanless IR, Sweeney G, Dhillon AP, et al. Lack of progressive hepatic fibrosis during long-term therapy with deferiprone in subjects with transfusion-dependent beta-thalassemia. Blood 2002; 100:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/52\">",
"      Pennell DJ, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107:3738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/53\">",
"      Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006; 107:3733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/54\">",
"      Pippard MJ, Weatherall DJ. Oral iron chelation therapy for thalassaemia: an uncertain scene. Br J Haematol 2000; 111:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/55\">",
"      Roberts DJ, Brunskill SJ, Doree C, et al. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev 2007; :CD004839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/56\">",
"      Pepe A, Meloni A, Capra M, et al. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica 2011; 96:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/57\">",
"      Pepe A, Rossi G, Meloni A, et al. A T2* MRI prospective survey on heart and liver iron in thalassemia major patients treated with deferasirox versus deferiprone and desferrioxamine in monotherapy. (Abstract 4267). Blood 2010; 116:1731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/58\">",
"      Mourad FH, Hoffbrand AV, Sheikh-Taha M, et al. Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients. Br J Haematol 2003; 121:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/59\">",
"      Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998; 103:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/60\">",
"      D'Angelo E, Mirra N, Rocca A, Carnelli V. Combined therapy with desferrioxamine and deferiprone: a new protocol for iron chelation in thalassemia. J Pediatr Hematol Oncol 2004; 26:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/61\">",
"      Maggio A, Vitrano A, Capra M, et al. Long-term sequential deferiprone-deferoxamine versus deferiprone alone for thalassaemia major patients: a randomized clinical trial. Br J Haematol 2009; 145:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/62\">",
"      De Domenico I, Ward DM, Kaplan J. Specific iron chelators determine the route of ferritin degradation. Blood 2009; 114:4546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/63\">",
"      Tanner MA, Galanello R, Dessi C, et al. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson 2008; 10:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/64\">",
"      Farmaki K, Tzoumari I, Pappa C, et al. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 2010; 148:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/65\">",
"      Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet 2003; 361:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/66\">",
"      Galanello R, Piga A, Alberti D, et al. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003; 43:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/67\">",
"      Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007; 136:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/68\">",
"      Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol 2008; 80:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/69\">",
"      Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107:3455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/70\">",
"      Voskaridou E, Plata E, Douskou M, et al. Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study. Br J Haematol 2010; 148:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/71\">",
"      Vichinsky E. Oral iron chelators and the treatment of iron overload in pediatric patients with chronic anemia. Pediatrics 2008; 121:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/72\">",
"      Taher A, Cappellini MD, Vichinsky E, et al. Efficacy and safety of deferasirox doses of &gt;30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol 2009; 147:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/73\">",
"      Shashaty G, Frankewich R, Chakraborti T, et al. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis. Oncology (Williston Park) 2006; 20:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/74\">",
"      Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood 2008; 111:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/75\">",
"      Chirnomas D, Smith AL, Braunstein J, et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood 2009; 114:4009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/76\">",
"      Cappellini MD, Bejaoui M, Agaoglu L, et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood 2011; 118:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/77\">",
"      Cappellini MD, Porter J, El-Beshlawy A, et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010; 95:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/78\">",
"      Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Blood 2010; 115:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/79\">",
"      Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with &beta;-thalassemia major. Haematologica 2012; 97:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/80\">",
"      Wood JC, Kang BP, Thompson A, et al. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Blood 2010; 116:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/81\">",
"      Taher AT, Porter J, Viprakasit V, et al. Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study. Blood 2012; 120:970.",
"     </a>",
"    </li>",
"    <li>",
"     Taher AT, Porter JB, Viprakasit V, et al. Deferasirox continues to reduce iron overload in non-transfusion-dependent thalassemia: A one-year, open-label extension to a one-year, randomized, double-blind, placebo-controlled study (THALASSA). Abstract 3258. Presented at the 54th Annual Meeting of the American Society of Hematology, Atlanta GA, 2013.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/83\">",
"      Voskaridou E, Christoulas D, Terpos E. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies. Br J Haematol 2011; 154:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/84\">",
"      Berdoukas V, Carson S, Nord A, et al. Combining two orally active iron chelators for thalassemia. Ann Hematol 2010; 89:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/85\">",
"      Grady RW, Galanello R, Randolph RE, et al. Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine. Haematologica 2013; 98:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/86\">",
"      Lee JW, Yoon SS, Shen ZX, et al. Iron chelation therapy with deferasirox in patients with aplastic anemia: a subgroup analysis of 116 patients from the EPIC trial. Blood 2010; 116:2448.",
"     </a>",
"    </li>",
"    <li>",
"     www.fda.gov/medwatch/safety/2007/safety07.htm#Exjade (Accessed on April 07, 2010).",
"    </li>",
"    <li>",
"     Boxed warning about deferasirox posted on the FDA website: www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm200850.htm. Accessed on April 7, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/89\">",
"      Economou M, Printza N, Teli A, et al. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta Haematol 2010; 123:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/90\">",
"      Yacobovich J, Stark P, Barzilai-Birenbaum S, et al. Acquired proximal renal tubular dysfunction in &beta;-thalassemia patients treated with deferasirox. J Pediatr Hematol Oncol 2010; 32:564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/91\">",
"      Wei HY, Yang CP, Cheng CH, Lo FS. Fanconi syndrome in a patient with &beta;-thalassemia major after using deferasirox for 27 months. Transfusion 2011; 51:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/92\">",
"      Neufeld EJ. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Blood 2006; 107:3436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/93\">",
"      Bergeron RJ, Wiegand J, Brittenham GM. HBED: the continuing development of a potential alternative to deferoxamine for iron-chelating therapy. Blood 1999; 93:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/49/25370/abstract/94\">",
"      Bergeron RJ, Wiegand J, Brittenham GM. HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning. Blood 2002; 99:3019.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7146 Version 25.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-A1F0AAE071-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_49_25370=[""].join("\n");
var outline_f24_49_25370=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2407611\">",
"      Goals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2407618\">",
"      - Beta thalassemia major",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      DEFEROXAMINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Use in thalassemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Risk of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Use in myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Use in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Use in acute iron poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DEFERIPRONE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19247545\">",
"      Dosing and side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19247476\">",
"      Comparison with deferoxamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19247636\">",
"      Comparison with deferoxamine and deferasirox",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Deferiprone plus deferoxamine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Use in severe cardiac complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DEFERASIROX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Use in transfusion-dependent beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15375128\">",
"      Use in transfusion-independent thalassemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2809410\">",
"      Deferiprone plus deferasirox",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13075577\">",
"      Deferoxamine plus deferasirox",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Use in sickle cell anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8346483\">",
"      Use in aplastic anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OTHER CHELATORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      General indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Treatment of specific disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Transfusion-dependent thalassemia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Myelodysplastic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7146\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7146|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/40/39565\" title=\"figure 1\">",
"      Iron chelating agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?3/36/3662\" title=\"figure 2\">",
"      Survival in beta thal major",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7146|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/0/15372\" title=\"table 1\">",
"      Costs iron chelation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/57/2970?source=related_link\">",
"      Acute iron poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/14/5352?source=related_link\">",
"      Aluminum toxicity in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=related_link\">",
"      Clinical manifestations and diagnosis of the thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/61/33748?source=related_link\">",
"      Hepatic iron concentration and hepatic iron index in the diagnosis of iron overload and hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/36/43591?source=related_link\">",
"      Long-term management of the thalassemic patient after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/54/25450?source=related_link\">",
"      Management of the complications of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=related_link\">",
"      Pathophysiology of beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/41/2709?source=related_link\">",
"      Patient information: Hemochromatosis (hereditary iron overload) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/14/7394?source=related_link\">",
"      Patient information: Thalassemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/39/7802?source=related_link\">",
"      Treatment of beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/42/44710?source=related_link\">",
"      Vibrio vulnificus infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_49_25371="HIV-associated lymphomas";
var content_f24_49_25371=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F79517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F79517&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    WHO classification of lymphoid malignancies associated with HIV infection (2008)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Lymphomas also occurring in immunocompetent patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Burkitt and Burkitt-like lymphomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Diffuse large B-cell lymphomas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Centroblastic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        - Immunoblastic (including primary CNS lymphoma)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Extranodal MALT lymphoma (rare)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peripheral T-cell lymphoma (rare)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Classical Hodgkin lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Lymphoma occurring more specifically in HIV-positive patients",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary effusion lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasmablastic lymphoma of the oral cavity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Lymphoma also occurring in other immunodeficiency states",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polymorphic B-cell lymphoma (PTLD-like) (rare)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MALT: marginal zone lymphoma of mucosa-associated lymphoid tissue; PTLD: post transplant lymphoproliferative disorder; CNS: central nervous system.",
"    </div>",
"    <div class=\"reference\">",
"     Source: Swerdlow, SH, Campo, E, Harris, NL, et al. (Eds). World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_49_25371=[""].join("\n");
var outline_f24_49_25371=null;
var title_f24_49_25372="Oncologic outcome VRT";
var content_f24_49_25372=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Oncologic outcomes after radical vaginal trachelectomy alone",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Author",
"       </td>",
"       <td class=\"subtitle1\">",
"        # of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Median follow-up, months (range)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recurrence (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Death (percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mathevet et al",
"       </td>",
"       <td>",
"        95",
"       </td>",
"       <td>",
"        76 (4 to 176)",
"       </td>",
"       <td>",
"        4 (4.2)",
"       </td>",
"       <td>",
"        3 (3.2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Covens",
"       </td>",
"       <td>",
"        93",
"       </td>",
"       <td>",
"        30 (1 to 103)",
"       </td>",
"       <td>",
"        7 (7.5)",
"       </td>",
"       <td>",
"        4 (4.3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plante et al",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        60 (6 to 156)",
"       </td>",
"       <td>",
"        2 (2.8)",
"       </td>",
"       <td>",
"        1 (1.4)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shepherd et al",
"       </td>",
"       <td>",
"        123",
"       </td>",
"       <td>",
"        45 (1 to 120)",
"       </td>",
"       <td>",
"        5 (4.1)",
"       </td>",
"       <td>",
"        4 (3.2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Burnett et al",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        31 (22 to 44)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Schlaerth et al",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        47 (28 to 84)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hertel et al",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        29 (1 to 128)",
"       </td>",
"       <td>",
"        3 (3)",
"       </td>",
"       <td>",
"        2 (2)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Current series",
"       </td>",
"       <td>",
"        36",
"       </td>",
"       <td>",
"        21 (3 to 60)",
"       </td>",
"       <td>",
"        1 (3)",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Total",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         548",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         &nbsp;",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         22 (4.0)",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         14 (2.6)",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Sonoda Y, Chi DS, Carter J, et al. Initial experience with Darget's operation: The radical vaginal trachelectomy. Gynecol Oncol 2008; 108:214. Copyright &copy; 2008 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_49_25372=[""].join("\n");
var outline_f24_49_25372=null;
var title_f24_49_25373="Known mutations ZAP 70 protein";
var content_f24_49_25373=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F68529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F68529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Known mutations in the ZAP-70 protein",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 289px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Locations of identified mutations and their consequences to the ZAP-70 protein are shown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_49_25373=[""].join("\n");
var outline_f24_49_25373=null;
var title_f24_49_25374="4 generation pedigree";
var content_f24_49_25374=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F55908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F55908&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 543px\">",
"   <div class=\"ttl\">",
"    An example of a 4-generation medical pedigree",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 523px; height: 375px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient denoted with arrow. From top, left to right: I. 1 = Paternal grandfather, died age 82 of unknown cause; I-2 paternal grandmother, alive age 77; I-3 maternal grandfather, died age 66, history of MI and hyperlipidemia; I-4 maternal grandmother, alive age 70. II-1 Father age 57; II-2 Mother, alive age 54 with coronary disease onset at age 52; II-3 Maternal uncle, alive age 52, with coronary disease onset at age 49; II-4 Maternal aunt, age 48; II-5 husband of II-4, age 50. III-1 sister, age 35; III-2 a sibling (gender unknown) who died at birth; III-3 patient, age 32; III-4 patient's husband, age 36; III-5 brother, age 31 with hyperlipidemia; III-6 brother, age 28 with hyperlipidemia; III-7 female cousin, age 20. IV-1 daughter, age 3.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_49_25374=[""].join("\n");
var outline_f24_49_25374=null;
var title_f24_49_25375="Bronchogenic carcinoma CT IV";
var content_f24_49_25375=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73208&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bilateral mediastinal lymph node enlargement in lung cancer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peripheral left upper lobe bronchogenic carcinoma with amorphous central calcification. Aortopulmonary window (long arrow), contralateral pretracheal, and retrocaval lymph nodes (short arrow), indicating N3 disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_49_25375=[""].join("\n");
var outline_f24_49_25375=null;
